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ABSTRACT 
Sodium Iodide Symporter (NIS), an intrinsic membrane glycoprotein is a key regulator of 
iodide access to thyroid gland.  NIS co-transports active I- and Na+ with the help of Na+/K+-
ATPase for the normal thyroid function. NIS protein expression occurs not only in thyroid 
cells but also in other extra thyroidal tissues like salivary gland, gastric mucosa, lactating 
mammary gland, placenta and kidney. Its expression has been reported in thyroid cancer 
which is exploited for diagnostic imaging and molecular radionuclide-based therapy of 
differentiated NIS expressing thyroid cancer. Retinoblastoma (RB), a malignant tumor of the 
eye arising from the developing retina is the most frequent primary intraocular malignancy of 
childhood. Delay in diagnosis and lack of awareness about the disease in resource-poor 
countries ultimately leads to high mortality rate and poor rate of eye salvage. The primary 
treatment for RB is chemotherapy with a regimen of etoposide, vincristine and carboplatin. 
Apart from chemotherapy, radiotherapy is another effective mode in treating RB. RB is a 
radiosensitive tumor and brachytherapy, a mild form of radiotherapy is used to treat small RB 
tumors with the help of a plaque containing radioactive material. Radiotherapy can be 
mediated via NIS, the possibility of NIS presence in RB tumors was therefore explored in this 
study. Since many of the RB patients in India are diagnosed late which end up in enucleation, 
the study was aimed to explore the expression of NIS protein in Grade D and Grade E RB 
tumors. Thus, RB, a non-thyroidal malignancy was investigated for the expression of NIS in 
human RB tumor samples as well as in an established standard RB cell line (Y79). The 
presence of therapeutic protein like NIS in a non-thyroidal tumor like RB could open a lot of 
therapeutic opportunities. 
NIS expression was analyzed in a cohort of 41 advanced stages RB tumor samples, classified 
as Grade D and E as per International Intraocular Retinoblastoma Classification (IIRC). 
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There were 23 Grade D and 18 Grade E tumors; 25 invasive and 16 non-invasive tumors 
within the cohort of 41 tumors. Invasive tumors analysed were either choroidal, optic nerve, 
scleral or with extra ocular invasion. Choroidal invasion was further divided into <3mm and 
>3mm invasion and optic nerve invasion as pre laminar, post laminar and surgical end of the 
optic nerve. In 21 tumor samples, NIS expression was analysed by immunohistochemistry, 
and in another 20 samples NIS protein expression was analysed by Flow cytometry. NIS 
protein expression was also studied by Western blotting in 6/41 tumor samples. NIS protein 
expression was observed in all 41 RB tumor samples. Membrane and cytoplasmic expression 
of NIS protein was prevalent in RB tumors when analysed immunohistochemically. Flow 
cytometry revealed that NIS protein expression was significantly higher in the RB cases of 
choroid and/or optic nerve invasion when compared to non-invasive tumors (P<0.05). 
Western blotting of NIS protein in RB showed bands at 75 kDa, 50 kDa and 25 kDa which 
revealed the different glycosylation status of the protein. Immunofluorescence, Flow 
cytometry and Western blotting studies in Y79 cell line also showed similar results to 
primary RB tumor samples. Immunofluorescence revealed cell surface as well as membrane 
staining in Y79 cells similar to IHC findings in tumor samples. Furthermore, a single protein 
band of 75 kDa was observed in Y79 on Western blotting revealing a differentially 
glycosylated status of NIS protein. Thus NIS is expressed in RB in various glycosylation 
forms.  In conclusion, using RB tumor samples the presence of NIS protein in a non-thyroidal 
tumor has been demonstrated. This study being the first report for RB thus opens a lot of 
opportunity for further research in modulating NIS expression for therapeutic opportunities in 
RB tumors. From the translational perspective of these findings, it will be critical to 
determine in vivo, if the NIS expression in RB tumours is functional for a radioiodide based 
therapy.  
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In the past two decades, studies on NIS expression in many cancers (thyroidal and 
extrathyroidal) reveal that there are multiple regulatory levels of NIS functional expression. 
These include transcriptional (gene), translational, posttranslational, distribution to 
intracellular organelles and targeting to the plasma membrane. Use of several compounds 
with known tumor-inhibitory effects has been shown to partially succeed in inducing 
endogenous NIS expression in thyroid and breast cancers. Lactoferrin (Lf) is a glycoprotein 
with iron-binding ability. Being a component of innate immunity, it is known to present at 
higher concentrations in mammalian milk colostrum and exocrine secretions. Bovine 
lactoferrin (bLf) is a multifunctional protein with its emerging anti-cancer biodrug potential. 
It can act also as a cell growth/cell differentiating agent as well as a transcriptional agent. 
Studies from our laboratory have recently shown that internalization of bLf through receptor 
mediated endocytosis, into the cell and nucleus can regulate gene transcription. bLf’s effect 
on NIS expression is not known. It was hypothesized that bLf could upregulate the NIS 
protein expression. Since the status of lactoferrin receptors in Y79 cell line is not known, it 
was therefore aimed to determine first if Y79 cells express lactoferrin receptors. The 
mRNAexpression of Lf receptor was detected in Y79 cells by qRT-PCR. Initial studies on Lf 
receptors in Y79 cells revealed prominently higher extent of endogenous expression of 
transferrin receptors and low-density lipoprotein receptor-related proteins-1 and -2 (LRP1 
and LRP2). It was aimed further to test whether bLf in partially iron saturated (Native-bLf), 
iron saturated (Fe-bLf) (>97 % saturation) and iron free (Apo-bLf) forms internalized in Y79 
cells. Interestingly, rapid internalization of all the three forms of bLf, Native-bLf, Fe-bLf and 
Apo-bLf at concentration of 12.5 nmol, in above 90 % of cells was observed, at 30 min 
incubation. Flow cytometric studies in Y79 cells also confirmed the uptake of three forms of 
bLfs at various concentrations. NIS protein expression after the three forms of bLf treatment 
was determined by Western blotting and found that the NIS protein expression was doubled 
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in 50 nmol concentration of Fe-bLf and 25 nmol concentration of Apo-bLf. Although it was 
important to ascertain the functional activity of the bLf induced NIS, functional assay like 
non-radioactive iodide uptake assay could not be performed. Y79, being a suspension cell 
line and non-radioactive iodide uptake assay being a sensitive colorimetric assay performed 
usually in monolayer cultures, the technical difficulty of adding and removing successive 
reagents for the time dependant assay in suspension cell lines restricted the determination of 
functional activity of expressed NIS.  
Since, the initial attempts to conduct iodide uptake assays for investigating functional status 
of NIS in RB cell line were unsuccessful, the focus of the study was shifted towards another 
strategy of overexpressing NIS through exogenous NIS gene delivery via receptor targeting. 
Therefore gene cloning experiments were performed to overexpress NIS gene in another 
extrathyroidal cancer cell line, MCF-7 (derived from a human breast cancer 
adenocarcinoma), as well as in Y79 cells for functional iodide uptake assay.  Vectors 
containing CMV, and EpCAM specific promoter driven NIS gene were used to establish 
stable transfectants. However, the attempts of establishing stable Y79 transfectant 
overexpressing NIS were again unsuccessful in preliminary experiments because of the 
difficulty in establishing a stable transfectant in suspension cells. 
An expression vector system with NIS gene and a tissue specific promoter, epithelial cell 
adhesion molecule (EpCAM) directed towards the EpCAM expressing tumor cells was 
cloned. EpCAM, a membrane glycoprotein is expressed at low level on the basolateral 
membrane in normal epithelial cells whereas expressed at high level on the apical membrane 
in cancer cells. This overexpression has been utilized in many cancers like breast cancer for 
receptor targeted therapeutic approaches. MCF-7 cells overexpress EpCAM therefore further 
studies were undertaken with this cell line. Although NIS is expressed endogenously in breast 
cancer, its expression is at insufficient level to exploit for radionuclide-based therapy. It was 
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hypothesized that if NIS was specifically overexpressed in breast cancer cells (MCF-7) via a 
tissue specific promoter (EpCAM) through receptor targeted gene delivery, it would induce 
functional activity of NIS leading to higher cellular iodide uptake. Stable transfectants of 
MCF-7, expressing NIS protein with CMV-promoter (used as a control) and EpCAM 
promoter were established. Real time PCR and Western blot analysis of the stable 
transfectants of MCF-7 confirmed significant overexpression of CMV-NIS over EpCAM-
NIS at the mRNA (P<0.005) and protein levels due to constitutional activity of the CMV 
promoter. These stable transfectants, MCF-CMV-NIS and MCF-EpCAM-NIS were 
employed for non-radioactive iodide uptake study which is a sensitive colorimetric assay to 
evaluate the functional expression of NIS protein in these transfectants. Iodide uptake was 
specifically observed in both the transfectants and no iodide uptake was observed in the 
untransfected MCF-7 cells. The functionality of NIS in these transfectants was also proved by 
conventional radioactive iodide uptake studies using 4µCi/mL Na125I. The uptake of non-
radioactive iodide and radioactive iodide was significantly higher (P<0.05) in MCF-EpCAM-
NIS cells than the MCF-CMV-NIS cells. The uptake of radioiodide by NIS was significantly 
(P<0.05) inhibited by Sodium perchlorate, an inhibitor of NIS. This shows that iodide uptake 
has been specifically via NIS. Efflux studies were performed and it was observed that 75% of 
the iodide has been released in first few min. This shows that the iodide taken up is associated 
with high efflux rate with minimal retention time. This proves the functionality of the NIS 
protein expressed by the stable transfectants. NIS overexpressing stable transfectants showed 
higher migratory ability than the control cells confirming the functional activity of 
overexpressed NIS and its role in cell migration. Altogether, the obtained results show that 
delivering NIS gene via a tissue specific promoter like EpCAM promoter seems to be the 
promising strategy for radionuclide based therapy in breast tumors.  
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Another attempt was made in delivering NIS plasmid DNA in EpCAM positive MCF-7 cell 
line via a nanoformulation using a polymer. Polyethylenimine (PEI) is a widely used polymer 
and a substitute for viral vectors for gene delivery. This study was further aimed to deliver 
NIS gene specifically to breast cancer cells (MCF-7) via PEI coated with EpCAM aptamer 
which served as a targeting ligand. It was hypothesised that the nanocomplex would 
specifically target breast cancer cells overexpressing EpCAM, a surface biomarker. Flow 
cytometry studies showed EpCAM aptamer (EpDT3)’s higher affinity towards EpCAM 
positive cells (MCF-7) and lower affinity towards EpCAM-low cells (MIOM-1) thus 
confirming EpDT3’s specificity. The nanocomplex was prepared by incorporating NIS 
pDNA inside PEI and by coating EpDT3 outside. The size and zeta potential of the 
nanocomplex was analysed by Zeta sizer and its shape and size by Transmission Electron 
Microscopy (TEM). NIS protein expression after gene delivery via nanocomplex was studied 
by Western blotting. Functional activity of the NIS gene delivered by the nanocomplex was 
also determined by both non-radioactive iodide uptake assays as well as by radioactive iodide 
uptake assay.  Dynamic light scattering (DLS) revealed that the nanocomplexes were ~ 100 
nm and with a zeta potential of -14.2 mV. The nanocomplexes remained stable in serum for 
72 h at a pH of 7.0. Western blotting after transfection of nanocomplexed NIS gene showed 
overexpression of NIS protein. Non-radioactive and radioactive iodide uptake assays 
demonstrated significant increase (P<0.05) in the functional activity of NIS indicating the 
efficacy of nanocomplex to deliver NIS gene. Higher uptake of iodide by the cells following 
delivery of nanocomplex confirms the capacity of the delivery system for selective and 
efficient targeting. Thus, in this study, a PEI based nanocomplex was formulated which 
carries a therapeutic gene inside and delivers it specifically to EpCAM positive breast cancer 
cells. Based on these findings, it is concluded that the nanocomplex retains the integrity of 
NIS pDNA, leads to its functional activity and is efficient at targeting EpCAM positive 
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cancer cells. This can be a potential mode of NIS gene therapy via non-viral vectors in 
EpCAM positive non-thyroidal cancers. 
 
In the last phase of the study, the gene expression status of important apoptotic regulatory 
molecules in RB tumors was analysed. Apoptosis is a natural process of programmed cell 
death which is regulated by both apoptotic and anti-apoptotic molecules. The important 
families involved in the apoptosis are Inhibitor of Apoptosis (IAP) and B-cell lymphoma 2 
(Bcl-2) family. Since the endogenous expression of apoptotic regulatory genes have not been 
explored before in RB, this study hypothesized that the expression of Bax and Bcl-2 from 
Bcl2 family, and survivin and four of its variants from the IAP family would be associated 
with clinical parameters like histopathological high risk factors, and the gene showing 
dominant status could be targeted by siRNA technology. This study was aimed to investigate 
the mRNA expression of Bcl-2, Bax, survivin and its splice variants in a cohort of 20 RB 
tumors. The information about these molecules is still lacking as far as RB tumors and their 
progression is concerned. The differential expression of these apoptosis regulatory genes in 
relation to clinicopathological features of RB was analysed at mRNA level by Real Time 
PCR. Bcl-2 was expressed in all the RB tumors whereas Bax was expressed in 80% of the 
tumors analysed. The Bcl-2 expression was significantly higher (P<0.001) in RB and the Bcl-
2/Bax ratio was remarkably higher in poorly differentiated tumors than well differentiated 
tumors, although no statistical significance was obtained. No positive or negative correlation 
between Bcl-2 and Bax with respect to their expression levels was found in RB tumors.  
 
Among survivin and its variants, Survivin-wild type (WT) was found to be the predominant 
form and all the anti-apoptotic variants such as Survivin-ΔEx3 and Survivin-3β were highly 
expressed in the tumor samples studied compared to pro-apoptotic variants such as Survivin-
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2β and Survivin-2α. A statistically significant higher expression was seen in RB tumor 
samples for Survivin-WT compared to Survivin-2β (P<0.05). A positive correlation with 
respect to the expression levels in tumor samples was observed among all the five variants of 
survivin. A statistical significant difference was found in Survivin-2α, Survivin-2β and 
Survivin-ΔEx3 for the differentiation of RB tumors (P<0.05). No significant correlation 
between Bcl-2/Bax and survivin was observed indicating that their expression levels are 
independent of each other. Considering the positive correlation of survivin members with RB 
tumor progression, it was further aimed to study the apoptotic effects on silencing the 
Survivin-WT and one of the anti-apoptotic splice variant, Survivin-ΔEx3 in Y79 cells. 
Silencing via siRNA technology of Survivin-WT in Y79 cell line showed higher pro-
apoptotic effects and increased caspase 3/7 activity in Y79 cells because silencing of 
Survivin-WT induced silencing of all variants. No pro-apoptotic effects were observed on 
silencing of Survivin-ΔEx3 alone. The findings thus suggest that overexpression of both 
survivin along with its variants and higher Bcl-2/Bax ratio cause the inhibition of apoptosis 
and thereby lead to progression of RB cancer. This study also suggests targeting survivin (a 
validated cancer target) in RB could be a viable option for targeted therapy.  
Taken together, it can be concluded from the entire study that for the first time expression of 
NIS in RB has been analysed and correlated with clinicopathological invasiveness of the 
tumor. This finding of a validated therapeutic gene such as NIS in RB can possibly pave the 
way for newer and specific treatment regimens in RB. The specificity of EpCAM based NIS 
gene therapy was demonstrated by employing breast cancer cell line as a proof of concept 
model via two modes 1) tissue specific promoter and 2) nanoformulation, both of which 
showed encouraging outcomes. The high prevalence of RB NIS expression in 100% of 
human samples studied indicates that it is upregulated with high frequency during malignant 
transformation of RB tumors, and therefore holds a potential diagnostic and therapeutic value 
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in RB. Moreover, delivering NIS gene through tissue specific promoter targeted delivery (to 
extrathyroidal cancers), it can serve both as a reporter and as a therapeutic gene, so that it is 
possible to image, monitor, and treat the tumors with radioiodide, just as in differentiated 
thyroid cancer. Importantly, further studies are needed to understand the functional NIS 
expression in RB cells and its regulatory factors. The radioiodide based therapeutic efficacy 
in RB will thus likely depend on manipulating NIS regulation. The NIS induction potential of 
emerging anti-cancer natural biodrug bLf needs to be investigated in detail for RB and other 
cancers. 
 In addition, this study also showed for the first time the upregulated expression of splice 
variants of survivin, Bax and Bcl-2 in RB tumors indicating their possible role in tumor 
progression and differentiation through apoptosis dysregulation. This study not only showed 
positive correlation of survivin and its variants with histopathological features of RB tumor 
but also presented survivin gene silencing as a viable option for targeted therapy in RB that 
should be investigated further in in vivo models at preclinical levels. 
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1. Review of Literature 
 Sodium Iodide Symporter (NIS) 1.1.
Sodium Iodide Symporter (NIS) is an integral plasma membrane glycoprotein which plays a 
pivotal role in thyroid hormonogenesis by mediating iodide (I-) transport into thyroid cells. 
Since I- is scarce in the environment, body has adapted to provide itself a sufficient I- for 
normal thyroid function. This process of active I- uptake in the thyroid is ensured by the NIS 
(Dai G, Levy O & N 1996; Smanik PA et al. 1996). This ability to concentrate iodide is 
utilized clinically for imaging and ablation of thyroid carcinomas by administration of 
radioactive iodide after thyroidectomy. Radioactive iodide therapy uses very small amounts 
of radioactive material to diagnose and treat abnormalities. Radioactive isotopes when 
administered in small dose are absorbed into the bloodstream in the gastrointestinal tract. 
This isotope is being concentrated to the specific target for its delivery and destroys the cells 
in the location. Radioiodide imaging is an important diagnostic tool for the evaluation of well 
differentiated thyroid carcinoma. Apart from diagnosis, iodide uptake also permits treatment 
for thyroid cancers, using I-131(Kogai & Brent 2012). Under normal physiology, NIS also 
mediates active I- transport into several extrathyroidal tissues, including lactating mammary 
gland, salivary glands and gastric mucosa. NIS cotransports two sodium ions (Na+) along 
with one I-.The driving force for the uptake process is transmembrane sodium gradient while 
electrochemical sodium gradient that allows NIS to be functional is maintained by Na+/K+-
ATPase pump (Figure 1.1). 
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 Figure 1.1Schematic representation of function of NIS 
 NIS transports 2 Na+ and 1 I- into the cytoplasm simultaneously by utilizing the energy 
generated Na+/K+ ATPase pump. 
1.1.1. Cloning of NIS 
Cloning of human NIS (hNIS) gene was done by screening human thyroid cDNA library 
based on homologous sequence of rat NIS (rNIS) (Smanik PA et al. 1996) which in turn was 
cloned from the FRTL-5 Fisher rat thyroid cell line derived cDNA library in Xenopus laevis 
oocytes (Dai G, Levy O & N 1996). hNIS and rNIS exhibit 84 % identity and 92 % similarity 
between them according to aminoacid sequence analysis. Apart from rNIS and hNIS, mouse 
NIS (mNIS) and porcine NIS (pNIS) have also been isolated (Perron B et al. 2001; Pinke LA 
et al. 2001; Selmi-Ruby S et al. 2003).  hNIS gene which is located at chromosome 19p12-
13.2 consists of 15 exons intervened by 14 introns (Smanik PA et al. 1997). hNIS has 643 
aminoacids which encodes a protein of predicted molecular mass of 69 kDa and a transcript 
of 3.7 kb while rNIS transcript is 2.8 kb and encodes a protein of 618 amino acids with a 
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predicted molecular mass of 65 kDa. The main dissimilarity between hNIS and rNIS is that 
there is an additional 5 amino acids in the extracellular loop between transmembrane domains 
XII and XIII and extra 20 amino acids in the cytoplasmic COOH terminus of hNIS. NIS 
protein contains 13 transmembrane domains with an intracellular carboxyl-terminus and an 
extracellular amino-terminus (Figure 1.2). In addition, loops between transmembrane 
domains I and II, III and IV, V and VI, VII and VIII, IX and X, and XI and XII are located 
intracellularly while loops between transmembrane domains II and III, IV and V, VI and VII, 
VIII and IX, X and XI, and XII and XIII are located extracellularly (Chung 2002).  
 
Figure 1.2 Schematic representation of NIS structure 
Schematic representation of NIS containing 13 transmembrane domains depicted in red 
colour. The three sites of N-linked glycosylation are depicted in green colour. The N-terminal 
is located extracellularly and C-terminal is located intracellularly (Micali et al. 2014) 
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1.1.2. Functions of NIS 
NIS belongs to the solute carrier family 5 (SLC5A) or the sodium/solute symporter family 
(SSSF) (De la Vieja et al. 2000). Majority of the members in this family are symporters and 
transport different molecules such as sugars, amino acids, vitamins, urea and anions (Jung 
2002; Wright 2013; Wright & Turk 2004). NIS like other members in the family uses a 
secondary active transport mechanism in order to translocate its substrate relies on the 
electrochemical gradient of Na+ as the driving force to transport iodide across the cell 
membrane. This electrochemical gradient of Na+ is maintained by the activity of Na+/K+-
ATPase (Bizhanova et al. 2009). Electrophysiological analysis of NIS revealed the 
translocation of two Na+ down their electrochemical gradient with the simultaneous 
translocation of one I- against its electrochemical gradient into cells (Figure 1.1). In addition, 
it has been reported that binding of Na+ to NIS occurs before iodide binding (Eskandari S et 
al. 1997). The affinity constants of Na+ and I- were determined to be 30mM and 30µM 
respectively for rat NIS (Eskandari S et al. 1997). Apart from iodide, NIS can also transport 
other monovalent anions like perchlorate (ClO4 -), astatine (At-), rhenium (ReO4-), and 
technetium (TcO4-) (Dadachova E & N 2004; Eskandari S et al. 1997; Van Sande J et al. 
2003; Zuckier LS et al. 2004 ). One iodide ion uptake by NIS is escorted by 162 molecules of 
water and one thiocyanate is escorted by 253 water molecules (Zeuthen, Belhage & Zeuthen 
2006). Perchlorate can act as a competitive inhibitor for NIS mediated iodide transport. 
Furthermore, radioactive forms of astatine, rhenium, and technetium have important 
implications for NIS-mediated radionuclide imaging and therapy. It has been reported that 
high energy alpha particle-emitter At211 efficiently kills tumor than I131 for NIS-mediated 
radioiodide therapy (Petrich T et al. 2006). In normal thyroid, thyroid stimulating hormone 
stimulates NIS expression (Bizhanova et al. 2009; Schlumberger et al. 2007) by activating the 
thyroid stimulating hormone (TSH) receptor which in turn initiates a signaling cascade 
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mediated by G-protein. This signaling cascade eventually increases NIS expression in the 
thyroid follicular cells and also modulates the plasma membrane targeting of NIS (Harun-Or-
Rashid M et al. 2010; Hou, Bojdani & Xing 2010; Huang et al. 2011a).  
1.1.3.  Post translational modifications of NIS 
Glycosylation sites on NIS were found to be conserved among species and three N-linked 
glycosylation sites on asparagines residues at position 225,297 and 485 were reported (Levy 
O et al. 1998). Inside the extracellular loop between VI and VII lies position 225 whereas 
positions 485 and 297 are located between XII and XIII within the last extracellular loop. 
Mutant NIS with abolished glycosylated sites were functionally similar to the wild type NIS 
and did not affect surface trafficking of the NIS protein (Levy O et al. 1998). 
Phosphatidylinositol 3-kinase (PI3K) pathway activation in MCF-7 cells lead to increased 
expression of underglycosylated NIS protein with no trafficking to the plasma membrane 
(Knostman et al. 2007). In another study, it was revealed that in thyroid cells, NIS regulation 
is affected by MEK (mitogen-activated protein kinase or extracellular signal-regulated kinase 
kinase) signaling (Vadysirisack et al. 2007) whereas a recent study in breast cancer showed 
MEK inhibition resulted in NIS lysosomal degradation (Zhang, Beyer & Jhiang 2013). Other 
than glycosylation, NIS is also a phosphoprotein and gets phosphorylated at positions S43, 
T49, S227, T577, and S581. Out of these sites, the potential sites which are responsible for 
NIS iodide transport velocity are S43 and S581(Vadysirisack DD et al. 2007). Apart from 
glycosylation and phosphorylation, NIS also contains leucine motif which is responsible for 
oligomerization of NIS at the cell membrane. Four leucine residues at positions 199, 206, 213 
and 220 present in transmembrane domain VI make up leucine zipper motif. One of the 
properties of NIS is its existence in different oligomeric forms which regulates targeting, 
stability and function (Sitte, Farhan & Javitch 2004; Veenhoff, Heuberger & Poolman 2002). 
An elaborate study by light scattering coupled with size exclusion chromatography on the 
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biochemical characteristics of NIS showed that NIS majorly exists as dimers or multimers 
and that atleast one disulphide bond is involved in the dimeric formation (Huc-Brandt et al. 
2011).  
1.1.4. NIS in thyroid cancer        
Of all human malignancies, thyroid cancer accounts for approximately one percent and is 
considered to be the most frequent endocrine malignancy (SI 2003). Out of various therapies 
for cancer, radioiodide therapy brings down the rate of recurrence and improves clinical 
outcome (Mazzaferri EL & SM 1994; Wartofsky L et al. 1998). For treatment of residual 
thyroid cancer, I131 is used for differentiated thyroid cancer which brings down the chances of 
recurrent cancer (Sawka et al. 2004). The ability of the NIS to uptake iodide and retain it in 
thyroid by organification is the basis for radioiodide therapy in clinical use. Thus NIS is 
used in the detection and targeted reduction of residual thyroid tumors in patients (EL 1999; 
Singer PA et al. 1996). Majority of the differentiated thyroid cancers has the ability to take up 
I131 because they express NIS. But, de-differentiated thyroid cancer poses a problem of no I131 
uptake as it has cold nodules (Kogai, Taki & Brent 2006). Apart from radioiodide uptake, the 
radioiodide also has to be accumulated, and this accumulation is the outcome of iodide influx 
and efflux. Due to dedifferentiation in some thyroid tumors, NIS expression/function is 
decreased and thus radioiodide therapy is rendered inactive (Jhiang SM et al. 1998; Ringel 
MD et al. 2001; Ryu KY et al. 1999).  In such cases the functional NIS expression has to be 
increased for effective radioiodide therapy. Functional NIS expression can be increased by 
increased levels of TSH (30U/L). A recent study reported recombinant human thyroid 
stimulating hormone (rhTSH) was used for enhancing the expression of functional NIS 
protein (Liu et al. 2011). This not only ensures radioiodide uptake but also stores iodide by 
increasing the thyroglobulin expression. However, many redifferentiating reagents like 
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Histone Deacetylase (HDAC) inhibitors, demethylating agents and retinoic acids are used to 
increase NIS expression and function in thyroid cancer cells (Kitazono et al. 2001). 
1.1.5. NIS in extra-thyroidal tissues 
NIS protein expression and NIS mediated radioiodide accumulation occurs not only in 
thyroid cells but also in few extra thyroidal cells (Figure 1.3) like salivary gland, gastric 
mucosa, lactating mammary gland, placenta and lacrimal glands (Cho JY et al. 2000; Jhiang 
SM et al. 1998; Josefsson M et al. 2002; Spitzweg C et al. 1999; Tazebay UH et al. 2000; 
Vayre L et al. 1999; Wapnir RA & S 2002). Though NIS is expressed functionally, these 
extra thyroidal cells can neither organify iodide for retaining the iodide nor the expressed NIS 
is responsive to TSH stimulation (N 1993). NIS is functionally expressed in the mammary 
gland during late pregnancy and lactation. The physiological importance of NIS expression in 
lactating mammary gland is to concentrate iodide in lactating milk for nursing newborns to 
synthesize their own thyroid hormone biosynthesis (N 1993). Like in mammary gland, hNIS 
is also expressed in salivary gland (Jhiang SM et al. 1998) and in gastric mucosa (Jhiang SM 
et al. 1998; Vayre L et al. 1999). The physiological significance of NIS expression in both 
salivary glands and stomach was suggested to be important for entero-thyroid circulation of 
iodide (Josefsson M et al. 2002).  As functional NIS is expressed in these extra thyroidal 
tissues, administration of radioactive iodide for thyroid cancer treatment can result in 
damaging side effects like gastritis, sialadentitis and xerostomia (Van Nostrand D, Neutze J 
& F 1986). A natural antimicrobial system called lactoperoxidase system producing H2O2, 
hypoiodite (IO-) with bactericidal activities, is also expressed in NIS-expressing extra 
thyroidal tissues (Bosch, Van Doorne & De Vries 2000).  
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Figure 1.3 Schematic representation of NIS expression detected in various normal cells 
and cancer cells.  
1.1.6. NIS as a reporter gene 
The first study used thyroid cancer cells at in vivo level to experiment the NIS transgene as a 
non-invasive molecular imaging tool (Shimura et al. 1997). Following this study, various 
studies were then performed with non-replicating adenovirus in cervical cancer (Boland et al. 
2000) and engineered oncolytic RNA virus in myeloma using NIS as an imaging gene (Dingli 
et al. 2004). Recent use of NIS as an imaging gene has been the focus of gene therapy 
research related to cardiovascular diseases. One of these studies showed that in NIS 
transfected hearts, imaging was possible using 99mTcO4 and I123 scintigraphy (Miyagawa et al. 
2005). Another group was able to quantify cardiac gene expression via micro-SPECT/CT 
imaging after NIS transfer in cardiac transplants (Ricci et al. 2008). NIS was also used as a 
reporter gene to track migration of immune cell like macrophage towards inflammation site 
(Seo et al. 2010). 
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1.1.7. NIS as a therapeutic gene                     
After the successful cloning of hNIS and the application of radioiodide in the treatment of 
thyroid cancer, many studies have stretched the use of NIS-mediated radioiodide therapy to 
non-thyroid cancers as well. Various studies have shown transfer of NIS gene to different 
cancer cells like colon cancer, breast cancer, glioma, melanoma, pancreatic cancer, 
myeloma, prostate cancer, ovarian cancer and follicular thyroid carcinoma (Boland A et al. 
2000; Dingli D, Russell SJ & 3rd 2003; Dwyer RM et al. 2006; Dwyer RM et al. 2005; 
Groot-Wassink T et al. 2002; Mandell RB, Mandell LZ & Jr 1999; Petrich T, Knapp WH & E 
2003 ; Shen DH et al. 2004; Sieger S et al. 2003; Spitzweg C et al. 2000). Transfecting NIS 
gene to cancer cells has to be specific in order to decrease the effect of radioiodide on the 
surrounding normal cells. For this reason, selective targeting of NIS to cancer cells was 
accomplished by using tissue specific promoters. Such selective targeting study was done in 
prostate adenocarcinoma LNCap cells, which were transfected with NIS gene driven by 
prostate-specific antigen (PSA) promoter. This resulted in prostate specific NIS expression,  
radioiodide accumulation and eventually an increased cancer cells specific cytotoxicity 
(Spitzweg C et al. 2000). In order to enhance iodide retention time in cells that have no NIS 
expression, thyroperoxidase (TPO) was co-expressed with NIS (Huang M et al. 2001). NIS as 
a therapeutic gene offers effective radioiodide therapy in thyroid as well as in non-thyroid 
cancers. Thus NIS with its diagnostic ability as well as with its therapeutic ability holds great 
possibilities in the clinical front.  
 Retinoblastoma  1.2.
Retinoblastoma (RB), a malignant tumor of the eye arising from the developing retina  is the 
most common primary intraocular malignancy of childhood (Figure 1.4). The estimated 
worldwide occurrence of RB is between 1 in 15,000 to 20,000 live birth children independent 
of ethnic group and sex (Broaddus E, Topham A & AD 2009; Suckling RD et al. 1982). In 
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most cases, diagnosis is made under the age of five years. In adults, RB is very rare but has 
been reported in certain cases (Biswas J et al. 2000). It is suggested that retinoblastoma 
diagnosed after childhood age develop from preexisting progenitor lesions. RB is the first 
disease in clinical history for which a genetic etiology of cancer has been described (Saxena 
P & J 2011). Furthermore, RB1 gene is also the first tumor suppressor gene to be identified 
(Jr 1971).  
 
 
Figure 1.4 Anatomical picture of an eye with retinoblastoma. 
RB picture (H&E stained) taken at the Ocular Pathology Laboratory, Sankara Nethralaya, 
India (Vandhana S et al. 2011) 
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1.2.1. Heritable versus non-heritable RB 
Majority of the patients (60%) develop RB in one eye only (unilateral RB) with occasional 
occurrence of multiple tumor foci (unilateral multifocal RB). In the rest 40% of the cases, 
both eyes are affected (bilateral RB) generally with more than one focus per eye (bilateral 
multifocal RB). In children, usually bilateral disease is diagnosed earlier than unilateral 
disease (Bishop JO & EC 1975). Biallelic RB1 gene inactivation has to occur for both 
heritable and non-heritable RB to develop. The first mutation (M1) of the RB1 gene is 
constitutional whereas the second mutation (M2) arise in somatic retinal cells, thus giving 
arise to heritable RB (Dimaras H et al. 2012). When both RB1 mutational events (M1 and 
M2) occur in one somatic retinal cell causing biallelic RB1 loss, it leads to the non-heritable 
RB (Figure 1.5). In addition to developing new tumors until retinal differentiation stops, such 
children are also at the risk of developing extraocular tumors throughout their lives (Eng C et 
al. 1993; Mohney BG et al. 1998; Wong FL et al. 1997). A person is prone to secondary 
cancers such as brain, skin, lungs if he/she carries a constitutional mutation of RB1 gene (Eng 
C et al. 1993) . Few cases of bilateral RB also develop as trilateral RB (pinealoblastoma). 
Trilateral RB arises at the pineal region of the brain and is associated with intracranial 
neuroblastic tumor (Kivelä 1999). Most of the unilateral RB cases are sporadic while 
majority of the bilateral RB cases are also sporadic and the remainder bilateral RB will have 
familial RB i.e., positive family history. Familial disease in a relative of children with RB is 
indicated by the presence of retinal scars or quiescent tumors (retinomas) which is identified 
by the examination of the fundus of the eye in all first degree relatives of children with RB 
(Gallie BL et al. 1982). 
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Figure 1.5 Genetics of heritable and non-heritable retinoblastoma. 
 Heritable RB occurs when both M1= constitutional RB1 mutation & M2=somatic RB1 
mutation occurs, whereas Non-heritable RB occurs when both the mutation occurs in the 
somatic cell. 
1.2.2. Genetics of retinoblastoma 
Occurrence of RB is explained by Knudson’s “two hit hypothesis” which points out that both 
copies of the RB1 gene has to be mutationally inactivated in the same developing retinoblast 
which would result in RB (Jr 1971; Knudson AG Jr, Hethcote HW & BW 1975) . In the 
hereditary form one copy of the RB1 gene is already mutated in the germ line and the next 
mutation i.e. “second hit” which occurs frequently during retinal development will inactivate 
the second copy of the RB1 gene. Another problem of the inherited mutation is that it is more 
likely to give rise to cancer in other tissues. When compared to hereditary form, somatic 
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mutations must occur in both alleles of the RB1 gene in the same retinoblast for 
nonhereditary RB. The RB1 gene which encodes for an important tumor suppressor protein is 
present on chromosome 13q14 and in normal conditions functions to inhibit cancer not only 
in the eye but also throughout the body (Bartek J, Bartkova J & J 1997; Friend SH et al. 
1986; Fung YK et al. 1987). It was found that though loss of RB1 gene can commence 
retinoma, it was inadequate for the growth of RB (Dimaras H et al. 2008). For the 
development of retinoma to RB, multiple genetic changes or mutational events like M3-Mn 
apart from mutation of both RB1 alleles (M1 and M2 mutation) is required (Corson TW & 
BL 2007; Dimaras H et al. 2008). The major genetic changes or mutational events that occurs 
are periodic gains and losses of chromosomes 1q,2p,6p and 13q,16p respectively which 
ultimately lead to RB (Corson TW & BL 2007). Recent studies have shown the correlation of 
RB1 gene mutational status with clinicopathological features of RB (Mohammad Javed Ali et 
al. 2010) and also its use in genetic counselling (Abidi et al. 2011). The other functions of 
RB1 gene apart from its involvement in RB development are management of important 
processes like miRNA regulation, DNA methylation and histone modification (Benetti R et 
al. 2008; Chi P, Allis CD & GG 2010; Lu J et al. 2007 ; Wen H et al. 2008 ). 
1.2.3. Diagnosis and classification 
Based on the location of the tumor, the signs of RB are leukocoria, strabismus, red eye, 
nystagmus (Abramson DH et al. 2003). Retinoblastoma has varying growth patterns with 
exophytic tumors growing into the subretinal space under the retina and endophytic tumors 
growing into the vitreous (Abramson DH et al. 2003). In 1960s, the Intraocular RB tumors 
were classified using Reese-Ellsworth (R-E) classification based on size and location of 
tumors (REESE AB & RM 1963). Later, international classification of retinoblastoma 
developed for intraocular tumors because of chemotherapy, which gave prominence on 
intraocular seeding (A 2005).  For extraocular tumors, International RB staging system was 
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proposed for uniform staging of patients with RB to cover disease’s entire (Chantada G et al. 
2006 ) (Table 1.1). 
 
Table 1.1 Classification of intraocular and extraocular Retinoblastoma 
Classification Stages 
Intraocular Group 1 Group 2 Group 3 Group 4 Group 5 
Reese-Ellsworth Small tumor less 
than 4 disc 
diameters 
Tumor size 
between 4-10 
disc diameter 
Tumor size 
larger than 10 
disc diameter 
Tumors larger 
than 10 disc 
diameter and 
extending 
anterior of the 
eye 
Tumors with vitreous 
seeding and covering 
more than half of the 
retina 
Intraocular Group A Group B Group C  Group D Group E 
International 
Classification of 
Intraocular 
Retinoblastoma 
Small tumors 
less than 3 mm 
Tumor size 
close to 3 mm 
Tumors with 
less vitreous 
and subretinal 
seeding 
Large tumors 
with more 
vitreous and 
subretinal 
seeding 
Large tumors with 
hemorrhage extending 
in front of the eye with 
very less chance of 
vision preservation 
Extraocular Stage 0 Stage I Stage II Stage III Stage IV 
International 
Retinoblastoma Staging 
System 
Includes patients 
treated 
conservatively 
Enucleated 
patients with 
complete 
resected intra-
ocular tumors 
Enucleated 
patients but 
with 
microscopic 
residual disease 
Includes 
patients with 
overt regional 
extension 
Includes patients with 
CNS disease 
 
1.2.4. Treatment and management 
Untreated RB tumors metastasizes via the optic nerve to central nervous system, through 
lymphatics to lymph nodes and through blood to bone marrow (Meel R, Radhakrishnan V & 
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S 2012). There are various treatments available for RB once the initial diagnosis has been 
done. These treatments mainly depend on various factors such as age of the child, tumor size, 
stage, localization, presence of vitreous seeds etc. The primary goal of treatment in RB 
management is child survival followed by saving vision and globe diagnosis at an early 
period helps in decreasing the mortality of the disease (Leander C et al. 2007). Currently, 
various treatments are available for RB which includes enucleation, laser photocoagulation, 
external beam radiotherapy, cryotherapy, brachytherapy and chemotherapy (Table 1.2 & 
1.3). Frequent follow up examinations are required even after successful treatment of RB. 
Retinoblastoma treatments are widely divided into three types. 1) Surgery 2) Chemotherapy 
and 3) Radiotherapy.  
 
Table 1.2 Table showing surgical treatments for retinoblastoma with its advantages and 
disadvantages  
Type of treatment Used for Advantages Disadvantages References 
Enucleation Advanced RB 
(Group E eyes) 
Prevents systemic 
metastasis 
Loss of vision (Wattiaux et al. 
2000) 
Thermotherapy Small tumors with 
no vitreous or 
subretinal seeds 
Provides complete 
regression of tumors 
Major complications like 
peripheral focal lens 
opacity and focal iris 
atrophy 
(Shields CL et al. 
1999 ) 
Cryotherapy Small anterior RB 
tumors 
Rapid necrosis of 
tumor tissue 
Increased risk of 
developing myopia, 
retinal detachment and 
shrinkage of sclera 
(Shields et al. 1989) 
Laser 
photocoagulation 
Small posterior 
RB tumors 
Acceptable option 
for selected 
intraocular tumors 
Retinal detachment and 
retinal ischaemia 
(Behr & Jean-Paul 
1997) 
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 Table 1.3 Table showing important non-surgical treatments for retinoblastoma with its 
advantages and disadvantages  
Type of treatment Used for Advantages Disadvantages References 
Systemic 
chemotherapy 
Group A/B 
retinoblastomas 
Reduces the risk of 
metastasis 
Not suitable for 
advanced tumors as it is 
non-responsive 
(Mintzer & Simanek 
2008; von Gersdorff 
et al. 2006) 
Intra-arterial 
chemotherapy* 
Less advanced 
cases of 
retinoblastoma 
Regression of 
subretinal seeds 
and vitreous seeds 
Mild complications like 
eyelash loss and 
forehead hyperemia 
(Abramson et al. 
2008) 
Brachytherapy Usually for 
intraocular 
melanoma, 
selective for 
retinoblastoma 
Effective in 
treating tumors 
with no vitreous or 
subretinal seeding 
Cataract and radiation 
retinopathy 
(Shields et al. 2001) 
External beam 
radiotherapy 
Large or multiple 
tumors unsuitable 
for other therapies 
Effective in 
preserving vision in 
eyes 
Facial deformity, 
retinopathy and 
neovascular glaucoma 
(Chan et al. 2009) 
 
* Carboplatin, Vincristine, Etoposide and Melphalan are mainly used 
1.2.5. Surgical treatments  
a) Enucleation: Enucleation is carried out for unilateral group E intraocular 
retinoblastoma and also in cases where chemotherapy has failed.  
b) Thermotherapy: Thermotherapy is a type of treatment where the tumor is relatively 
small and they are heated upto 42-60 degrees. Multiple techniques are followed for 
tumor ablation, whether it is ≤3 mm or greater than 3 mm resulting in regression in 
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86% of tumors (Shields CL et al. 1999 ). When the tumors are large, they require 
rigorous treatment resulting in ocular complications like lens opacity. 
c) Cryotherapy: In the cryotherapy treatment, tumors are subjected to -90°C and are 
allowed to freeze which causes crystal formation, cell rupture, and damage to vascular 
endothelium. Usually tumors that are less than 3 mm are used for this therapy and are 
cured completely (Abramson, Ellsworth & Rozakis 1982). No serious aftereffects 
apart from shrinkage of sclera and development of myopia are observed for this 
treatment (Shields et al. 1989). 
d) Laser photocoagulation: This technique is used for tumor upto 2 mm in height. Argon 
(532 nm) laser is used to coagulate blood supply to the tumor. At monthly intervals, 
multiple sessions of few seconds of 350 mW are given to coagulate the blood supply 
(Chawla, Jain & Azad 2013). The aftereffect of laser therapy is that it may lead to 
retinal ischemia (Murphree et al. 1996). 
1.2.6. Chemotherapy 
In advanced tumor cases, intravenous chemotherapy is used. To decrease the probability of 
trilateral RB in the cases of hereditary retinoblastoma, multiple infusions of chemotherapeutic 
drugs like carboplatin, vincristine and etoposide are administered (Villegas VM et al. 2013 ).  
Apart from the three main drugs, other chemotherapeutic drugs that are in use for RB 
treatment are cyclophosphamide, melphalan and thiotepa (Meel R, Radhakrishnan V & S 
2012). 
a) Neoadjuvant chemotherapy: Neoadjuvant chemotherapy is used to reduce the tumor 
bulk before going for radiotherapy or enucleation. Standard doses of vincristine 
etoposide and carboplatin are used for neoadjuvant chemotherapy and adjuvant 
chemotherapy (Meel R, Radhakrishnan V & S 2012).  
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b) Chemoreduction: Sufficient reduction in tumor demands atleast six cycles of 
chemotherapy. Anything less than six cycles results in recurrence of subretinal seeds 
and recurrence of tumor. A combinational treatment of chemotherapy and focal 
consolidation therapy has been reported to be more potent in tumor management than 
chemotherapy alone (Gombos DS et al. 2002; Rodriguez-Galindo C et al. 2003; 
Schefler AC et al. 2007 ; Shields CL et al. 2006 ; Shields CL et al. 2004).  
c) Periocular chemotherapy: Studies on local chemotherapy for treatment are necessary 
to overcome the systemic side-effects of systemic chemotherapy. Systemically 
administered drugs has limited entry to avascular structures like sub-retinal and 
vitreous spaces leading to recurrence of subretinal and vitreous seeds (Shields et al. 
2002). Studies have shown that locally delivering carboplatin to periocular structures 
in an aqueous solution had therapeutic effect in group C and D RB along with adverse 
effects (Kiratli, Kocabeyoğlu & Bilgiç 2007; Mulvihill et al. 2003; Schmack et al. 
2006). Currently clinical trials are on to deliver carboplatin to periocular space where 
there is a controlled release of the drug (Lin & O'Brien 2009; Van Quill et al. 2005). 
d) Intraarterial chemotherapy: Earlier  studies showed an encouraging outcome after 
injecting melphalan intraarterially in patients with vision stabilizing (Abramson et al. 
2008). But later studies cautioned about carcinogenic effects resulting from several 
sessions of intraarterial chemotherapy (Vijayakrishnan et al. 2010). In another study, 
intra-arterial chemotherapy, a local chemotherapy was performed with melphalan 
drug (Vajzovic LM et al. 2011). Though, there was tumor reduction in 75% eyes, it 
presented with adverse effects like myostitis, vitreous hemorrhages and high-risk 
characteristics (Vajzovic LM et al. 2010).  Another study with intra-vitreal 
administration of melphalan (Ghassemi F & CL 2012), showed better tumor control 
but the higher concentration (50µg) of melphalan caused hypotonia and phthisis bulbi.  
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1.2.7. Radiotherapy 
Radiotherapy is effective in treating RB as it is a radiosensitive tumor. 
a) Brachytherapy: Plaque or brachytherapy is known as internal radiation therapy 
usually performed for small tumors. Radioactive material is placed in a plaque made 
of gold or lead and the plaque is sewn near the tumor. Brachytherapy is not associated 
to the risk of secondary cancers (Shields et al. 2001). 
b) External Beam Radiotherapy (EBRT): EBRT is the most effective therapy in treating 
multiple tumors. Over a period of five weeks, a dose of 45 Gray is given to the 
patient. This treatment is associated with ocular damage and rise of secondary cancers 
(Roarty, McLean & Zimmerman 1988). However, in a recent study, EBRT has been 
termed as a highly potent therapy in controlling tumors and preserving vision (Chan et 
al. 2009). 
1.2.8. Targeted therapy - Potential pre-clinical application 
Although different treatments are available for RB, newer treatment modalities are always in 
demand which can overcome the side effects of the current treatments. Newer treatments 
include newer molecules exclusively expressed in RB which can be targeted for therapy. As a 
first report from our lab, in a cohort of 43 RB tumor samples, epithelial cell adhesion 
molecule (EpCAM) was found to be expressed in all the tumors (Krishnakumar S et al. 
2004), and this overexpression was then exploited for delivering an EpCAM siRNA via a 
gold nanoparticle coated with EpCAM antibody in RB cells (Mitra et al. 2013). More 
recently, the EpCAM molecule was targeted in another study in RB to deliver doxorubicin 
specifically to EpCAM positive cells thus inhibiting cellular proliferation (Subramanian et al. 
2012). In another study in RB, it was shown that overexpression of T-cell lymphoma invasion 
and metastasis 1(Tiam1) correlated with the invasion of the tumors (Adithi et al. 2006) and 
this was proved in a subsequent study where the silencing of Tiam1 in RB results in 
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modulation of cell invasion. This study thus provided evidence of using Tiam1 as one of the 
potential target for therapy (Subramanian et al. 2013). Another potential target explored in 
RB was High Mobility Group AT-hook 2 (HMGA2) (Venkatesan et al. 2009) and its 
silencing resulted in regulatory changes in RB cells thus showing a potential for targeted 
therapy (Venkatesan et al. 2012). Role of miRNA such as, miR 17-92 cluster in invasion was 
shown in RB and therefore it was suggested that targeting this particular cluster would benefit 
in the therapy of RB (Kandalam MM et al. 2012). A miRNA profiling of RB patients serum 
sample revealed important miRNAs involved in RB progression and it was thus inferred that 
their corresponding target genes could provide information about prospective biomarkers in 
RB (Beta et al. 2013).  
 Lactoferrin 1.3.
Lactoferrin (Lf) is a glycoprotein present in bodily secretions and plays a key role in natural 
defence of the body. It is a ~78-80 kDa single-chain iron binding multifunctional protein 
which regulates iron absorption in the intestine (Kanwar RK & JR 2013). Apart from 
regulating iron absorption, it also regulates immune responses, renders protection to the body 
against microbial infection and enhances intestinal cell growth (Kanwar et al. 2008). Bovine 
lactoferrin (bLf) from the milk is also reported to have anti-carcinogenic, anti-inflammatory, 
anti-microbial and immunomodulatory properties (Kanwar RK & JR 2013). Recent research 
on bLf has shown its potential to become one of the safest natural food for cancer therapy 
(Berlutti et al. 2011; Gibbons, Kanwar & Kanwar 2010; Kanwar et al. 2014; Tsuda et al. 
2010). 
1.3.1. Structure of Lf 
Lf protein consists of 690 amino acids and is folded into a homologous N and C terminal 
lobes each containing two domains namely N1& N2 and C1 & C2 respectively. The domains 
contain an iron-binding site and a glycosylation site (Baker & Baker 2005). The N lobe and C 
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lobe are joined by a unique 10-15 residue, alpha helical peptide (Figure 1.6). Lf also has 
strong binding affinity towards ferric ion (Fe3+) and carbonate ion (CO32-) which renders anti-
oxidant property to the molecule (Mulder et al. 2008).  
 
 
Figure 1.6 Structure of Lactoferrin 
A polypeptide chain showing two symmetrical lobes: N-lobe and C-lobe. The two lobes are 
connected via a hinge region containing α-helix which renders flexibility to the molecule. 
Within each lobe there are two domains depicted as N1, N2, C1 and C2 (García-Montoya et 
al. 2012).  
1.3.2. Forms of Lf 
Lf in its natural state has less iron content (around 15-20%) and this allows the molecule to 
strive for iron from outside its environment (Tsuda et al. 2004). There are three states of iron 
saturation for Lf 1) Apo-Lf which is iron free, 2) monoferric form of Lf containing only one 
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Fe3+ ion and 3) hololactoferrin form which is has two Fe3+ ions (Baker & Baker 2005; 
Kanwar RK & JR 2013). Lf has high affinity for iron mainly because of the presence of 4 
protein ligands which impart negative charges to bind Fe3+. To balance the binding of CO32- 
ion binding, an Arg side chain and a helix N-terminus is present. Apart from Fe3+ binding, Lf 
has affinity for various other metals like selenium (Se), Gallium (Ga3+) and Aluminium (Al3+) 
(Baker & Baker 2005). Lf is internalized into the cells via the lactoferrin receptors (LfR), 
transferrin receptors, and also the low-density lipoprotein receptor-related proteins −1 and −2 
(LRP1 and LRP2) (Naot et al. 2005). Fe-bLf nanocomplexes is shown to internalize via Lf, 
transferrin and LRP receptors in a recent study from our lab (Kanwar et al. 2014). 
1.3.3. Potential benefits of bLf in cancer medicine 
1.3.3.A. Anti-cancer effects 
bLf’s potential as an anti-cancer agent has been studied in various types of cancers both at in 
vitro as well as at in vivo level. In lung cancer, tumor suppression was observed in transgenic 
mice expressing hVEGF-A165 after oral administration of bLf at 300mg/kg of body weight 
for 6 weeks. Apart from the tumor suppression, level of tumor necrosis factor-α and other 
anti-inflammatory cytokines like IL-4 and IL-10 was significantly decreased after treatment 
with bLf (Tung et al. 2013). Similarly, in a murine model of squamous cell carcinoma and 
fibrosarcoma, bLf showed efficient reduction in tumor growth after direct administration to 
the tumors (Wolf et al. 2007). In colon carcinoma, combination of azoxymethane and bLf 
showed better treatment effect than azoxymethane alone (Tsuda et al. 1998). Apart from bLf, 
human Lf (hLf) treatment in breast cancer cells also showed effective growth arrest of cancer 
cells at G1 to S transition phase of the cell cycle (Damiens et al. 1999). Studies from our lab 
have established bLf as a natural product with anti-cancer effect in various cancer models 
(Gibbons, Kanwar & Kanwar 2010; Kanwar, Mahidhara & Kanwar 2012; Kanwar et al. 
2014). One report from our lab has shown that when different stages of iron saturated bLf 
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was administered to a C57BL/6 mice carrying tumor, the high iron content form of bLf 
showed higher activity in augmenting cancer chemotherapy (Kanwar et al. 2008). In another 
study, anti-oxidative effect of bLf was established in H2O2 exposed colon cancer cell line, 
HT29 when Apo-bLf and 100% Fe-bLf treatment showed an increase in antioxidant enzymes 
(Burrow, Kanwar & Kanwar 2011). Thus the above study proved the anti-oxidative effect of 
bLf in cancer. 
1.3.3.B. bLf as transcriptional activator 
Lf on binding to the cell surface enters inside the cell through Lf binding sites (LBS) and 
binds to the nucleus (Garré et al. 1992). There are specific LBS like GGCACTTGC which is 
known to activate the transcriptional activity of a reporter gene containing the sequence (He 
& Furmanski 1995). Out of the two domains of Lf, highly charged N-terminal domain is 
responsible for binding to DNA (Kanyshkova et al. 1999). There are other recent studies 
which report that the Lf after binding to nucleus induces changes at the genetic level such as 
modulating the activity of immune and epithelial cells (Gifford, Ishida & Vogel 2012). Lf is 
also considered to be a stimulator for cellular growth (Cornish et al. 2004). In a recent study 
from our lab, Fe-bLf was shown to possess therapeutic effect on mice for osteoarthritis by 
dissoluting calcium pyrophosphate crystals in joints thus proving anti-arthritic effect of Fe-
bLf (Samarasinghe, Kanwar & Kanwar 2014). 
 Breast cancer 1.4.
Breast cancer is a global disease affecting 1.38 million women per year worldwide (Ferlay et 
al. 2010). In India, the survival rate of breast cancer patients at 10 years is 77% (Dinshaw et 
al. 2005). In Australia, the chance of women developing breast cancer in their lifetime is 1 in 
8 ( Australian Institute of Health and Welfare & Cancer Australia 2012. Breast cancer in 
Australia: an overview  2012).  
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1.4.1. Risk factors 
Age primarily decides the incidence of occurrence of breast cancer among women. The rate 
of increase in breast cancer slows down after menopause which shows that it is hormone 
dependent. African Americans suffer from lower survival rate owing to the excessive rate of 
poorly differentiated tumors than the white population, thus making race or ethnicity as one 
of the determinants for higher risk for breast cancer (Libson & Lippman 2014). External 
factors also increase the risk of breast cancer. One of them is the hormone replacement 
therapy which doubled the risk of breast cancer when it was given along with progestin and 
oestrogen (Chlebowski et al. 2009). Exposure to radiation and alcohol consumption also 
increase the likelihood of breast cancer. Younger women are more prone to radiation related 
risk (Hancock, Tucker & Hoppe 1993) whereas increase in 10g/day of alcohol presents a 9% 
chance of breast cancer (Smith-Warner et al. 1998). 
1.4.2. Breast cancer therapy 
1.4.2.A. Surgery 
Ablation of breast and lymph nodes known as “Radical mastectomy” was practiced early in 
the 19th century which increased the survival rate but later in the 20th century, much benign 
method was practised where only a part of the breast was removed. Mastectomy leads to the 
complete removal of the breast which disfigured the body, and this problem was later on 
addressed via the breast conservation methods. In the breast conservation methods, only 
tumors were curtailed using neoadjuvant therapy and for tumors that do not respond to 
chemotherapy, oncoplastic surgery was practised (Fisher et al. 2002). 
1.4.2.B. Radiation 
Radiation therapy not only reduces the mortality rate but also decreases recurrence (Clarke et 
al. 2005). The overall survival in high risk patients after partial mastectomy increased with a 
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follow up of radiation therapy (Group 2011). Treatment with radiation is well planned and 
given in tangential angles to avoid short-term and long-term effects.  
1.4.3. Chemotherapy 
Breast cancer is a systemic disease and adjuvant therapy is given for patients where there is a 
chance of relapse. The drugs that are administered for chemotherapy are anthracycline based 
drugs, cyclophosphamide, methotrexate and fluorouracil (CMF) which decreased the 
mortality among breast cancer patients (Group 2012). Neo-adjuvant chemotherapy prior to 
surgery gives the advantage to assess the tumor in vivo, and also to curtail the size of the 
tumor thus enabling breast conservation. However, neoadjuvant therapy was found to have no 
effect on overall survival of patients (Wolmark et al. 2001). 
1.4.4. Targeted therapy 
The principle molecule in breast cancer which is targeted is human epidermal growth factor 
receptor 2 (HER2) because of its overexpression. In addition to chemotherapy, a monoclonal 
antibody, Trastuzumab targeting HER2 protein showed beneficial effects such as reducing 
the recurrence of the disease. Inspite of Trastuzumab reducing the recurrence by half, many 
patients still had progression in their disease. This unresponsiveness was because of the 
heterodimerisation of the HER2 members (Gajria & Chandarlapaty 2011). This dimerization 
was surpassed by introduction of another antibody called Pertuzumab (Libson & Lippman 
2014). Various tyrosine kinase inhibitors like lapatinib (Blackwell et al. 2010), neratinib and 
afatinib are also in use for the treatment of breast cancer (Libson & Lippman 2014). 
Recently, clinical trials of an antibody-drug conjugate of Trastuzumab and Mertansine 
showed promising results of progression free survival of patients (Verma et al. 2012).  
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1.4.5. After effects of breast cancer treatment 
Both radiotherapy and chemotherapy attributes to after effects in breast cancer. Radiotherapy 
is considered to be a better treatment in controlling locally progressed and early stage breast 
tumors but induces coronary artery disease. Earlier, high radiation treatment was given wide 
open to the entire chest area, but current radiation techniques are confined to a smaller 
portion of breast with little or no effects to the heart (Paszat et al. 1998). Congestive heart 
failure is the cardiovascular toxicity associated with the chemotherapy treatment. Treatment 
with the drug, Trastuzumab leads to cardiac malfunction but it becomes reversible once the 
administration is discontinued (Ewer et al. 2005). Another part of the body that chemotherapy 
affects is bone. In a trial premenopausal women who underwent chemotherapy for breast 
cancer was shown to have decreased bone mineral densitometry which increases the risk of 
fractures (Headley et al. 1998). Chemotherapy also affects the reproductive ability in women 
by exhausting the follicle pool in a dose dependent manner (Sonmezer & Oktay 2004). 
1.4.6. Triple negative breast cancer 
Triple negative breast cancer’s (TNBC) characteristics are under-expression of HER2 and 
absence of progesterone receptor (PR) and estrogen receptor (ER) (Schmadeka, Harmon & 
Singh 2014). In comparison to non-TNBC, the disease tend to metastasize quickly to central 
nervous system in TNBC patients (Rakha & Chan 2011). Around 75% of tumors from 
women with triple negative phenotype carries mutation in the BRCA1 gene (Foulkes, Smith 
& Reis-Filho 2010). The treatment options for TNBCs are limited as they are non-responsive 
even for the highly potent treatments given for non-TNBCs. Proliferative index of the TNBC 
tumors play a role in prognosis of disease as higher proliferation rate shows higher pathologic 
complete response (pCR) whereas lower pCR is associated with lower proliferation rate 
(Keam et al. 2011). Extensive studies on TNBCs have revealed subtypes such as Basal-like 
(BL), Immunomodulatory (IM), Mesenchymal (M) and Luminal Androgen Receptor (LAR) 
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with specific genes expression which may be targeted for therapy (Schmadeka, Harmon & 
Singh 2014). 
1.4.7. NIS based gene therapy  
As mentioned earlier in section 1.1.5, NIS is expressed in lactating mammary gland which 
eventually led to the discovery of NIS expression in more than 80% of breast cancer 
(Tazebay et al. 2000). Unlike membrane expression of NIS in lactating breast, NIS 
expression was more in the cytoplasm in the cancer tissues. Cysteinyl-tRNA synthetase 
gene was found to be associated with the membrane targeting of NIS in estrogen receptor 
positive breast cancer subtype. Thus, different genes could be responsible for membrane 
targeting of NIS in different subtypes of breast cancer (Beyer et al. 2011b). A study on 
TNBC’s revealed 65% of them showing a positive NIS expression (Renier et al. 2010). As 
radioiodine uptake of NIS is concerned, a recent study showed not only positive NIS gene 
expression but also radioiodine uptake by 50% of breast cancer tissues (Damle, Narkar & 
Badwe 2011). Out of twenty three metastatic breast cancer patients, eight showed NIS 
expression and two out of eight showed positive iodide uptake. This shows that only a 
fraction of breast cancer metastatic cases can accumulate iodine (Wapnir et al. 2004). NIS 
based gene therapy could be achieved only by introducing exogenous NIS gene for a 
significant iodide accumulation. Use of non-replicative adenovirus for NIS gene expression 
in BC cell line, MDA-MB-231 showed NIS gene expression as well as reduced survival 
post radioiodine administration (Riesco-Eizaguirre et al. 2011).  
 Epithelial Cell Adhesion Molecule (EpCAM) 1.5.
The EpCAM, a transmembrane glycoprotein first discovered in colon carcinoma (Herlyn M 
et al. 1979), is expressed in normal epithelium and over expressed in various cancers (Went 
PT et al. 2004). In normal epithelial cells, EpCAM is expressed on the basolateral side of the 
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membrane but in cancer cells, over expression across the membrane is observed (Yanamoto S 
et al. 2007). When compared to EpCAM in healthy epithelia, EpCAM expressed in cancer 
cells are in hyperglycosylated state (Munz M et al. 2008). It has a multitude of functions 
owing to its different localization. EpCAM was found to be strongly expressed in carcinomas 
of various origins, including colon and rectum (Herlyn M et al. 1979), prostate (Poczatek RB 
et al. 1999; Zhang S et al. 1998), liver (de Boer CJ et al. 1999; Ruck P et al. 2000; Sansonno 
D & F 1993), esophagus (Kumble S et al. 1996; Martin IG et al. 1999), lung (Kubuschok B et 
al. 1999; Piyathilake CJ et al. 2000), head and neck (Takes RP et al. 1997 ), pancreas (Szala S 
et al. 1990) and breast (Edwards DP et al. 1986).  
1.5.1. EpCAM-discovery and function 
EpCAM had been discovered multiple times by different groups independently and with each 
discovery it received the name of the respective monoclonal antibody or cDNA clone used. 
Various synonyms of EpCAM are Epithelial GlycoProtein-2 (EGP- 2), Epithelial Specific 
Antigen (ESA), GA733-2 and Tumor-Associated Calcium Signal Transducer 1 (TACSTD1) 
(Okegawa T et al. 2004). EpCAM mainly has three domains which are extracellular domain 
(EpEX), a single transmembrane domain and an intracellular domain (EpICD) (Okegawa T et 
al. 2004). The extracellular domain inturn contains three domains which are epidermal 
growth factor like (EGF) domain, a thyroglobulin repeat domain and a cysteine-poor domain 
(Figure 1.7).  
  
                                                                                                                                      Chapter 1 
39 
 
 
 Figure 1.7 Protein structure of EpCAM 
EpCAM protein structure is shown as a tetramer. The N-terminus is located extracellularly 
and C-terminus is located intracellularly. The polypeptide chain is depicted as a bent loop 
within TY domain positioning the EGF-like domain towards the plasma membrane. The red 
arrows depict the cleavage sites for two proteases which releases the intracellular region. 
Figure adapted from (Baeuerle PA & O 2007). 
 
One of the basic functions in multicellular organisms is cell to cell interaction and cell 
adhesion molecules (CAMs) are necessary for this process. Apart from cell adhesion, CAMs 
are involved in various other processes like cell migration, signaling, cell cycle and 
morphogenesis (Litvinov SV et al. 1997). Cell adhesion is crucial in regulating various 
cellular functions including contact-inhibition (Craig & Brady-Kalnay 2011) which plays a 
critical role in organogenesis (Fagotto & Gumbiner 1996). There are basically four CAM 
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families: the cadherins, the selectins, the integrins and the immunoglobulin CAM 
superfamily. EpCAM which was reported by different groups independently does not fall 
under any of the four families.  When compared to other CAMs which are expressed in 
almost all normal tissues, EpCAM expression is limited to only epithelial cells. Since in the 
early days of EpCAM discovery its function was associated only with cell adhesion, it was 
proposed that EpCAM is a CAM (Basak S et al. 1998). However recent work on EpCAM has 
revealed its role in many other processes such as cell migration, signaling, differentiation and 
proliferation apart from cell adhesion. In addition to this being a biomarker, EpCAM has a 
regulatory function at morphological level in stem cells/progenitor cells (Schnell, Cirulli & 
Giepmans 2013). Differential glycosylation is considered to be one of the elements for altered 
functions of EpCAM in malignant cells compared to normal cells. In human, EpCAM has 
three N-glycosylation sites, Asn198, Asn111 and Asn74 (Schön et al. 1993; Thampoe, Ng & 
Lloyd 1988). Among the three, Asn198 is important of all as its glycosylation is linked with 
protein stability and expression at the cell surface (Munz et al. 2007). Moreover, the half-life 
of the protein decreased to 7 h from 21 h on removal of all the three glycosylation sites 
establishing the importance of the post-translational modification (Schnell, Cirulli & 
Giepmans 2013). Such differential glycosylation in cancer compared to normal epithelia has 
been reported in various molecules such as E-cadherin and integrins (Hakomori 1996; Pinho 
et al. 2011). While EpCAM was considered as an adhesion molecule, in comparison to E-
cadherin, it had a reduced adhesion property (Litvinov et al. 1994). Interestingly, a study 
showed that when both EpCAM and E-cadherin were co-expressed, EpCAM interrupted E-
cadherin association with the cytoskeleton thus weakening the adhesion property of E-
cadherin (Litvinov et al. 1997).          
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1.5.2. EpCAM gene              
The EpCAM gene is present on the chromosome 2p21 with a total of nine exons and is 
approximately of the size 14 kb (Calabrese G et al. 2001; Linnenbach AJ et al. 1993). 
EpCAM is conserved across many species not only at gene level but also at protein level 
among man, mouse and gorilla (Schnell, Cirulli & Giepmans 2013). The mRNA is around 1.5 
kb and all the reported open reading frames encode a protein of 314 aminoacids (Perez MS & 
LE 1989). Mutations in EpCAM gene have been reported in Lynch syndrome and congenital 
tufting enteropathy with different germLine deletions are the cause in disrupting the 3’end of 
the EpCAM gene in Lynch syndrome (Ligtenberg MJ et al. 2009), then in congenital tufting 
enteropathy it’s the four different mutations that cause decreased expression of EpCAM 
protein (Al-Mayouf SM et al. 2009; Sivagnanam M et al. 2008; Sivagnanam M et al. 2010). 
Another study showed that the primary cause of uncontrollable diarrhea in infants to be 
associated with mutations in the EpCAM gene (Sivagnanam M et al. 2008). Cloning and 
characterization of EpCAM promoter has been done (Gires O et al. 2003; Gires O et al. 2004; 
McLaughlin PM et al. 2004) and the promoter activity has been restricted to EpCAM 
expressing cells (Baeuerle PA & O 2007; McLaughlin PM et al. 2004). The specific 
expression of EpCAM is contributed by the region 687 to 341bp which is upstream of the 
transcription start site (TSS) (McLaughlin PM et al. 2004). The amount of EpCAM 
expression is directly related to the transcriptional activity of a 1.1 kb EpCAM fragment 
upstream of TSS (Gires O et al. 2004). Moreover it was reported that only 177 bp of the 5’ 
flanking sequence is required to drive reporter gene expression (McLaughlin PM et al. 2004).  
1.5.3. EpCAM signaling 
Regulated intracellular membrane proteolysis (RIP) is a conserved mechanism in 
transmembrane proteins where ectodomain is shed after the ligand induction followed by the 
shedding of the intracellular domain (Brown et al. 2000). RIP is shown to be involved in the 
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EpCAM induced proliferation and the proteases associated with it are metalloprotease 
ADAM17 also known as TACE (Tumor necrosis factor-α-converting enzyme) and γ-
secretase containing PS-2 (Maetzel et al. 2009). EpCAM is an oncogenic signaling molecule 
involving the Wnt/β-catenin pathway, thus promoting cell invasion (Yamashita T et al. 2009). 
β-catenin is accumulated in the cell in the presence of Wnt signaling, interacts and activates 
various genes like c-myc, vascular endothelial growth factor which are involved in 
carcinogenesis (Huelsken & Behrens 2002). Several other possible proteolytic pathways have 
been suggested which regulates EpCAM signaling thus controlling EpCAM’s numerous 
functions (Schnell, Kuipers & Giepmans 2013). 
1.5.4. EpCAM in cancer 
There are various studies that contradicts EpCAM’s role in cancers. Earlier it was shown that 
when EpCAM cDNA was transfected into murine colorectal carcinoma cells, there was a 
decrease in tumor incidence and metastasis (Edwards DP et al. 1986). In contrast, later on 
other studies showed that either silencing of EpCAM using siRNA or inducing expression of 
EpCAM in HEK293 cells causes either decreased invasion of cancer (Osta WA et al. 2004; 
Yamashita T et al. 2009; Yanamoto S et al. 2007) or enhanced colony formation and 
metabolism (Münz M et al. 2004) respectively. EpCAM is also reported as a marker for 
various cancer initiating stem cells. For instance both EpCAM positive hepatocellular 
carcinoma stem cells and EpCAM positive pancreatic cancer stem cells showed potential to 
initiate tumors (Yamashita T et al. 2009). EpCAM expression in tumors has been correlated 
with improved clinical outcomes only in few cases. Improved patient survival in renal clear 
cell carcinoma was associated with high EpCAM expression in primary tumor (Klatte T et al. 
2009; Seligson DB et al. 2004). Likewise in thyroid carcinoma, high EpCAM expression in 
tumors was associated with improved survival of the patient (Ensinger C et al. 2006; Ralhan 
R et al. 2010).Various studies indicating the contribution of  EpCAM towards promoting 
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carcinogenesis have also been reported. High EpCAM expression was associated with 
decreased survival and large tumors in breast cancers (Gastl G 2000; Spizzo G et al. 2004). 
EpCAM expression increased proportionally from low grade to high grade intraepithelial 
neoplasia in cervical squamous epithelia (Litvinov SV et al. 1996). Similarly in prostate 
cancer, EpCAM expression increased from normal via prostatic intraepithelial neoplasia to 
adenocarcinoma (Poczatek RB et al. 1999). 
 
In the case of head and neck squamous cell carcinoma, inconsistent connection of EpCAM is 
mainly attributed to the heterogeneity of tumors (Laimer et al. 2008). In certain group of 
esophageal cancer patients, high survival rate was related to high EpCAM expression 
(Rossen K & HK 2001) whereas one research group found EpCAM to be involved in 
decreased survival. There are certain groups who found no such correlations with grade of the 
tumors (Stoecklein NH et al. 2006). Similarly no differences in EpCAM expression were 
found among different grades of epithelial ovarian cancer. In another study on stomach, lung 
and prostate cancer, EpCAM expression had no significant correlation with any of the tumor 
properties or survival (Went P 2006). But another study in epithelial ovarian cancer, reveals 
differences among different histological subtypes and that overexpression is directly related 
to decreased overall survival of the patient (Spizzo G et al. 2006). The basic problem for such 
contradictions in the role of EpCAM lies in the use of different monoclonal antibodies and 
different scoring methods while analyzing tumors. Nonetheless the part of EpCAM in 
carcinogenesis cannot be overlooked.  
1.5.5. Therapy based on EpCAM 
Using EpCAM, vaccination strategies have been developed: 1) fragment of EpCAM-specific 
antibody combined with TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) 
(Bremer E et al. 2004 ; Bremer et al. 2004; Mosolits et al. 2004) and 2) toxin fused with 
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EpCAM antibody fragments (Di Paolo et al. 2003; Flatmark et al. 2013). One of the 
monoclonal antibodies, adecatumumab in combination with taxotere is currently under 
clinical trials for prostate cancer (Marschner et al. 2010) is a human IgG of intermediate 
affinity and is showing encouraging results (Schmidt et al. 2012). A bispecific antibody 
called Catumaxomab (Removab®); anti-EpCAM mouse-rat hybrid was developed and was 
used in EpCAM positive patients to treat malignant ascites. But, the treated patients produced 
antibodies against the bispecific antibody in a Phase II study (Ruf et al. 2010; Sebastian et al. 
2007; Zeidler et al. 1999). EpCAM aptamer based therapy showed some promise when it was 
experimented on multiple tumor cell lines and resulted in rapid internalization and renal 
clearance (Shigdar et al. 2011). However, more studies have to be performed before it can be 
considered as a viable option. 
 Another way of EpCAM based therapy was to generate immunoliposomes or nanoparticle 
which were loaded with anti-cancer drugs and coated with EpCAM specific ligand to show 
high therapeutic index. A study on immunolipososmes loaded with doxorubicin coated with 
anti-EpCAM fragment, scFv 4D5MOCB showed good tumor localization. But such high 
localization was also observed in non-targeted liposomes owing to enhanced permeability 
and retention effect (Hussain et al. 2007; Maeda et al. 2000). In the case of EpCAM targeted 
nanoparticle loaded with paclitaxel for treating retinoblastoma cells, a study from our 
laboratory showed higher specificity and moderate uptake (Mitra et al. 2011). In another 
study from our laboratory targeting EpCAM, showed conjugate of EpCAM aptamer and 
doxorubicin to deliver the drug selectively to RB cells (Subramanian et al. 2012). In a recent 
study, anti-EpCAM fusion toxin was developed using bioorthogonal click chemistry for 
tumor targeting which reported a better therapeutic execution (Simon et al. 2013). 
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 Survivin 1.6.
Survivin has been extensively studied and considered to be a quintessential target for cancer 
therapy. One of the many reasons for it to be considered to be an ideal target is its over 
expression in cancer cells and its role in blocking the apoptosis (Altieri 2003a; Kanwar et al. 
2001; Samarasinghe et al. 2012).  Apart from its role in apoptosis inhibition it also plays a 
major role in regulating cell division in normal cells (Johnson & Howerth 2004). Reports 
from our laboratory and others have shown that survivin is involved in a number of 
downstream signaling cascade mechanisms which enhance cancer proliferation (Kanwar, 
Kamalapuram & Kanwar 2011).  
1.6.1. Structure and function 
Survivin belongs to the inhibitor of apoptosis protein (IAP) family and is the smallest 
member of the IAP family with survivin gene encoding a 16.5 kDa protein.  The protein 
contains only one Baculovirus IAP repeat (BIR) domain which is at the N-terminal and has 
an amphipathic C-terminal-helix (Chantalat et al. 2000). The main function of survivin in 
normal cells is in mitosis and the chromosomal passenger complex (CPC) which regulates 
mitosis contains survivin apart from Aurora B kinase, INCENP and Borealin (Altieri 2010; 
Baratchi, Kanwar & Kanwar 2010; Coumar et al. 2013) (Figure 1.8). In cancers, survivin 
functions by inhibiting the programmed cell death (Rudin et al. 2012) via inhibition of 
caspase-3 and caspase-7. The inhibition could be either direct mechanism where the survivin 
binds to caspases or indirect inhibition where survivin binds to XIAP, another member of 
IAP to form a complex which prevents activation of caspases (Dohi et al. 2004).  Recent 
study revealed that survivin expression regulates autophagy in a way that up-regulation of 
survivin completely inhibits autophagy process (Wang et al. 2011).  
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Figure 1.8 Schematic representation of survivin protein. 
The Baculovirus IAP repeat (BIR) domain and coiled coil domain are depicted along with 
nuclear export signal (NES). The functional domains are the phosphorylation sites at Thr 34, 
Thr 117 and Ser 20. The protein partners for survivin are Aurora B, INCENP, Borealin, 
Smac/Diablo and Hsp90 are also depicted (Pennati, Folini & Zaffaroni 2008).  
1.6.2. Splice variants of survivin 
Alternative splicing is a process which generates distinct protein isoforms from a common 
mRNA precursor (Schwerk & Schulze-Osthoff 2005). Splice variants of survivin are with 
definite functions of their own and are also conserved among species from which it can be 
comprehended that they possess a role in the apoptotic machinery of survivin (Wenzel et al. 
2000). In humans, six splice variants have been reported and they are Survivin-WT, Survivin-
2α, Survivin-2β, Survivin-3α, Survivin-3β and Survivin-ΔEx3 (Huang et al. 2011b) (Figure 
1.9). The protein arising from the variants have similar N-terminal sequence, Baculovirus 
IAP repeat (BIR) domain but a different C-terminal region. Specific residues that are 
conserved within the BIR domain among the splice variants are S20 which is key in 
maintaining the survivin and XIAP binding and its phosphorylation disrupts the antiapoptotic 
properties (Dohi, Xia & Altieri 2007). Second residue that is shared by the variants is T34, 
dephosphorylation of this residue initiates mitochondrial apoptotic pathway (O'Connor et al. 
2000).  Other common residues among the variants that have been reported are T48 (Barrett, 
Colnaghi & Wheatley 2011), L64 (Sun et al. 2005) and D71(Song, Yao & Wu 2003), which 
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are all involved in the anti-apoptotic functions. Out of all variants, only two splice variants 2β 
and 3β share sequence identity in the carboxyl domain with the wild type survivin 
(Necochea-Campion et al. 2013). Survivin homodimerises and the splice variants modulates 
its activity by forming heterodimers (Caldas, Honsey & Altura 2005).  
 
Figure 1.9 Schematic illustration of 6 survivin splice variants containing common exon 1 
and exon 2.  
1.6.2.A. Survivin-WT  
The wild type survivin contains 4 exons, a 426 bp transcript translated into a 142 aminoacids 
(Caldas, Honsey & Altura 2005). The localization of Survivin-WT is in the mitochondria of 
cancer cells which shows a role in pathogenesis of tumor (Jha et al. 2012) .  
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1.6.2.B. Survivin-2α 
Survivin 2α is formed by the addition of 197 bp from intron 2 but only two nucleotides are 
coding as it has an early stop codon giving rise to shortest survivin variant. When compared 
to normal cells, Survivin 2α expression is as high as 95 times in lung cancer, colorectal 
cancer and 150 times in medulloblastoma (Caldas, Honsey & Altura 2005). This elevated 
expression in cancers is correlated with poor survival outcome and drug resistance (Span et 
al. 2006).  
1.6.2.C. Survivin-2β 
This splice variant is derived by the introduction of 69 bp nucleotide fragment from intron 2 
(Mahotka et al. 1999). Survivin 2β expression and its link to clinicopathological features have 
been controversial due to contradictory reports. While few studies in colorectal carcinoma 
and astrocytoma have reported that upregulation in survivin 2β expression is correlated to 
worse survival outcomes (Antonacopoulou et al. 2010; Huang et al. 2011b) , whereas other 
studies on the same cancers have reported expression of survivin 2β to be associated with 
positive outcomes (Yamada et al. 2003). In various other cancers, positive and negative 
correlation of survivin 2β expression has been drawn out with clinical stages and survival 
outcome, thus making survivin 2β as one of the most contradicted splice variants (Necochea-
Campion et al. 2013).  
1.6.2.D. Survivin-3α 
Introduction of 209 bp from intron 2 generates survivin 3α (Huang et al. 2011b). The status 
of survivin 3α in cancer is not much studied. In one of the studies in neoplasms of brain, 
survivin 3α was not detetected (Huang et al. 2011b). A recent study on breast cancer 
suggested a possible role of survivin 3α in tumor development because survivin 3α was 
absent in normal breast tissues whereas it was detected in breast tumors (Moniri Javadhesari 
et al. 2013). 
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1.6.2.E. Survivin-3β 
Survivin 3β is generated on the introduction of 165 bp nucleotide fragment from intron 3 
(Badran et al. 2004). The expression of survivin 3β in cancers is not as high as the other 
variants’s expression in cancers. A study in oral squamous cell carcinoma showed a slight 
increase in survivin 3β expression compared to normal mucosa but it did not mount up to 
statistically significant (De Maria et al. 2009). In colorectal cancers, studies did show 
statistically significant higher levels of survivin 3β expression, but it did not correlate with 
the clincopathological features of the tumors (Antonacopoulou et al. 2010). However in 
breast cancer though, higher expression of survivin 3β was associated with decreased survival 
(Span et al. 2006).  
1.6.2.F. Survivin-ΔEx3 
Survivin ΔEx3 is created by deletion of 102 bp of exon 3 and a frameshift (Mahotka et al. 
1999) . It is one of the splice variants that have been discovered early. Its expression and its 
significance in the prognosis of the disease have been studied in various cancers. In majority 
of the cancers studied like breast (Span et al. 2006),  cervical (Futakuchi et al. 2007) and 
thyroid (Vandghanooni et al. 2011), expression of ΔEx3 have been elevated in cancer tissues 
when compared to normal tissues.  The higher expression has been associated with advanced 
tumor grade and stages in prostate cancer (Lopergolo et al. 2012), breast cancer (Span et al. 
2006) and glioblastoma (Lopergolo et al. 2012). Survivin ΔEx3 localises in the nucleus 
because of the nuclear localization signal (NLS) found in the sequence which also helps in 
removing cytoplasmic survivin ΔEx3 (Mahotka et al. 2002b). The subcellular localization of 
survivin ΔEx3 was found to be in the mitochondria and this mitochondrial accumulation was 
responsible for inhibition of mitochondrial mediated apoptosis in cancers. Inhibition of 
apoptosis is via the binding of survivin ΔEx3 with apoptotic molecule, Bcl-2 with the help of 
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a BH2 domain (Caldas et al. 2005). A recent study showed that survivin ΔEx3 is involved in 
angiogenesis and regulation in endothelial cell homeostasis (Caldas et al. 2007). 
1.6.3. Survivin as a target for therapy 
Survivin is considered as a prime target for cancer therapy mainly because of its high 
turnover rate and selective expression in cancers (Altieri 2013; Kanwar et al. 2001; Morrison 
et al. 2011). Antisense nucleotides were the first rival molecules used against survivin. 
LY2181308 and locked nuclei acid oligonucleotides were synthesized and these molecules 
showed encouraging anti-cancer activity and safety (Hansen et al. 2008; Molckovsky & Siu 
2008). Blocking survivin expression in lymphoma generated the activity of cytotoxic T-
lymphocyte and made the tumors susceptible to B7-1-mediated immunotherapy (Mao et al. 
2006). RNA interference mechanism was introduced in targeting survivin to decrease 
survivin at mRNA and protein level. In in vivo studies, survivin gene silencing resulted in 
promising results (Davis et al. 2010). In a recent study on breast cancer, targeting both 
survivin WT and survivin ΔEx3 proved to be comprehensive strategy as promotion in 
proliferation and apoptosis was observed (Zheng et al. 2011). Although, survivin is stabilized 
by molecular chaperone Hsp90, inhibition of either of the molecules individually does not 
mount upto therapeutic value but its dual inhibition has the potential of targeted therapy 
(Kunath et al. 2003a). Multiple survivin dominant mutants have been used to target survivin 
in cancer. T34A dominant mutant of survivin was shown to enhance the sensitivity of 
cisplatin and doxorubicin in breast cancer cells (Xu et al. 2012). Another survivin mutant, 
C84A mutant fused to cell-penetrating poly-arginine peptide has shown to induce apoptosis 
in cancer cells (Cheung et al. 2010; Kanwar et al. 2001). A combination of both T34A and 
C84A mutants have shown to have powerful killing of cancer cells than when these were 
used alone (Zhang et al. 2008). From our lab, a mutant form of survivin, SurR9-C84A have 
been shown in a study where it enhances the expression of neuronal and cell cycle markers in 
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differentiated neurons along with increasing the cell viability (Baratchi et al. 2010). In 
another recent study from our lab, Fe-bLf in nanoformulation was shown to target survivin in 
colon cancer stem cells thus inducing apoptosis by activating both extrinsic and intrinsic 
pathways (Kanwar et al. 2014).  
 Bcl-2 family 1.7.
Bcl-2 gene (B-cell lymphoma 2) was discovered in follicular B-cell lymphoma gene. This 
gene is present on the chromosome 18q21.3 and its translated product was involved in 
inhibition of cell death (Tsujimoto & Croce 1986). Apoptotic pathways are divided into two 
1) intrinsic pathway and 2) extrinsic pathway (Figure 1.10). The intrinsic pathway is 
regulated by the Bcl-2 family of proteins, and is stimulated by various activities within the 
cell like cytokine deprivation, cytotoxic drugs and radiation (Cory & Adams 2002; Pickering 
et al. 2006). From the permeabilized mitochondria, cytochrome c releases first which binds to 
APAF-1 and activates procaspase to caspase 9, which then stimulate a multitude of caspases 
activation leading to apoptosis. The extrinsic pathway is induced by the activation of CD95, 
TNF-related apoptosis inducing ligand (TRAIL), Tumor necrosis factor receptor 1 family 
proteins which in turn triggers the caspase cascade by enrolling caspase-8 (Walczak & 
Krammer 2000). In human, approximately 17 Bcl-2 proteins have been identified and each 
characterized with 4 regions of sequence homology known as Bcl-2 homology (BH) 
domains. All the Bcl-2 members share atleast one of the BH domains. The members of the 
Bcl-2 family are classified into three groups (Dewson & Kluck 2010). 
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Figure 1.10 Schematic representation of molecular pathways of apoptosis. 
Extrinsic pathway depicts the DISC complex formation and caspase 8 activation. Intrinsic 
pathway depicts the release of cytochrome c from mitochondria which activates caspase 9. 
Caspase 3 is then activated by both caspase 8 and 9 which leads ultimately to death of the 
cell (Favaloro et al. 2012). 
  
                                                                                                                                      Chapter 1 
53 
 
1.7.1. Anti-apoptotic members of Bcl-2 family 
The anti-apoptotic members of this sub-family are Bcl-2, Bcl-xl, Bcl-w and induced myeloid 
leukemia cell differentiation (Mcl-1) proteins. The characteristic of these members are they 
have all the four BH domains including a hydrophobic C terminal part. The difference 
between anti-apoptotic and pro-apoptotic members are the absence of BH4 domain in pro-
apoptotic members which may be responsible for the anti-apoptotic activity (Khemtémourian 
et al. 2006). Bcl-2 is present on the mitochondrial membrane and confers a protective effect 
on mitochondria by preserving the membrane integrity, thus inhibiting apoptosis to occur. 
Bcl-2 exhibits anti-apoptotic activity mainly in three ways. First method is by inhibiting the 
oligomerization of Bax/Bak, thus blocking the release of apoptosis inducing molecules. 
Second is by inactivating Bax by binding to it, thereby inhibiting apoptosis. Third method is 
by preventing the activation of caspase-9 by directly blocking the release of cytochrome c. 
Likewise, Bcl-xl through BH3 domains of Bax and Bak interacts with them and prevents 
apoptosis (Khemtémourian et al. 2006; Simonen, Keller & Heim 1997). Mcl-1 on the other 
hand is a protein with quick turnover and regulates cell survival by involving in the 
development of T and B lymphocytes (Yang-Yen & Hsin-Fang 2006).  
1.7.2. Pro-apoptotic members of Bcl-2 family 
Bax, Bak and Bok are the main pro-apoptotic members and they have similar sequences in all 
domains except BH4 domain which is absent (Reed 2006). Since Bax does not possess a clear 
BH3 domain, it is prone to activation by P53. During apoptosis, Bax protein oligomerizes 
after integration with the mitochondria leading to the release of cytochrome c and stimulation 
of caspases (Petros, Olejniczak & Fesik 2004). Similarly, during apoptosis Bak also 
oligomerizes after integration with the mitochondria (Chipuk et al. 2004).   
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1.7.3. BH3-only members 
The members of this family are BH3 interacting domain (Bid), Bcl-2-associated death 
promoter (Bad), Bcl-2-interacting killer (Bik), BCL-2-interacting mediator of cell death ( 
Bim), Bcl-2-modifying factor (Bmf), Harakiri (Hrk),  (death inducer binding to vBcl-2 
and apoptosis-activating factor, APAF-1) Diva, phorbol-12-myristate-13-acetate-induced 
protein  1 (PMAIP1; also known as NOXA) and p53 upregulated modulator 
of apoptosis (Puma). The entire above mentioned are pro-apoptotic molecules with only BH3 
domains as common. These members are activated by various cellular processes like 
phosphorylation, transcriptional upregulation and truncation (Zha et al. 1996). BH3-only 
proteins have a characteristic dual function, where it regulates Bcl-2 family members both 
positively and negatively. Bid is the most studied molecule and it is involved in the intrinsic 
pathway by linking death receptors to mitochondrial amplification loop. Bid with its strong 
pro-apoptotic activity targets mitochondria and it activates Bax and Bak. The rationale behind 
Bid’s pro-apoptotic activity is its subcellular localization (Zinkel, Gross & Yang 2006). 
Phosphorylation activates Bim and Bmf whereas dephosphorylation releases Bad molecule. 
Caspases cleaves Bad molecule when transforming growth factor β1 induces apoptosis (Zhu 
et al. 2002). Bim along with Bid are the only BH3 members which releases cytochrome c 
from mitochondria (Kuwana et al. 2005).  
1.7.4. Bcl-2 in cancer and therapy 
Trademark of cancers is the inhibition of apoptosis and overexpression of Bcl-2 has been 
shown in number of cancers. Few cellular processes that induce the Bcl-2 overexpression are 
DNA hypermethylation, chromosomal translocation and deregulation of miRNAs specific for 
Bcl-2 (Strasser et al. 1990). Various strategies to counteract Bcl-2 overexpression in cancer 
have been practiced. The first drug to target Bcl-2 mRNA was Oblimersen sodium, an 
antisense oligonucleotide. Though initial preclinical and clinical studies were successful, it 
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failed subsequently because of increased expression of other Bcl-2 members (Marcucci et al. 
2003). Another therapeutic molecule was ABT-737, which was a mimic of Bad bound with 
great affinity to Bcl2, Bcl-xl and Bcl-w (Lee et al. 2007a). The mimic, ABT-737 showed 
appreciable positive outcome in the preclinical studies (Tse et al. 2008). However, clinical 
trials in small cell lung cancer patients, ABT-263, an oral derivative of ABT-737 showed a 
disappointing overall response rate (Rudin et al. 2012).  
1.7.5. Bax in cancer and as a biomarker 
Bcl-2-associated X (Bax) protein was the first pro-apoptotic member to be discovered among 
the Bcl2 family. As a result of alternative splicing, Bax gene generates four variants, namely 
Bax α, β, Δ and Σ. Bax is considered as one of the futuristic biomarker related to apoptosis 
(Zhou et al. 1998). Regulation of apoptosis relies on the amount of homodimerisation or 
heterodimerisation of Bax and Bcl-2 in the cell. Increased sensitivity to drugs is attained 
when there is an increased amount of Bax/Bax homdimers in the cell (Toshiyuki & Reed 
1995). Several cancers like breast, lung and ovary have analyzed the possibility of Bax being 
a predictive biomarker (Krajewski et al. 1995; Kupryjańczyk et al. 2003). It was found in a 
study that loss of Bax function in a gastrointestinal cancer tissue led to the progression of 
cancer (Duval & Hamelin 2002). Another study with colorectal carcinoma showed that 
patients who lacked Bax expression had 5.33 times higher mortality rate than the patients 
with high Bax expression (Katkoori et al. 2010). A recent research conducted in oral 
squamous cell carcinoma, concluded that high expression of Bax was significantly associated 
with increased proliferation leading to an increased response to radiotherapy (Bose et al. 
2012).  
 Polyethyleneimine: A potent non-viral vehicle for gene delivery 1.8.
Polyethylenimine (PEI), a cationic polymer, has been used as an efficient nonviral vector for 
gene delivery both in vitro as well as in vivo (Clamme, Azoulay & Mély 2003; Fischer et al. 
                                                                                                                                      Chapter 1 
56 
 
1999; Kichler et al. 2001). Every third atom of this organic macromolecule is an amino 
nitrogen group which can be protonated. Irrespective of PEI form i.e., linear or branched, it 
forms complexes with DNA. The ability of the PEI to trap DNA is attributed to many linker 
amino groups which also render PEI buffering capacity (Klotz, Royer & Sloniewsky 1969). 
Molecular weight of the PEI determines the toxicity and transfection efficiency of PEI. 
Higher the molecular weight, higher the cytotoxicity and transfection efficiency (Kichler et 
al. 2001).  Although when compared to viral transfection systems, PEI has low transfection 
efficiency, but is still considered as a potent transfection agent. 
1.8.1. Forms of polyethyleneimine 
PEIs are basically in two forms. One is linear polyethyleneimine (lPEI) and the other one is 
branched polyethyleneimine (bPEI) (Figure 1.11). Both are widely used as gene delivery 
vehicles. Since PEI has high positive charge on the surface it readily interacts with DNA and 
RNA which are negatively charged molecules (Neu, Fischer & Kissel 2005). The synthesis of 
bPEI can be carried out in two methods. One is by acid catalyzed polymerization of aziridine 
either in alcohols or aqueous solutions (Kunath et al. 2003b; von Harpe et al. 2000) in which 
the reaction is controlled by standardizing concentration of the initiator and temperature. 
Second method of bPEI synthesis is bulk polymerization of anhydrous aziridine at a lower 
temperature (Dick & Ham 1970). The lPEI is synthesized through polymerization of 2-ethyl-
2-oxazoline followed by hydrolysis (Brissault et al. 2003). For in vivo applications, lPEI was 
considered to be more applicable compared to bPEI because lPEI has less cytotoxicity and 
high efficient transfection property (Wiseman et al. 2003). For example, commercially 
available transfection agents for lPEI are jetPEI and ExGen500 (Mintzer & Simanek 2008). 
Both jetPEI and ExGen500 is linear PEI of 22 kDa. They are superior transfection reagents 
used both at in vitro and in vivo levels. 
                                                                                                                                      Chapter 1 
57 
 
 
Figure 1.11 Chemical strutures of PEI 
Image showing the chemical structures of the linear PEI (lPEI) and branched PEI (bPEI) 
(Kafil & Omidi 2011).  
1.8.2. Endosmolysis 
PEI with its high positive charge effectively condenses DNA forming polyplexes. These 
PEI/DNA polyplexes are internalized into the cells via endocytosis (von Gersdorff et al. 
2006) (Figure 1.12). In 1997, “proton sponge” hypothesis was proposed which hypothesized 
that PEI with its unprotonated amines absorb protons which are pushed into the lysosome 
resulting in a high intake of Cl- ions and water. This prompts the osmotic swelling of the 
vesicle, leading to rupture of lysosomes and release of polyplexes into the cytoplasm (Behr & 
Jean-Paul 1997). However, the endosmolytic activity depends on the size of the polyplexes. 
The smaller particles does not efficiently deliver gene without the help of endosmolytic 
compounds unlike the larger polyplexes (Wattiaux et al. 2000).    
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Figure 1.12 Schematic representation of delivery of DNA via polymer. 
Positively charged polymer binds with negatively charged DNA to form an overall positive 
complex which enters the cell on interaction with negatively charged cell membrane. 
Nanocomplex enters inside the cell via endocytosis and the dissociated DNA from the 
complex enters the nucleus after the endosomal escape of the complex (Jin et al. 2014).  
1.8.3. Transfection of the PEI complexes 
Molecular weight of the PEI determines its transfection efficiency. A study analyzed the 
transfection efficiency of a range of PEI from 0.6 to 70 kDa and concluded that higher 
molecular weight PEIs result in higher transfection efficiency but it is also associated with 
higher cytotoxicity (Fischer et al. 2003; Mintzer & Simanek 2008). The reason for the higher 
toxicity is necrosis of the cells which is caused as a result of aggregation and accumulation of 
the complexes on the cell surface (Fischer et al. 1999). For an optimal transfection with PEI, 
a low molecular weight of 5 to 25 kDa was suggested to be effective (Neu, Fischer & Kissel 
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2005). Higher transfection efficiency of low molecular weight PEI can be achieved by 
increasing the PEI amine/DNA phosphate (N/P) ratio (Kunath et al. 2003b). 
1.8.4. Modifications of the PEI molecule 
PEI structure is modified to enhance its transfection efficiency and various strategies have 
been employed for the improvement. One of the extensive modifications done on PEI is 
PEGylation which imparts a hydrophilic nature to PEI thus preventing the polymer’s 
interactions with erythrocytes and plasma proteins (Mintzer & Simanek 2008). Polyethylene 
glycol (PEG) alone or N-hydroxy succinamide (NHS) activated PEG are conjugated with PEI 
for transfection studies (Ogris et al. 1999). Two characteristics of PEG attached to PEI 1) 
length and 2) density, determine the transfection efficiency in vitro. A shorter PEG with high 
density conjugated to PEI efficiently transfected oligonucleotides (Kunath et al. 2003a). But 
another study with siRNA showed that PEI conjugated to longer PEG with less density was 
more effective (Mao et al. 2006). Though at in vivo level, the PEI-g-PEG copolymers showed 
increased circulation with less toxicity, no gene expression was observed (Merdan et al. 
2005). This loss in gene expression was attributed to two factors. The first factor was the PEI-
g-PEG copolymer had a reduced binding with the cell membrane due to loss of surface 
charge which hindered its interaction (Godbey, Wu & Mikos 1999). The second factor is a 
hampered transfer of gene after cellular uptake (Walker et al. 2005). It was shown by another 
study that by modifying the primary and secondary amine group of PEI with cholesteryl 
chloroformate, improved transfection efficiency could be achieved (Wang et al. 2002). 
Another study reported a lesser toxicity for both forms of cyclodextrin (CD)-modified PEI. 
With increasing concentration of cyclodextrin, a reduced cytotoxicity was observed in 
prostatic carcinoma cells for both forms of CD-modified PEI. Though a higher cellular 
uptake was observed, less transfection rate was observed for CD-bPEI due to hindrance by 
the cyclodextrin conjugation.  This problem was addressed by conjugating adamantine-
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terminated PEG with the CD-PEI and the in vivo studies with the new modification showed 
excellent biodistribution and no toxicity (Pun et al. 2004).  
1.8.5. Targeting receptors via PEI  
In hepatocytes, specific gene transfer was directed to ASGPr-receptors using bPEI linked to 
galactose through four-carbon spacer (Zanta et al. 1997). In dendritic cells, mannose was 
used for gene delivery because of high expression of mannose receptors. DNA was delivered 
in a mannose receptor mediated by using Mannose-bPEI25 and efficiency via this conjugate 
was higher than the non-conjugated PEI (Avraméas et al. 1996). Another receptor mediated 
endocytosis was observed with transferrin conjugated with PEI/DNA polyplexes which 
showed improved cell internalization. In many cancer cells, epithelial growth factor (EGF) 
receptors are overexpressed and this was exploited for receptor mediated delivery. An 
enhanced uptake of EGF polypeptide tagged to bPEI25/DNA was observed in tumor cell 
lines (Blessing et al. 2001). Peptides have been used to conjugate with PEI for specific and 
receptor mediated delivery. One such peptide is RGD peptide which was conjugated with 
bPEI25 and it showed ligand receptor delivery and enhanced gene expression (Kunath et al. 
2003a). Antibodies or its fragments have been conjugated with PEI for specific delivery. In 
one study, anti-CD3 antibody targeting T cell receptor-CD3 molecule was tagged with 
bPEI800 first followed by the DNA. This antibody-PEI conjugate transfected human T cell 
leukemia cells with a higher transfection efficiency (Kircheis et al. 1997). However, the 
drawbacks of the study were the huge size of the antibody and potential rise of 
immunogenicity.   
1.8.6. Cytotoxicity of PEI 
The free PEI causes cytotoxicity by membrane damage before the internalization and 
inducing stress inside the cell after internalization (Godbey, Wu & Mikos 2001). This 
cytotoxicity effect of PEI has led researchers to synthesize biodegradable PEI by introducing 
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reducible disulfide linkages or ester groups. PEI treated with dimethyl-3,3’-
dithiobispropionimidate showed reduced toxicity (Gosselin, Guo & Lee 2001), whereas a 
synthesized reducible linear PEI behaved similar to PEI but with increased cell viability (Lee 
et al. 2007b). Likewise, a synthesized oligo (L-lactic acid-co-succinic acid) was conjugated to 
1200 Da PEI for reduced cytotoxicity. Though this modification achieved the goal along with 
increased transfection efficiency, it underwent rapid degradation (Petersen et al. 2002).  
 Aptamers 1.9.
Aptamers, the in vitro selected single-stranded, short DNA or RNA oligonucleotides 
selectively bind to target molecules because they form secondary structures with aligned 
conformations (Kanwar et al. 2010). The coining of the term aptamer (Ellington & Szostak 
1990) and its synthesis called “SELEX” (Systemic Evolution of Ligands by Exponential 
enrichment) (Tuerk & Gold 1990) was published by two different groups at the same time.  
1.9.1. Advantages of an aptamer 
Aptamers are considered to be more advanced than the antibodies for several reasons. 
Antibodies can be raised only for those molecules, for which an immune response is elicited 
and thus the restrictive generation of antibodies. In case of aptamers, it can be generated for 
any molecules including toxins, proteins, phospholipids, sugars and other nuclei acids 
(Lauridsen & Veedu 2012). Aptamers are capable of distinguishing targets even with slight 
difference in their structures  such that they can bind to even hidden epitopes which are not 
accessible for antibodies (Kanwar, Roy & Kanwar 2011). The aptamers retain functionality 
even at an ambient temperature due to the formation of 3-dimensional structure which makes 
them resistant to pH and temperature changes. During chemical synthesis, the aptamers can 
be custom-synthesized for increased stability, for immobilization and also add signaling 
properties. The synthesis of aptamers is highly reproducible and pure, thus avoiding the 
batch-to-batch variation like antibody production. In addition, aptamers owing to its small 
                                                                                                                                      Chapter 1 
62 
 
size does not elicit immune response in vivo which is the biggest advantage in terms of 
therapeutic application (Szeitner et al. 2014).  
The few drawbacks that have limited aptamer’s use as therapeutic agents are its rapid 
clearance from the body due to its small size and its degradation in the presence of nucleases 
(Table 1.4). The degradation rate can be however slowed down by chemical modification 
(Hu & Zhang 2013). One of the main modifications to overcome nuclease degradation is 
addition of unnatural bases like locked nucleic acid (LNA) which imparts high resistance. A 
study proved this by modifying a R06 aptamer by adding LNA which showed a higher 
binding affinity along with higher nuclear resistance against trans-activating responsive 
(TAR) RNA element of HIV (Lebars et al. 2007). Aptamers are generated via a process 
called as systematic evolution of ligands by exponential enrichment (SELEX) which opened 
opportunity for various target molecules. 
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Table 1.4Advantages and disadvantages of aptamers and antibodies 
 Advantages Disadvantages 
Aptamer 1. Chemically synthesized and easily 
scalable 
2. Chemical production, so free of 
bacterial or viral contamination 
3. Smaller size 
4. Non-immunogenic 
5. High stability 
6. Conjugation with dyes or functional 
groups easily introduced 
7. High specificity against any targets 
1. Shorter half-life because of small size 
2. Highly dependent on chemical modifications 
for stability in the presence of serum 
Antibody 2 High circulating half-lives inside the body 
3 Resistant to nuclease degradation 
• Prone to bacterial or viral contamination 
because of biological synthesis 
• Large size compared to aptamer 
• Conjugation partners leads to reduced 
activity 
 
1.9.2. SELEX 
The procedure of SELEX requires a solid surface on which a target molecule is attached. This 
targeted molecule is then subjected to a pool of random RNA or DNA oligonucleotides which 
binds to the target molecule based on their specificity. This is followed by a washing step 
which removes unbound oligonucleotides leaving a good amount of bound oligonucleotides. 
These bound oligonucleotides are then amplified by PCR which results in double-stranded 
DNA converted to single stranded DNA before subjecting it to another round of selection. 
Repetitive selection cycles screens the high affinity oligonucleotides and these candidates are 
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then separated and sequenced (Figure 1.13). The most important step in the SELEX 
methodology is the initial cycle where the experimental conditions are lenient with prolonged 
incubation period. However, in the final steps of the selection, conditions turn rigorous 
(Szeitner et al. 2014). Various modifications of the SELEX were introduced for a better 
affinity and specificity over a period of twenty years. Negative SELEX (Bassett et al. 2004), 
Subtractive SELEX (Wang et al. 2003), Cell-SELEX (Shangguan et al. 2006), Chip SELEX 
(Collett, Cho & Ellington 2005) and Atomic force microscopy-SELEX (AFM-SELEX) 
(Miyachi et al. 2009) are the few developed forms of SELEX over the native one.  
 
Figure 1.13 Schematic illustration of SELEX methodology. 
Target is first immobilized on the bead which is then subjected to a random nucleotide 
library, after multiple washes; the bound oligonucleotides are amplified by PCR and cloned. 
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1.9.3. Aptamer as diagnostic agents 
Aptamer, due to their many advantages, are widely explored as diagnostic agents in different 
fields. An optimal diagnostic agent should possess characteristics such as specificity, stability 
under physiological conditions, reliability, quick detection and most importantly sensitivity. 
Since aptamers fulfill the above conditions, they are used not only to detect different 
molecules but also used as an imaging probe (Radom et al. 2013). Aptamers have been used 
as a biosensor by combining it with a molecular beacon. A study on human neutrophil 
elastase (HNE) showed a unique biosensor which had a DNA aptamer to HNE, a fluorescent 
molecular beacon and a siDNA which was complementary to both the beacon and the 
aptamer. The siDNA competitively bound to either the aptamer or the beacon thus enhancing 
the sensitivity of the biosensor (He et al. 2010). A new biosensor with three different 
aptamers specific for cocaine, adenosine and potassium was generated and it was reported to 
be highly sensitive even at micromolar ranges (Zhang et al. 2010).  Like biosensors, aptamers 
are also used as electrochemical sensors where the aptamer is coated on an electrode and 
when the aptamer binds to its target, a measurable change in the current flow occurs. Using 
the concept of aptamer based electrochemical sensors, studies using cocaine-DNA aptamer 
(Swensen et al. 2009) and interferon-γ aptamer  (Zhang et al. 2012) have shown the concept 
to be feasible. The conjugation of aptamers with radiolabelled compounds for imaging has 
been used extensively in clinical front with technologies like Single-Photon Emission 
Computed Tomography (SPECT) and Positron Emission Tomography (PET). One of the 
studies explored the possibility of tagging radioactive compound, 99mTc with a DNA aptamer 
targeting matrix metalloprotease-9 for studies in brain tumors (Stamenkovic 2003) and gave 
satisfactory results.  
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1.9.4. Aptamers as therapeutic agents: Aptamer-drug conjugates 
For therapy, aptamers are mainly used either to deliver a therapeutic compound to the target 
molecule or to inhibit a particular target molecule. Although, few therapeutic aptamers have 
advanced to clinical trials, so far FDA have approved only one aptamer named Pegaptanib,  
directed against vascular endothelial growth factor (VEGF)-165 for vascular ocular disease 
(Ng et al. 2006). Chemotherapy in cancer lacks selectivity and this is the reason for 
associated side-effects. This problem was addressed in a study where a commonly used 
cancer drug, doxorubicin was conjugated with an aptamer targeting tyrosine kinase 7. This 
conjugate had various advantages like high affinity, preservation of aptamer specificity and 
drug cytotoxic effects along with reduced toxicity to non-targeted cells due to the conjugate 
internalization via the receptors (Shangguan et al. 2006). There were studies which made 
these conjugates into bifunctional by introducing iron oxide nanoparticles. In prostate cancer, 
an aptamer targeting prostate specific membrane antigen was conjugated to 
superparamagnetic iron oxide nanoparticles (SPION) which allowed imaging via specifically 
targeting cancer cells (Wang et al. 2008). Similarly, liposomes are also coated with aptamer 
to target cells. A recent study showed the preparation of a liposome coated with sgc8 aptamer 
having affinity towards leukemia CEM-CCRF cells was labeled with fluorophores for both 
the carrier and the load. The targeted liposome exhibited a specific targeting and release of 
drugs within 30 mins of incubation thus establishing the advantages of aptamer mediated 
delivery of drugs (áO’Donoghue & B 2010). Apart from delivering drugs, aptamers are also 
conjugated with siRNAs to silence specific genes. In another study, a CD4 aptamer-siRNA 
chimera was shown in humanized mice to have protective effect against HIV vaginal 
transmission by specifically knocking down HIV genes (Wheeler et al. 2011).  
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 Conclusion 1.10.
For the progression of RB, various molecules which are endogenously expressed play major 
role. The main genes involved are apoptotic regulatory genes which are either over expressed 
or under expressed in the cancer cells compared to the normal cells. The inter-play between 
these molecules determines the rate of progression of RB tumors. Apart from apoptotic 
regulatory genes, various other genes such as NIS, whose role in normal cell is not associated 
to apoptosis, in cancer condition comes into the forefront in enhancing the disease. The main 
goal of the study was to deduce the role of NIS in RB and stimulation of basal NIS using 
transactivating agent such as bLf. Apart from deducing the role of NIS in RB, NIS was also 
delivered in breast cancer in a targeted and specific approach using modified 
nanocomplexes. Furthermore, the role of dysregulated apoptotic molecules was also studied 
in RB. Thus, unraveling the mechanism of various molecules associated with the RB and 
breast cancer would help in understanding and targeting NIS, Bcl-2, Bax and survivin better. 
 Hypotheses 1.11.
1) NIS expression has been studied in various extra-thyroidal cancers. This study 
hypothesized that if NIS was expressed in RB tumors, it would be associated with 
clinical parameters like histopathological high risk factors and tumor differentiation. 
Further it was hypothesized that bLf could upregulate the endogenous NIS protein 
expression in Y79, an RB established cell line from ATCC (American Type Culture 
Collection). 
2) Basal level NIS expression in breast cancer has been studied extensively. Although 
NIS is expressed, the endogenous NIS is insufficient for radioiodide therapy. In this 
study, it was hypothesized that if NIS was specifically overexpressed in breast cancer 
cells (MCF-7) via a tissue specific promoter (EpCAM) through receptor targeted gene 
delivery, it would induce functional activity of NIS leading to higher cellular iodide 
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uptake. It was also hypothesized that NIS gene could be effectively delivered in a 
nanoformulation (nanocomplex) decorated with EpCAM aptamer for its specific 
delivery in EpCAM positive breast cancer cells (MCF-7), the successful delivery 
would then enhance the iodide uptake. 
3) The endogenous gene expression of apoptotic regulatory molecules has never been 
studied in primary RB tumors before. This study explored the expression of Bax and 
Bcl-2 from Bcl2 family, and survivin and four of its variants from the IAP family. It 
was hypothesized that the expression of these apoptotic regulatory molecules would 
be associated with clinical parameters like histopathological high risk factors. 
 Novelty of the project 1.12.
The novelty of this project is for the first time, NIS expression and its correlation with 
histopathological features of RB tumors has been studied. Other than RB, the prospect of 
EpCAM specific overexpression of NIS gene in breast cancer cells and its delivery in 
nanoformulation has been explored. Also the endogenous status of the apoptotic regulatory 
molecules in RB has never been studied. Therefore, this study intended to bridge the 
knowledge gap in the correlation of apoptotic regulatory genes (Survivin-WT, Survivin-2α, 
Survivin-2β, Survivin-3β, Survivin-ΔEx3, Bax and Bcl-2) with the histopathological high 
risk factors of the RB tumors. In addition, the prospect of survivin targeting using RNAi 
technology for silencing the dominant player among the urvivin variants and its apoptotic 
effects has been explored. 
 Research questions addressed 1.13.
1) Is NIS expressed in RB? If expressed, is it correlated with the histopathological 
features of the tumor? If NIS is expressed in RB cell line, Y79, can the NIS gene 
expression be transcriptionally activated? 
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2) Can Y79 cells efficiently internalize bLf? Can iron free and iron saturated forms 
upregulate the endogenous NIS expression of Y79 cells? 
3) Can NIS gene be specifically over expressed in breast cancer cells? Can NIS plasmid 
be specifically delivered to breast cancer cells via a nanoformulation? 
4) Are survivin & its variants, Bax and Bcl-2 expressed in primary RB tumors? Are 
survivin, Bax and Bcl-2 correlated with each other and show any correlation with 
histopathological features of the primary RB tumors? Can the expressed survivin and 
its variants in RB be effectively targeted via siRNA technology? 
 
 70 
 
Chapter 2 
 
 
Materials and Methods 
 
 
 
 
 
                                                                                                                                      Chapter 2 
71 
 
2. Materials and Methods 
Methodology for Chapter 3 experiments 
The project work was undertaken as per the MOU signed between Vision Research 
Foundation, Sankara Nethralaya and Deakin University. 
 RB Tumor processing 2.1.
RB tumor tissues were harvested immediately after enucleation for molecular biology studies 
before the fixation of the globe in formalin.  
 RB Tumor specimens and ethics approval  2.2.
The tumor samples were obtained from enucleated eyes as part of therapy at Larsen & 
Toubro Ocular Pathology laboratory, Sankara Nethralaya, Chennai, India.  Normal retinal 
tissues were collected from cadaveric eyes which were donated to C.U.Shah eye bank, 
Sankara Nethralaya, Chennai, India. The study with primary RB tumor samples was reviewed 
by the ethics committee of Vision Research Foundation, Sankara Nethralaya Institute (Ethics 
clearance number: 186-2009-P). Tumors were diagnosed as RB and graded by ocular 
oncologist based on MRI and ocular fundus photography. The eye ball was grossed as per 
The International Retinoblastoma Staging Working Group (IRSWG) provided guidelines 
(Sengupta et al. 2013). For every eye ball that was grossed, sixteen sections were taken. Four 
breadloaf sections, four pupil optic sections, four lateral globe and four surgical end of optic 
nerve were taken. From the pupil optic nerve sections or lateral globe sections, whichever had 
the best tumor sections, were taken for the immunohistochemistry study. All 41 tumors were 
classified as group D and group E according to International Intraocular Retinoblastoma 
Classification (IIRC) (Murphree 2005). Histopathological classification of the tumors was 
made according to the differentiation and invasion of the ocular coats (Finger PT, Harbour 
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JW & ZA 2002; Sastre X et al. 2009). RB tumors were considered well differentiated when 
rosettes were present in more than 80% of their area. In the absence of rosettes, the tumors 
were considered poorly differentiated. The rest of the RB tumors were considered to be 
moderately differentiated (Gómez-Martínez et al. 2012). In the study of NIS expression in 
RB, 41 tumors were collected from 41 eyes from the patients whose mean age was 3 years. 
Out of the 41 tumors, 30 were poorly differentiated, 3 were moderately differentiated and 8 
were well differentiated tumors. 33 tumors were unilateral and 8 were bilateral (Table 2.1). 
Apart from this, all the tumors were also analyzed for choroidal, optic nerve, scleral and extra 
ocular invasion. Choroidal invasion was further divided into <3mm and >3mm invasion, 
whereas for optic nerve invasion, pre laminar, post laminar and surgical end of the optic 
nerve were analysed (Sastre X et al. 2009). The tumors with invasion of choroid > 3mm and 
optic nerve invasion such as post laminar and surgical end of OP nerve will be taken further 
for post enucleation chemotherapy for 6 cycles and brachytherapy when the invasion spill 
over into orbit or invade to sclera. RPE invasion alone was not considered as invasive case. 
Only cases with choroidal and/or optic nerve invasion were considered to be invasive cases. 
The entire study was conducted according to the principle tenets of the Helsinki Declaration. 
The interpretation of the histology was done by two ophthalmic pathologists, Dr.Jyotirmay 
Biswas and Dr.S.Krishnakumar from Sankara Nethralaya, Chennai, India. 
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Table 2.1 Characteristics of tumor cohort used in NIS expression study 
Serial 
No. 
Clinico-pathological information of RB tumors studied for NIS  
Histopathological 
report 
IIRC 
grade 
Invasion 
status 
Age
/Sex 
Laterality Differen
tiation 
Treatment 
modality 
Follow up 
1 
 
Anterior chamber 
invasion, focal 
RPE and focal 
choroidal 
invasion<3mm 
D I 2yr/
M 
OD PD NC No specific 
ocular complaints 
2 
 
Multiple foci of 
RPE invasion, 
choroid invasion 
measuring >3mm, 
prelaminar 
invasion of optic 
nerve 
D I 2yr/
F 
OS PD NC 8 cycles of post 
chemotherapy 
3 
 
Multiple foci of 
choroid invasion 
measuring >3mm, 
No optic nerve 
invasion 
D I 3yr/
M 
OD/OU PD C 
7 cycles 
No specific 
ocular complaints 
4 
 
Multiple tumor 
lobules in contact 
with RPE and focal 
choroid invasion < 
3 mm. No Optic 
E I 2yr/
F 
OS PD NC No specific 
ocular complaints 
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Nerve invasion 
5 
 
Choroid invasion 
measuring >3mm 
prelaminar, 
laminar and early 
post laminar 
invasion of optic 
nerve. 
D I 3yr/
F 
OD MD NC 5 cycles of post 
chemotherapy 
6 
 
RPE invasion, 
focal choroidal 
invasion 
approximately < 
3mm, pre laminar 
and laminar 
invasion of optic 
nerve. 
E I 2yr/
F 
OD/OU PD NC No specific 
ocular complaints 
7 
 
Focal tumor 
clusters are seen in 
post laminar 
portion of optic 
nerve. No 
choroidal invasion 
D I 9yr/
F 
OD PD NC 6 cycles of post 
chemotherapy 
8 
 
Choroidal invasion 
measuring >3mm, 
prelaminar and 
laminar invasion of 
optic nerve 
D I 4yr/
F 
OD PD C 
17 cycles 
Post 
chemotherapy 
continued in 
Malaysia 
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9 
 
Diffuse choroidal 
invasion measuring 
>3mm, no invasion 
of optic nerve 
D I 10m
on/F 
OS WD NC 6 cycles of post 
chemotherapy 
10 
 
RPE invasion, no 
choroidal invasion, 
prelaminar, 
laminar and post 
laminar(moderate) 
invasion of optic 
nerve 
D I 4yr/
M 
OD MD NC 6 cycles of post 
chemotherapy 
11 
 
Diffuse choroidal 
invasion > 3mm 
D I 3yr/
M 
OD PD NC 5 cycles of post 
chemotherapy 
12 
 
Focal invasion of 
choroid measuring 
<3mm 
D I 2yr/
F 
OD MD NC No specific 
ocular complaints 
13 
 
Non-Invasive E NI 4yr/
M 
OD PD NC  
14 
 
Non-Invasive D NI 2yr/
M 
OD PD NC  
15 
 
Non-Invasive E NI 2.5y
r/F 
OS WD NC  
16 
 
Non-Invasive D NI 1.5y
r/M 
OS/OU WD C 
2 cycles 
No specific 
ocular complaints 
17 
 
Non-Invasive D NI 5yr/
M 
OD PD NC  
                                                                                                                                      Chapter 2 
76 
 
18 
 
Non-Invasive D NI 7yr/
F 
OS PD NC  
19 
 
Non-Invasive D NI 1yr/
M 
OD PD NC  
20 
 
Non-Invasive D NI 5yr/
F 
OS PD NC  
21 Prelaminar, 
laminar invasion of 
optic nerve. No 
choroidal invasion. 
E I 1mo
n/M 
OS WD 
 
 
NC 
6 cycles of post 
chemotherapy 
22 No choroidal 
invasion and no 
invasion of optic 
nerve. 
E NI 4yr/
F 
OD PD 
 
NC  
23 Choroidal invasion 
<3 mm. 
Prelaminar, 
laminar and 
minimal post 
laminar invasion of 
optic nerve. 
E I 5yr/
F 
OD/OU PD 
 
NC No specific 
ocular complaints 
24 RPE invasion. No 
choroidal invasion 
and no optic nerve 
invasion. 
E NI 3yr/
F 
OS PD NC  
25 RPE invasion. No 
choroidal invasion 
and no optic nerve 
E NI 2yr/
M 
OS PD 
 
NC  
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invasion. 
26 Diffuse choroidal 
invasion measuring 
>3 mm invasion 
into anterior, 
middle fibres of 
sclera, full 
thickness optic 
nerve invasion. 
E I 4yr/
M 
OS PD 
 
NC Chemotherapy 
advised. No 
follow up 
27 Invasion of 
choroid, measuring 
<3 mm. 
Prelaminar, 
laminar and 
minimal post 
laminar invasion of 
optic nerve. 
E I 3yr/
F 
OD PD 
 
NC 3 cycles of post 
chemotherapy 
28 No invasion of 
optic nerve and no 
invasion of 
choroid. 
D 
 
NI 3yr/
M 
OS/OU PD 
 
C 
6 cycles of 
chemotherap
y 
No specific 
ocular complaints 
29 RPE invasion. 
There is no 
invasion of 
choroid. 
Prelaminar 
invasion of optic 
nerve is seen. 
D 
 
I 2yr/
F 
OD/OU WD 
 
C 
2 cycles of 
chemotherap
y 
No specific 
ocular complaints 
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30 No invasion of 
choroid and no 
invasion of optic 
nerve. 
E 
 
NI 3yr/
M 
OS WD C 
2 cycles of 
chemotherap
y 
 
31 No choroidal 
invasion. 
Prelaminar 
invasion of optic 
nerve. 
E 
 
I 8mo
n/F 
OS/OU WD 
 
C 
5 cycles of 
chemotherap
y 
No specific 
ocular complaints 
32 No invasion of 
choroid. Minimal 
prelaminar 
invasion of optic 
nerve. 
D I 5yr/
M 
OS PD 
 
NC  
33 Choroidal invasion 
with < 3mm. No 
invasion of optic 
nerve. 
D 
 
I 2yr/
F 
OD PD C 
7 cycles of 
chemotherap
y 
No specific 
ocular complaints 
34 Focal RPE 
invasion. No 
choroidal invasion. 
Prelaminar and 
laminar invasion of 
optic nerve. 
E I 1mo
n/M 
OD WD 
 
NC No specific 
ocular complaints 
35 No invasion of 
choroid and optic 
nerve 
D NI 3yr/
F 
OS PD 
 
NC  
36 No invasion of 
choroid, no 
invasion of optic 
E NI 3yr/
F 
OS PD 
 
NC  
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nerve 
37 No invasion of 
choroid, 
prelaminar 
invasion of optic 
nerve. 
D I 1yr/
M 
OD/OU PD 
 
NC No specific 
ocular complaints 
38 Choroidal invasion 
>3mm, prelaminar, 
laminar and 
minimal post 
laminar invasion of 
optic nerve. 
E I 4yr/
F 
OD PD 
 
NC No specific 
ocular complaints 
39 Choroid invasion 
<3 mm. No 
invasion of optic 
nerve. 
D I 5yr/
M 
OS PD 
 
NC No specific 
ocular complaints 
40 No invasion of 
choroid. No 
invasion of optic 
nerve. 
E NI 2yr/
M 
OS PD 
 
NC  
41 Focal RPE 
invasion. 
Prelaminar, 
laminar invasion of 
optic nerve. 
E I 3yr/
M 
OD PD 
 
NC No specific 
ocular complaints 
 
Tumor cohort characteristics : Abbreviations: I – Invasive, NI – Non-invasive, M– male, F – 
female, yr – year, mon – Month, OD – right eye (unilateral), OS – left eye (unilateral), OU – 
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both eyes (bilateral), PD – Poorly differentiated, MD – Moderately differentiated, WD – Well 
differentiated, C-Chemotherapy, NC – Non-Chemotherapy, ON -Optic nerve, RPE – retinal 
pigment epithelium. 
 
 Immunohistochemistry for NIS in RB tumors 2.3.
Immunohistochemistry was performed for NIS in 21 RB tumors. In brief, 5-μm-thick 
paraffin-embedded tumor sections were de-paraffinized through three changes of xylene and 
re-hydrated through graded alcohols to distilled water (Figure 2.1). Antigen retrieval was 
performed with 10 mM citrate buffer (pH, of 6.0), using the pressure cooker method. 
Endogenous peroxidase activity was neutralized in the investigated sections with 3% H2O2 in 
H2O for 10 min, and the slides were incubated with mouse monoclonal anti-human NIS 
antibody (clone FP5A; Thermo Scientific, USA) at 1:100 dilution over night at 4ºC. 
Immunostaining was performed as recommended by the supplier, (Novolink Polymer kit, 
Leica Microsystems Inc., Bannockburn, IL). Novolink polymer provided in the kit was used 
as the secondary antibody and the tumor sections were incubated in the polymer for 1 h. The 
immunoreactivity was revealed by 3, 3′-diaminobenzidine (DAB) and counterstained with 
hematoxylin. Intermittent washing between the steps was performed using TBS (pH of 7.6). 
For negative controls, the same procedure was performed in the absence of the primary 
antibody. Any cells that appear brown were considered positive for the expression of NIS 
antigen. Immunostaining was evaluated based on the percentage of positive cells and its 
staining intensity. The average percentage positivity was calculated for each case after 
scanning ten tumor fields.  Numerical score was assigned for each staining intensity with 3 as 
strong, 2 as intermediate, 1 for weak and 0 for negative. Calculation of histochemical score 
(H-Score) was done as reported (Detre S 1995).   
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 Figure 2.1 Schematic representation of deparaffinisation of RB tumor sections 
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 Flow cytometric (FC) analysis of NIS protein in RB tumors 2.4.
RB tumor tissues (20 in number) and were collected, homogenised and washed. The cells 
were resuspended in FC buffer containing ice-cold phosphate buffered saline, 10 % fetal 
bovine serum, and 1 % sodium azide. Primary antibody, mouse monoclonal antibody against 
hNIS (17795; Abcam) with a final dilution of 1:50 was incubated with the cells for 60 min at 
37°C. After the incubation period, cells were washed thrice (at 400× g for 5 min each) with 
ice-cold PBS. Fluorescein isothiocynanate (FITC)-conjugated anti-mouse IgG secondary 
antibody (Sigma Aldrich, USA) was used with a final dilution of 1:750 and incubated for 30 
min in dark at 37°C. After the secondary antibody incubation, cells were washed thrice 
(centrifugation at 400× g for 5 min each) with ice-cold PBS. Cells were analyzed on a FACS 
Calibur flow cytometer (BD Biosciences, San Jose, CA, USA); with the CellQuest software 
program (BD Biosciences, USA). In flow cytometry, change in the relative protein 
expression was defined for cells that had a shift of fluorescence intensity when compared to 
the unstained and secondary antibody (FITC) alone stained cells.  
 Immunoblotting for NIS protein in RB tumors 2.5.
Approximately 100 mg from 6 RB tissues was homogenized in radioimmunoprecipitation 
assay lysis buffer containing 50 mM of Tris HCl (pH 7.6), 1 % NP40, 0.28 % of 
Deoxycholate , 0.1 % SDS,1 mM of EDTA, 150 mM of sodium chloride, 1 % PMSF (Sigma 
Aldrich, USA), and 250 μl of 1 mg/mL Protease Inhibitor Cocktail (Sigma Aldrich, , USA). 
Tissues were then sonicated at 80 cycles/min. Protein estimation was carried out by the 
method of Bradford (Bradford 1976) . 50 μg of each sample was run on a 12 % SDS-PAGE 
and then electrophoretically transferred onto nitrocellulose membrane. Nonspecific sites were 
blocked with 5% nonfat dry milk. The blots were incubated with mouse monoclonal antibody 
against hNIS (17795; Abcam) (1:500) and rabbit polyclonal antibody against hNIS (104920; 
Abcam) (1:500) overnight at 4°C. The blots were then incubated with their respective 
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horseradish peroxidase-conjugated secondary antibodies Anti-mouse IgG-HRP and Anti-
rabbit IgG-HRP (1:2000) (Sigma Aldrich, USA) for 2 h. After intermittent washes with TBS-
T (Tris buffered saline-Tween 20), the immunoreactive bands were detected by ECL using 
the Supersignal West Femto-maximum sensitivity substrate (Thermo Scientific, USA). 
Antibodies against β-actin (1:2000; Sigma Aldrich, USA) were used as the loading control. 
The NIS band intensity was measured using a densitometer (BIORAD GS 800, USA) and 
Quantity One software. The NIS band optical density thus obtained was then normalized with 
respect to the loading control β-actin using Image J software (NIH). 
 Determination of NIS protein in RB cell line (Y79 cells) 2.6.
2.6.1. Maintenance of Y79 cell lines 
Human Retinoblastoma cell line, Y79 was purchased from American Type Culture Collection 
(ATCC, U.S.A) and was maintained in Roswell Park Memorial Institute 1640 medium 
(RPMI 1640, Sigma Aldrich, USA) supplemented with 10 % fetal bovine serum. The Y79 
cell line was grown in a 5 % CO2 incubator at 37°C. 
2.6.2. Flow cytometric analysis of NIS protein in Y79 cells 
5x105  Y79 cells were collected and the cells were processed for flow cytometry as mentioned 
in section 2.4 with the same primary antibody and secondary antibody dilution. 
2.6.3. Immunofluorescence of NIS protein in Y79 cells 
Y79 cells (4x105cells/mL) were collected and washed. The cells were fixed with 4 % 
paraformaldehyde (PFA) for 20 min. After the fixation, cells were washed and blocked with 
blocking buffer containing 0.2% Triton X 100 and 5 % FBS for 1 h at 37°C.  Primary 
antibody, mouse monoclonal antibody against hNIS (17795; Abcam) with a final dilution of 
1:50 was incubated with the cells overnight at 4°C. After the incubation period, cells were 
washed thrice (at 400× g for 5 min each) with ice-cold PBS. Fluorescein isothiocynanate 
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(FITC)-conjugated anti-mouse IgG secondary antibody (Sigma Aldrich, USA) was used with 
a final dilution of 1:60 and incubated for 2 h in dark at 37°C. After the secondary antibody 
incubation, cells were washed thrice (centrifugation at 400× g for 5 min each) with ice-cold 
PBS. The cells were fixed onto a slide and mounted using a mounting medium containing 
DAPI. The cells were visualized using a Leica SP5 confocal microscopy and the images were 
processed using LAS version software. 
2.6.4. Immunoblotting of NIS protein in Y79 cells 
5x105 Y79 cells were collected and the cells were processed for immunoblotting as 
mentioned in section 2.5 with anti-human NIS mouse monoclonal antibody (17795; Abcam) 
(1:500) used as primary antibody. Secondary antibody was anti-mouse IgG conjugated to 
HRP (Sigma Aldrich, USA) (1:1000) used. The protein lysate was tested for endogenous 
control, GAPDH. Anti-human gapdh rabbit monoclonal antibody (1:1000) was used as 
primary antibody and anti-rabbit IgG conjugated to HRP (1:80,000) was used as secondary 
antibody. The immunoreactive bands were detected by the ECL method. 
2.6.5. RNA isolation of Y79 cells 
Total RNA was isolated from 5X105 Y79 cells using the TRIzol reagent (Life technologies, 
USA). The cells were collected and washed with PBS. TRIzol® Reagent was added, vortexed 
and incubated at 37°C for 5 min. After the incubation period, chloroform was added to 
denature the protein present in the samples. The samples were centrifuged at 14,000 rpm for 
15 min to separate the aqueous layer. To the aqueous phase, isopropanol was added to 
remove all soluble salts and incubated at 37°C for 20 min. After the incubation period, the 
samples were centrifuged at 14,000 rpm for 10 min. The pellet was washed with 70% ethanol 
and air-dried. The air-dried pellet was resuspended in RNase free water and was quantified in 
BioSpec-Nano spectrophotometer (Shimadzu Biotech, Japan). 
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2.6.6. cDNA conversion or Reverse Transcriptase PCR (RT-PCR) 
SuperScriptTM III first strand synthesis system (Life Technologies, Australia) was used to 
convert the isolated Y79 RNA into cDNA. A concentration of 1 μg of total RNA was used 
for the conversion which was carried out as per manufacturer’s instructions. To 1 μg of RNA, 
1 µL of 50 μM oligo (dT) 20 and 1 μl of 10 mM dNTP mix was added. This mixture was 
made up to 10 μl by adding nuclease-free water (Applied biosytems, Australia). The mixture 
was then incubated at 65oC for 5 min in a Takara PCR thermal cycler (Scientifix, Australia) 
and then immediately incubated in ice for 1 min. The cDNA synthesis mixture was prepared 
as described in Table 2.2 and 10 μl of it was added to each tube. Samples were incubated in a 
PCR thermal cycler for 50 min at 50oC, 85oC for 5 min and finally at 4°C. The cDNA was 
stored at -20oC until further use.      
Table 2.2 Components of a mastermix for RT-PCR reaction 
REAGENT VOLUME(µL) 
per reaction 
10X RT Buffer 2 
25mM MgCl2 4 
0.1 M DTT 2 
Rnase Out 1 
Superscript 1 
Total volume per reaction  10.0 
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2.6.7. Quantitative Real Time PCR (qRT-PCR) for lactoferrin receptors (Lf) 
In Y79 cells, mRNA level of three Lf receptors, low-density lipoprotein receptor-related 
proteins-1 and -2 (LRP1 and LRP2) and Transferrin receptor (Tfr) was investigated by qRT-
PCR using SybrGreen RT-PCR kit (BioRad, Australia). The PCR reaction mixture containing 
100 ng of cDNA was prepared by adding 7.5 µL of  SYBR Premix Ex TaqTM , 0.4 µL of 
sense (0.2 µM) and antisense primer (0.2 µM) of LRP1, LRP2, Tfr and GAPDH. GAPDH 
was used as the endogenous control. The reaction mix was made upto 15 µL by adding 
nuclease free water. The samples were placed in a PCR thermal cycler (iQ5, Biorad). The 
cycling conditions were initial denaturation step at 94oC for 5 min followed by 50 cycles of 
denaturation step at 94oC for 30 s then an annealing step for 30 seconds for respective 
primers and an extension step at 72oC for 1 min. Lf receptors expression was normalized with 
GAPDH expression. The data was then analysed by Livak method (Relative Quantification) 
(Livak KJ & TD 2001). The expression of both the genes in each sample was analyzed in 
triplicate for statistical comparisons. The primers and its respective annealing temperature are 
described in the Table 2.3. 
Table 2.3 List of primers used in the bLf study 
Gene Primer Sequence Annealing 
Temperature 
(°C) 
LRP1 F:  5’-AGAAGTAGCAGGACCAGAGGG-3’ 
R:  5’ ACAGTACCCAGGCAGTTATGA 3’ 
59°C 
LRP2 F:  5’-CGGAGCAGTGTGGCATATTTTC-3’ 
R:  5’-CAGGTGTATTGGGTGTCAAGGC-3’ 
55°C 
TFR F:  5’-TGTAGGCTGCCCATTGTAAC-3’ 
R:  5’-CAGAATTCCCACACATCCACT-3’ 
55°C 
GAPDH F:  5’-CCATCACCATCTTCCAGGAG-3’ 
R:  5’-CCTGCTTCACCACCTTCTTG-3’ 
60°C 
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Abbreviations: TFR - Transferrin receptors, LRP1- low-density lipoprotein receptor-related 
proteins-1, LRP2- low-density lipoprotein receptor-related proteins-2 and GAPDH- 
Glyceraldehyde 3-phosphate dehydrogenase. 
 Preparation of bovine lactoferrin (bLf) 2.7.
The experimental work involving bLf was performed in N-LIMBR laborartory, Deakin 
University, Australia. 
2.7.1. Treatment of glasswares 
All the glasswares used for bLf preparation was treated with 30% nitric acid (HNO3) for 24 h 
for removal of metal ions. After the treatment, the glasswares were dried and autoclaved for 
further use.  
2.7.2. Preparation of Native bLf 
5 g of Native bLf powder was dissolved in 50 mL of sterile milliQ water with pH adjusted to 
5.8. A portion of the prepared Native bLf was aliquoted and stored at -20°C. 
2.7.3. Preparation of Apo bLf  
Both iron free (Apo) and iron saturated (Fe) forms of bLf were prepared according to the 
standardized methods mentioned in (Kanwar, Mahidhara & Kanwar 2012). Apo bLf was 
prepared from the prepared native bLf by adjusting the pH to 2.06 with 6 N HCl. On pH 
reduction, the reddish brown colour of the Lf changes to ivory white colour indicating the 
removal of bound iron in bLf molecules. The preparation was then extensively dialysed 
against 0.1 M citric acid using a 50 kDa molecular weight cut off spectra/pro dialysis tube 
(Pacific laboratory, Blackburn, Australia). The dialysis was carried out for 48 h at 4°C with 
continuous stirring and a change in citric acid every 12 h. The pH of Apo-bLf was then 
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changed to 8.0 with 10 M sodium hydroxide (NaOH) at the end of dialysis. A portion of the 
Apo bLf was aliquoted and stored at -20°C. 
2.7.4. Preparation of Fe bLf 
An aliquot of Apo bLf was taken as a starting material for the preparation of iron saturated 
bLf. Initially, 0.1 M NaHCO3 was added to the Apo bLf solution and the pH was adjusted to 
8.2 using 6 M NaOH. Freshly prepared Fe-NTA solution containing 0.3M ferric 
nonanhydrate and 0.6M nitrilotriacetate acid disodium salt was added drop-wise to the 
solution. The solution was stirred continuously with pH maintained at 8.0. The colour of the 
solution changes from ivory to deep marrow red indicating the iron complex formation. The 
solution was allowed to stir for 1 h. Dialysis of the sample was done against milli Q for 48 h 
at 4°C with change of milliQ every 12 h. The samples were stored at -20°C for further use. 
SDS-PAGE of all the three forms of bLfs were performed (Figure 2.2).  
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 Figure 2.2 SDS-PAGE showing the purified form of bLf 
Purified and dialysed form of Apo-bLf, Fe-bLf and Native-bLf were electrophoresed in a 10% 
SDS-PAGE gel. 50µg of protein was loaded for all forms of bLf. The protein bands migrated 
at a molecular weight of 78 kDa.  
2.7.5.  Iron estimation in Fe-bLf 
The procedure for measuring iron saturation in all the three preparartions of bLf (Native-bLf, 
Apo-bLf and Fe-bLf) was modified from the previously described method by King (1982). 
To 1 mL of each test solution [Native-bLf, Apo-bLf, Fe-bLf, blank (water) and iron standards 
(Ferric ammonium sulphate)] 50 µL of ascorbic acid was added and mixed well. The 
solutions were incubated for 5 min and then 100 µL of 65% tricholoroacetic acid was added 
to each tube. The solutions were allowed to incubate for 10 min after shaking vigorously for 
30 s. after the incubation period, the solutions were centrifuged at 1,000 rpm for 20 min. 100 
µL of alkaline acetate was added to 500 µL of the supernatant from each bLf sample, iron 
standards and blank, which was immediately followed by the addition of 75 µL of tripyridyl 
solution and incubation for 10 min. After the incubation period, 200 µL of each sample was 
transferred to an optically clear 96-well plate and absorbance was read in Asys Expert Plus 
microplate reader (Asys Hitech) at 550 nm. Iron concentration was estimated by using the 
below shown formula in all the samples. Estimated iron is shown in the Figure 2.3. 
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             Figure 2.3 Iron content in bLf 
Iron was estimated in all three forms of bLf. Native-bLf had 30% of iron content, Apo-bLf 
had 3% iron content and Fe-bLf had 97.5 % bLf content.  
2.7.6. Cellular internalization of bLf in Y79 cells by confocal microscopy 
Internalization of all three forms of bLf (Native-bLf, Apo-bLf and Fe-bLf) was studied in 
Y79 cells. 1x105 Y79 cells were seeded in a 6 well plate. The cells were treated with 12.5 
nmol of Native-bLf, Apo-bLf and Fe-bLf for 30 min by incubating the plates at 37°C. After 
the incubation period, the cells were washed with PBS and fixed with 4% paraformaldehyde 
(4% PFA) for 20 min. Following the incubation period, the cells were washed and were 
permeabilised using 0.1% Triton X 100 for 1 min on ice.  The cells were then washed and 
blocked with 3% porcine gelatin for 1 h at 37°C. Blocking was followed by washing the cells 
twice with PBS and incubation with primary antibody, goat anti-bLf (Bethyl Scientific, 
Australia) at a dilution of 1: 250 for 1 h at 37°C. Post primary antibody incubation, the cells 
were washed twice with PBS and incubated with secondary antibody, anti-goat FITC at a 
dilution of 1:100 (Sigma Aldrich, USA) for 1 h at 37°C in dark. Post-secondary antibody 
incubation, the cells were washed with PBS twice. The cells were coated onto a PLL coated 
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slide, allowed to dry and mounted using a Fluoro shield 4’, 6-diamidino-2-phenylindole 
(DAPI). The slides were then viewed using a confocal microscope. A minimum of five 
images from 5 different fields were captured for quantitative analysis.  
2.7.7. Cellular internalization of bLf in Y79 cells by flow cytometry 
Cellular uptake/internalization of all three forms of bLf in Y79 cells was studied by flow 
cytometric analysis. 1x105 Y79 cells were seeded in a 6 well plate. The time allowed for 
uptake was increased to 48 h compared to 30 min used to study internalization by 
immunofluorescence. The different concentrations used were 12.5 nmol, 25 nmol, 37.5 nmol, 
50nmol, 62.5nmol and 75 nmol for all three bLfs. After 48 h of incubation at 37°C, the cells 
were collected and washed with PBS. Cells were fixed with 4% paraformaldehyde for 20 
min, permeabilized with 0.1% Triton-X-100 for 1 min. Cells were then blocked with 3% 
porcine gelatin for 1 h at 37°C. Following blocking, cells were incubated with anti-bovine 
bLf specific polyclonal antibody raised in goat at 1:250 dilution (Bethyl Scientific, Australia) 
for 1 h at 37°C. Cells were washed and then incubated with secondary anti-goat IgG- FITC 
antibody (Sigma Aldrich, USA) at 1:100 dilution for 1 h in dark at 37°C. After washing with 
PBS, the cells were suspended in 500 µL of PBS analysed by flow cytometry (Canto II, BD 
Biosciences, USA).  
Methodology for Chapter 4 experiments 
 Molecular cloning 2.8.
A full length human NIS cDNA driven by CMV promoter in the pCMV6-AC vector was 
purchased from Origene (U.S.A). Another plasmid, EGP2 expressing NIS gene under the 
influence of EpCAM promoter was cloned. Cloning procedure is described below  
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2.8.1. Competent cell preparation by CaCl2 method 
Competent cells are bacterial cells which has fragile cell walls through which foreign DNA 
can enter. These bacterial cell walls can be made fragile and competent by exposing them to 
either chemical environment (CaCl2) or electrical field (electroporation). Exposing them to 
such treatments leaves the bacterial cell wall porous thus enabling easy uptake of DNA. For 
this study, competent cells were prepared by the CaCl2 method and the competent cells used 
were E.coli DH5-α. From the glycerol stock of E.coli DH5-α, a small amount was inoculated 
in a 5 mL Luria Bertani (LB) broth and incubated overnight in a shaking incubator at 37°C. 
The following day, from the activated culture, 50 µL was added to a 50 mL of LB broth and 
incubated for 2.5 h in a shaking incubator at 37°C. After the incubation period, an aliquot of 
15 mL from the 50 mL culture was centrifuged at 5,000 rpm for 5 min at 4°C. To the pellet, 5 
mL of cold 0.1M CaCl2 was added, mixed and centrifuged at 5,000 rpm for 5 min at 4°C. 
Supernatant was discarded and addition of 0.1M CaCl2 and the centrifugation step was 
repeated thrice. To the pellet, cold 0.1M CaCl2 was added again and incubated in ice for 1.5 
h. After the incubation period, cells were centrifuged and the pellet was resuspended in 0.1M 
CaCl2. The competent cells were used immediately for transformation.  
2.8.2. Transformation by heat-shock method 
Transformation is a basic technique where a foreign DNA is inserted into a bacterium for 
replication of the DNA (Alexandrine Froger & Hall 2007). In order to utilize this property of 
transformation, most of the plasmids are designed to possess bacterial origin of replication 
and an antibiotic resistance gene for selection of transformed colonies in bacteria. Heat-shock 
method of transformation was performed for this study. To the 100 µL of freshly prepared 
competent cell, 250 ng of CMV-NIS plasmid was added, mixed and incubated in ice for 10 
min. After 10 min of incubation, the vial was immediately transferred to a 42°C water bath 
for 90 s.  Immediately after 90 s, the vial containing competent cells and plasmid was 
                                                                                                                                      Chapter 2 
93 
 
incubated in ice for further 10 min. Following the heat shock treatment, the contents of the 
vial was transferred to a 1 mL of LB broth free of antibiotics and incubated in a shaking 
incubator at 37°C for 1 h. From the 1mL of cultured LB broth, 100 µL was plated onto a LB 
plate containing 25 µg/mL kanamycin antibiotic because of the presence of kanamycin 
resistance gene on CMV-NIS plasmid. The plate was incubated at 37°C overnight. The 
following day, kanamycin resistant colonies were picked, inoculated in a 5 mL LB broth 
containing kanamycin antibiotic and incubated at 37°C in a shaking incubator plasmid 
isolation procedures. 
2.8.3. Minipreparation of plasmid DNA 
Isolation of plasmid DNA in a small scale from bacteria is known as mini-prep. The usual 
method for recovering plasmids is the alkaline lysis method. In this study, a QIAprep Spin 
Miniprep kit (Qiagen) was used to isolate CMV-NIS plasmid. The overnight grown bacterial 
culture containing CMV-NIS plasmid was centrifuged at 5,000 rpm for 10 min at 4°C. The 
supernatant was discarded and the pellet was resuspended with 250 µL of resuspension 
buffer, Buffer P1 (RNAse and lyse blue added) (Buffer composition described in Appendix). 
The suspension was always kept in ice. To the suspension, 250 µL of lysis buffer, Buffer P2 
was added and mixed by inverting gently. The suspension turned blue. To the mix, 350 µL of 
neutralization buffer, Buffer N3 was added and inverted immediately for mixing. The 
solution turned white and cloudy. The solution was centrifuged at 13,000 rpm for 10 min at 
4°C. After the centrifugation, the supernatant was applied onto a spin column and centrifuged 
for 1 min. The flow-through was discarded and 500 µL of Buffer PB was added to the 
column and centrifuged for 1 min. The flow-through was discarded and 750 µL of Buffer PE 
was added to the column and centrifuged for 1 min. The flow-through was discarded and the 
column was centrifuged for 3 min to remove residual ethanol. The spin column was placed in 
a fresh 1.5 mL vial and 50 µL of Buffer EB was added to the centre of the column. The 
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column was allowed to stand for 1 min and centrifuged for 2 min. The eluted CMV-NIS 
plasmid was run on an agarose gel to confirm the correct size. CMV-NIS plasmid was stored 
at -20°C until further use. 
2.8.4. Maxi-preparation of plasmid DNA 
Isolation of plasmid DNA in a large scale from bacteria is known as maxi-prep. In this study, 
a Plasmid Maxi kit (Qiagen) was used to propagate CMV-NIS plasmid. The overnight grown 
bacterial culture containing CMV-NIS plasmid (100 mL) was centrifuged at 6,000 rpm for 15 
min at 4°C. The bacterial pellet was resuspended in 10 mL of ice-cold resuspension buffer, 
Buffer P1 (RNAse A added) (Buffer composition described in Appendix). The pellet was 
dissolved until no clumps remained in the solution. To the suspension, 10 mL of lysis buffer, 
Buffer P2 was added and was mixed gently by inverting. The suspension was allowed to 
incubate for 5 min at room temperature. After incubation, 10 mL of ice-cold neutralization 
buffer, Buffer P3 was added to the suspension. The tube was inverted immediately for proper 
mixing. The solution turned less viscous. The suspension was incubated for 20 min in ice. 
After incubation period, the sample was centrifuged at 12,000 rpm at 4°C for 30 min. The 
supernatant was added to a fresh tube and centrifuged at 12,000 rpm at 4°C for 15 min. The 
Qiagentip-500 was equilibrated by 10 mL of equilibration buffer, Buffer QBT. The column 
was allowed to empty by gravity flow. To the equilibrated Qiagentip, the supernatant of step 
5 was added and allowed to enter the resin. After the supernatant has passed the Qiagentip, it 
was washed with 2x30 mL of wash buffer, Buffer QC. After the washing step, the Qiagentip 
was placed in a fresh tube and the DNA was eluted by adding 15 mL of elution buffer, Buffer 
QF. To the eluted DNA, 10.5 mL of isopropanol was added to precipitate the DNA. The 
sample was centrifuged at 11,000 rpm for 30 min at 4°C. After the centrifugation, the 
supernatant was discarded. The pellet was washed with 5 mL of 70 % ethanol by centrifuging 
at 11,000 rpm for 10 min at 4°C. The supernatant was discarded and the pellet was air-dried 
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till the remnant ethanol evaporated. To the air-dried pellet, required volume of 1XTE buffer 
(pH 8.0) was added and resuspended. The correct size and quality of the CMV-NIS plasmid 
was analyzed on an agarose gel. 
2.8.5. Restriction digestion 
Restriction digestion enables DNA to be cut with the help of specific restriction enzymes at 
specific regions which results in compatible ends which are in turn capable of a desired 
ligation. CMV-NIS plasmid and EGP2-TK plasmid were digested using specific restriction 
enzymes like BamHI and XhoI. Using these restriction enzymes, NIS gene was extracted 
from the CMV-NIS plasmid and EpCAM vector backbone was extracted from the EGP2-TK 
plasmid. The reaction mix for restriction digestion consists of 250 ng of the plasmids, 2 µL of 
10X Buffer 4, 30 units of BamHI and XhoI and nuclease free water to make it up to 20 µL. 
The components in the reaction mix were mixed gently by pipetting up and down. The 
restriction digestion reaction was set for 3 h at 37°C. The digested product along with 
undigested sample was analyzed in an agarose gel.  
2.8.6. Gel elution 
The restricted digested product from the agarose gel was eluted using MinElute Gel 
Extraction Kit (Qiagen). The NIS gene from the digested CMV-NIS plasmid and EpCAM 
vector backbone from the digested EGP2-TK plasmid was excised from the agarose gel with 
a clean sharp scalpel. The gel slice was weighed and 3 volumes of solubilisation buffer, 
Buffer QG were added to 1 volume of gel. Incubation was done at 50°C for 10 min. One gel 
volume of isopropanol was added to the sample and was mixed by inverting the tube several 
times. The sample was applied to the MinElute column and centrifuged for 1 min at 11,000 
rpm. The flow-through was discarded and 500 µL of Buffer QG was added to the column and 
centrifuged for 1 min at 11,000 rpm. The flow-through was discarded and 750 µL of Buffer 
PE was added to the column and centrifuged for 1 min at 11,000 rpm. The flow-through was 
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discarded and the column was centrifuged for an additional 1 min at 11,000 rpm. The 
MinElute column was placed in a 1.5 mL vial and 10-15 µL of Buffer EB was added at the 
center of the membrane. The column was allowed to stand for a min and then centrifuged for 
1 min at 11,000 rpm. The eluted DNA was analyzed on an agarose gel for the correct band 
size.                            
2.8.7. Ligation 
Ligation is one of the key steps in the process of recombinant DNA technology. With the 
help of ligase enzymes, desired genes can be added or pasted onto a carrying vector. The 
eluted NIS gene and EpCAM vector backbone containing sticky ends was ligated using T4 
DNA ligase enzyme (Promega). The ligation reaction was set in a volume ratio of 1:3 of 
vector: gene insert. The total ligation reaction contained 1 volume of EpCAM vector 
backbone, 3 volume of NIS gene, 2 µL of 10X ligase buffer, 1 µL of T4 DNA ligase enzyme 
with nuclease free water made upto 20 µL. The reaction mixture was incubated at 16°C 
overnight. The ligated sample (EpCAM-NIS) was run in an agarose gel to check for the 
correct plasmid size. 
 Establishment of CMV-NIS and EpCAM-NIS stable transfectants of MCF-7 2.9.
cells 
2.9.1.  Maintenance of cell lines 
Human breast cancer cell lines, MCF-7, purchased from ATCC (U.S.A) was maintained in 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich, USA) supplemented with 10% 
foetal bovine serum. MIO-M1 (Human Retinal Müller glial cell line) was a gift from G.A. 
Limb, UCL Institute of Ophthalmology, London, England (Limb GA et al. 2002) and was 
maintained in DMEM medium supplemented with 10% foetal bovine serum. All the cell lines 
were grown in a 5 % CO2 incubator at 37°C. 
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2.9.2. Generation of stable MCF-7 transfectants 
MCF-7 cells were seeded on a 6-well plate at 1x105 cells. Transfection was performed after 
the cells attained 80% confluency. The transfection complexes were prepared with 
Lipofectamine TM 2000 transfection reagent (Invitrogen, USA) for both CMV-NIS plasmid 
and EpCAM-NIS plasmid. After 20 min of incubation, the complexes were added to cells in 
separate wells for each plasmid complex. After 4 h of incubation at 37°C in a 5% CO2 
incubator, the old DMEM medium was replaced with fresh DMEM medium containing 
serum for a further 48 h of incubation at 37°C in a 5% CO2 incubator before adding Geneticin 
(G418) (1mg/mL), an antibiotic for selection of positive clones. Geneticin containing media 
was added to the transfected cells for a period of 14 days. After 14 days, the survived cells 
were transferred to a separate dish till the cells become confluent in the dish. The survived 
cells was then analysed for NIS expression at mRNA and protein level. 
2.9.3. Overexpression of NIS in stable transfectants determined at mRNA level by qRT-
PCR 
5x105 cells of stable MCF-7 transfectants (MCF-CMV-NIS and MCF-EpCAM-NIS) were 
collected and the cells were processed for RNA isolation, cDNA conversion as mentioned in 
section 2.6.5 and 2.11.2.  qRT-PCR was performed as mentioned in section 2.11.3 with the 
NIS and GAPDH primers given in Table 2.4.  
Table 2.4 List of primers used in the NIS study 
Primers Sequence Amplicon size (bp) 
NIS FP:5’-TGCGGGACTTTGCAGTACATT-3’;  
RP:5’-TGCAGATAATTCCGGTGGACA-3’ 
132 
GAPDH FP:5'-ACCCACTCCTCCACCTTTGA-3';  
RP:5’ CTGTTGCTGTAGCCAAATTCGT-3' 
100 
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2.9.4. Overexpression of NIS in stable transfectants determined at protein level by 
Western blotting 
5x105 cells of stable MCF-7 transfectants (MCF-CMV-NIS and MCF-EpCAM-NIS) were 
collected and the cells were processed for immunoblotting as mentioned in section 2.5 with 
anti-human anti-NIS mouse monoclonal antibody (Abcam) (1:500) used as primary antibody. 
Secondary antibody was anti-mouse IgG-HRP conjugate (Sigma Aldrich, USA) (1:1000) 
used. The loading control was β-actin. Mouse monoclonal anti-human β-actin (Sigma 
Aldrich, USA) (1:4000) was used as primary antibody and anti-mouse-IgG HRP conjugate 
(Sigma Aldrich, USA) (1:7,000) was used as secondary antibody. The immunoreactive bands 
were detected with the Super Signal West Femto Chemiluminescent Substrate (Thermo 
Scientific, USA). The NIS band intensity was measured using a densitometer (BIORAD GS 
800, USA). The NIS band density thus obtained was then normalized with respect to the 
loading control β-actin using Image J software (NIH). 
2.9.5. Migration assay 
For the normal functioning of organisms and embryonic development, cell migration and 
invasion processes play a key role. One of the assays to study cell migration is the wound 
healing assay. The stable transfectants, MCF-CMV-NIS and MCF-EpCAM-NIS were seeded 
in a 6-well plate and allowed to grow till it attained full confluency.  A wound/scratch was 
created to the cell monolayer using a 200 µL pipette tip.  Fresh DMEM media with serum 
was added to the cells after washing with PBS to remove floating cells. Photographs of the 
wound in both controls as well as in the MCF-CMV-NIS and MCF-EpCAM-NIS were 
captured at 0 and 24 h using confocal microscope. 
2.9.6. Radioiodide Uptake Assay in the stable transfectants 
The standard assay for sodium iodide symporter (NIS) function is based on the measurement 
of radioiodide uptake (NaI125) in NIS-expressing cells. Radioactive iodide uptake studies in 
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the stable transfectants, MCF-CMV-NIS and MCF-EpCAM-NIS were performed as 
described (Carlin S et al. 2000). 1x106 cells of MCF-CMV-NIS and MCF-EpCAM-NIS were 
collected, washed with ice-cold incubation buffer (composition mentioned in appendix) and 
then incubated with 1mL of incubation medium containing 4 µCi/mL Na125I and 10µM of 
NaI for 2h. After the incubation period, the supernatant was discarded and the cells were 
washed with ice-cold incubation buffer. Cells were lysed using lysis buffer and collected as 
pellet. Activity was counted in the pellet using 2470 WIZARD2 Automatic Gamma Counter 
(Perkin Elmer, USA). 
2.9.7. Non-radioactive iodide uptake assay in the stable transfectants 
Iodide uptake assay is the basis of determining the function of NIS in NIS expressing cells. A 
spectrophotometric assay (reaction shown below) measuring the uptake of iodide in the stable 
transfectants, MCF-CMV-NIS and MCF-EpCAM-NIS was performed as described (Waltz F, 
Pillette L & Y 2010). Initially NaI standards were assayed for plotting the standard graph. 
NaI standards at 100, 200, 300, 400, 500, 600 and 700 nM was prepared in water and 
distributed in triplicates in a 96-well plate. To the NaI, 100 µL of ammonium cerium (IV) 
sulfate and 100 µL of sodium arsenite solutions were added and incubated for 30 min in dark. 
The absorbance at 420 nm was recorded immediately on a SpectraMax Plus 384 Absorbance 
Microplate Reader (Molecular Devices, USA). The stable transfectants, MCF-CMV-NIS and 
MCF-EpCAM-NIS was seeded at a density of 1x104 cells in a 96-well plate. The next day, 
the cells were washed with cold uptake buffer (composition mentioned in appendix) and the 
residual supernatant was discarded. Cells were then incubated with NaI (10µM) for 15, 30, 45 
and 60 min in dark. After the incubation period, NaI was decanted and washed with cold 
uptake buffer. To the cells, 100 µL of water, 100 µL of ammonium cerium (IV) sulfate (10.5 
mM) and 100µL of sodium arsenite solutions (24 mM) were added and incubated for 30 min 
in dark. After the incubation period, the plate was immediately read on a SpectraMax Plus 
                                                                                                                                      Chapter 2 
100 
 
384 Absorbance Microplate Reader (Molecular Devices, USA) at 420 nm. The logarithmic 
conversion of the means of A420 vs. iodide standard concentrations was taken for plotting 
the calibration curve. The iodide concentrations in the stable transfectants, MCF-CMV-NIS 
and MCF-EpCAM-NIS were determined after linear regression of the calibration curve. 
 
Reaction between As(III) and Ce(IV) cataluyzed by iodide (Sandell-kolthoff reaction) (Waltz, 
Pillette & Ambroise 2010). 
2.9.8. Inhibition of uptake by Sodium perchlorate 
Inhibition of iodide uptake was performed to show whether the iodide uptake is via NIS. 
1x106 cells of MCF-CMV-NIS and MCF-EpCAM-NIS were collected, washed with ice-cold 
incubation buffer and then incubated with 1mL of incubation medium containing 1mM 
sodium perchlorate, 4 µCi/mL Na125I and 10 µM of NaI for 2 h. After the incubation period, 
the supernatant was discarded and the cells were washed with ice-cold incubation buffer. 
Cells were lysed using lysis buffer and collected as pellet. Activity was counted in the pellet 
using 2470 WIZARD2 Automatic Gamma Counter (Perkin Elmer, USA). 
2.9.9. Efflux of iodide 
To determine the rate at which iodide is effluxed out, efflux assay was performed. 1x106 cells 
of MCF-CMV-NIS and MCF-EpCAM-NIS were collected, washed with ice-cold incubation 
buffer and then incubated with 1mL of incubation medium containing 4 µCi/mL Na125I and 
10 µM of sodium iodide for 2 h. After the incubation period, the supernatant was discarded 
and the cells were washed with incubation buffer. Cells were lysed using lysis buffer and 
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collected as pellet. This was noted as 0 mins.To the pellet, incubation buffer was added again 
and incubated further. Supernatant was collected in various time points (15, 30 and 60 min). 
Activity was counted at each time point in the supernatant as well as in the pellet using 2470 
WIZARD2 Automatic Gamma Counter (Perkin Elmer, USA). 
 Preparation and characterisation of nanocomplex  2.10.
Polyethyleneimine (PEI), a cationic polymer, has been used as an efficient nonviral vector for 
gene delivery in vitro as well as in vivo (Antoine Kichler et al. 2001). In this study, a 
nanocomplex of PEI/NIS pDNA coated by an EpCAM aptamer (EpDT3) was prepared and 
characterised. 
2.10.1. PEI nanocomplex preparation 
For the preparation of the complexes, NIS pDNA and PEI were mixed in water by pipetting 
at various weight ratios such as 1:1.25, 1:2.5, 1:3.75, 1:5, 1:6.25 and 1:7.5 by keeping NIS 
pDNA concentration constant. PEI/NIS pDNA complexes were formed on the basis of 
electrostatic attraction.  The complex formation was observed in agarose gel when the 
complexes were electrophoresed. For the nanocomplex formation, EpDT3 aptamer at 
increasing concentration starting from 50 nM till 200 nM was added to the PEI/NIS pDNA 
complex and incubated at 37° for 10 min. The formed nanocomplex was run in an agarose gel 
after 10 min of incubation. 
2.10.2. Dynamic Light Scattering 
The ζ-potential and particle size of the nanocomplexes were measured using a Zetasizer Nano 
ZS (Malvern Instruments Ltd., United Kingdom). Biostability of the prepared nanocomplexes 
in the presence of serum was also measured for 3 days by analyzing the ζ-potential and 
particle size at various period of time. 
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2.10.3. Transmission Electron Microscope 
Transmission electron microscope is a higher resolution microscope which uses electrons to 
form an image. The size and shape of the prepared nanocomplexes were imaged by 
transmission electron microscopy (TEM). A 20 µL of the cell suspension was placed on a 
carbon coated grid for 10 to 15 min allowing the particles to settle down.  The grid was 
removed and 20 µL of 3% Uranyl acetate was placed on the grid for 5 min.  Then the grid 
was removed, air dried and screened in the JEOL JEM1400 Transmission Electron 
Microscope at an accelerating voltage of 80 kV. Electron Micrographs were taken using the 
Olympus Keenview CCD camera attached to the microscope.   
2.10.4. Determination of NIS protein expression in the nanocomplex delivered cells 
5x105 cells of MCF-7 were seeded and transfection of NIS plasmid was done using different 
delivery vehicle such as lipofectamine, PEI alone and nanocomplex. The NIS expression after 
the transfection was analysed using immunoblotting. Immunoblotting was performed as 
mentioned in section 2.5.  
2.10.5. Nonradioactive iodide and radioactive iodide uptake assay 
The iodide uptake assay by both radioactive assay as well as non-radioactive assay was 
performed for the nanocomplex as described earlier in section 2.9.6 and 2.9.7. 
 
Methodology for Chapter 5 experiments 
 RB Tumor processing 2.11.
General information about primary RB tumor sample details and RB tumor processing have 
been mentioned in section 2.1 and 2.2 of this chapter. For the study of  Bcl-2, Bax and 
survivin splice variants expression in RB, twenty tumors were collected from 20 eyes for the 
study from the patients whose mean age 1.9 years. Out of the 20 tumors, 10 were poorly 
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differentiated, 5 were moderately differentiated and 5 were well differentiated tumors. Eight 
tumors were non-invasive and 12 were invasive and all 20 tumors were unilateral (Table 
2.5). Apart from this, all the tumors were also analyzed for choroidal, optic nerve, scleral and 
extra ocular invasion. Choroidal invasion was further divided into focal invasion, <3mm and 
>3mm, whereas for optic nerve invasion, pre laminar, post laminar and surgical end of the 
optic nerve were analysed (Sastre X et al. 2009). The entire study was conducted according to 
the principle tenets of the Helsinki Declaration.  
Table 2.5 Characteristics of tumor cohort used in survivin splice variants, Bax and Bcl-
2 expression study 
S.No Clinico-pathological information of RB tumors studied for NIS 
Histopathological 
features 
IIRC 
grade 
Invasion 
status 
Age/Sex Laterality Differentiation Treatment 
modality 
1 Focal RpE invasion. No 
Invasion of Choroid. 
D NI 2yr/M OS WD NC 
2 Choroidal invasion 
>3mm. Laminar and 
Post-Laminar invasion 
of the Optic nerve. 
D I 1yr/M OS MD NC 
3 No Invasion of Choroid, 
No Invasion of Optic 
Nerve. 
D NI 2yr/M OD PD NC 
4 Choroidal Invasion D I 3yr/F OD MD NC 
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>3mm. Pre-Laminar 
invasion of optic nerve. 
5 Focal Invasion of 
Choroid <3mm. Pre 
Laminar invasion of 
Optic Nerve 
D I 1.6yr/F OD MD NC 
6 No Choroidal Invasion. 
Pre-Laminar invasion of 
Optic Nerve. 
D NI 2yr/M OS PD NC 
7 Invasion of Choroid, 
<3mm, Laminar Pre-
Laminar and minimal 
Post-Laminar invasion 
of Optic Nerve 
D I 2yr/M OS PD NC 
8 No Invasion of Choroid, 
No Invasion of Optic 
Nerve 
D NI 2mon/M OD PD NC 
9 Focal Invasion of 
Choroid >3mm. 
Invasion of Pre-Laminar 
portion of Optic Nerve. 
D I 2yr/M OS WD NC 
10 Choroidal Invasion 
<3mm. No Invasion of 
Optic Nerve 
D I 5yr/M OS PD NC 
11 Focal choroidal Invasion 
measuring <3mm. Pre-
Laminar invasion of 
Optic Nerve. 
E I 7mon/M OS MD NC 
12 Focal choroidal invasion 
measuring <3mm .No 
E I 1yr/F OD WD NC 
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laminar and post 
laminar invasion of 
optic nerve. 
13 No choroidal invasion, 
prelaminar invasion of 
optic nerve. 
E NI 3yr/M OS MD NC 
14 No Invasion of Choroid, 
No Invasion of Optic 
Nerve 
E NI 2mon/M OS WD NC 
15 Invasion of the choroid 
measuring >3mm. Pre-
laminar invasion of the 
optic Nerve. 
E I 2yr/M OS PD C 
8 cycles 
16 Choroidal invasion 
measuring > 3mm. 
Prelaminar invasion of 
optic nerve. 
E I 2.5yr/M OS PD NC 
17 No choroidal Invasion.  
No Optic Nerve 
Invasion 
E NI 1mon/F OD WD NC 
18 Choroidal invasion 
measuring >3mm, Pre-
Laminar Laminar and 
Minimal Post-Laminar 
Invasion of Optic Nerve. 
E I 4yr/F OD PD NC 
19 Choroidal invasion 
measuring >3mm. Pre-
Laminar and Laminar 
Invasion of Optic Nerve. 
E I 2yr/M OD PD NC 
20 No Invasion of Choroid. E NI 3yr/F OS PD NC 
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Tumor cohort characteristics : Abbreviations: I – Invasive, NI – Non-invasive, M– male, F – 
female, yr – year, mon – Months, OD – right eye (unilateral), OS – left eye (unilateral), OU – 
both eyes (bilateral), PD – Poorly differentiated, MD – Moderately differentiated, WD – Well 
differentiated, C-Chemotherapy, NC – Non-Chemotherapy, ON -Optic nerve, RPE – retinal 
pigment epithelium. 
2.11.1. RNA isolation of the tumors 
Frozen RB tissues were homogenized and total RNA was isolated using the TRIzol reagent 
(Life technologies, USA) as mentioned in the section 2.6.5.  
2.11.2. cDNA conversion of the tumor RNA 
After the total RNA was assessed for its concentration and purity, 1 µg of it was converted to 
cDNA using the High Capacity cDNA Reverse Transcription kit (Invitrogen, USA). The total 
volume of the RNA mixture for cDNA conversion is 10 µL consisting of 1 µg of RNA, 1 µL 
of 10X RT buffer, 0.4 µL of 25X dNTP mix (100mM), 1 µL of 10X RT random primers, 0.5 
µL of multiscribe reverse transcriptase enzyme, 0.5 µL of RNase inhibitor and nuclease free 
water to make up the volume to 10 µL. The samples were mixed and loaded in a 
thermocycler (Eppendorf, India) with the thermal cycler conditions as mentioned in Table 
2.6. The cDNA obtained was stored at -20°C until further use.  
 
Table 2.6 Cycling conditions for RT-PCR 
TEMPERATURE (°C) TIME (min) 
25 10 
No Invasion of Optic 
Nerve 
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37 120 
85 5 
4 ∞ 
 
2.11.3. qRT-PCR for survivin splice variants, Bax and Bcl-2 
In 20 RB tumors, mRNA level of five survivin splice variants, Bax and Bcl-2 was 
investigated by using RT² SYBR® Green qPCR Mastermix (SABiosciences, USA). The PCR 
reaction mixture containing 100 ng of cDNA was prepared by adding 5 µL of 2 X SYBR 
green reagents, 0.2 µL of sense and antisense primer (10µM) of respective primers. The 
reaction mix was made upto 10 µL by adding nuclease free water. GAPDH was used as the 
endogenous control. The samples were placed in a PCR thermal cycler, ABI Prism 7500 
Sequence Detector (Applied Biosystems, Lab India, Chennai, India). The cycling conditions 
were initial denaturation step at 50°C for 2 min, 95oC for 5 min followed by 40 cycles of 
denaturation step at 95oC for 15 s then an annealing temperature at 60°C for 1 min and melt 
curve stage at 95°C for 15 s, 60°C for 60 s, 95°C for 30 s and 60°C for 15 s. The target gene 
expression was normalized with GAPDH expression. The data was then analysed by Livak 
method (Relative Quantification) (Livak KJ & TD 2001). The expression of all the genes in 
each sample was analyzed in triplicate for statistical comparisons. The primers and its 
respective amplicon size are described in the Table 2.7. 
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Table 2.7 List of primers used in the survivin splice variants, Bax and Bcl-2 study 
MOLECULE PRIMER SEQUENCE AMPLICON 
SIZE (bp) 
GAPDH Forward Primer 5'ACCCACTCCTCCACCTTTGA3' 100 
Reverse Primer 5'CTGTTGCTGTAGCCAAATTCGT3' 
Bax Forward Primer 5’CCTGTGCACCAAGGTGCCGGAACT3’ 98 
Reverse Primer 5’CCACCCTGGTCTTGGATCCAGCCC3’ 
Bcl-2 Forward Primer 5’ ATGTGTGTGGAGAGCGTCAA3’ 135 
Reverse Primer 5’ ACAGTTCCACAAAGGCATCC3’ 
Survivin WT Forward Primer 5’GACCACCGCATCTCTACATTC3’ 193 
Reverse Primer 5’TGCTTTTTATGTTCCTCTATGGG3’ 
Survivin ΔEx3 Forward Primer 5’GCTGGGAGCCAGATGACG3’ 71 
Reverse Primer 5’TCCGCAGTTTCCTCAAATTCTTT3’ 
Survivin 2-α Forward Primer 5’GCTTTGTTTTGAACTGAGTTGTCAA3’ 62 
Reverse Primer 5’GCAATGAGGGTGGAAAGCA3’ 
Survivin 2-β Forward Primer 5’CGGGCACGGTGGCTTA3’ 93 
Reverse Primer 5’CAACCGGACGAATGCTTTTT3’ 
Survivin 3-β Forward Primer 5’GAAAAAATTGGAAGCCAGATTCAG3’ 85 
Reverse Primer 5’ACAGACCCTGGCAAACATCAG3’ 
 
 Silencing of Survivin-WT and Survivin-ΔEx3 in RB cell line (Y79 cells) 2.1.
2.1.1. Maintenance of Y79 cell lines 
Human retinoblastoma cell line, Y79 was maintained as mentioned in section 2.6.1 
2.1.2. qRT-PCR for survivin splice variants, Bax and Bcl-2 in Y79 cells 
5x105 Y79 cells were collected and the cells were processed for RNA isolation, cDNA 
conversion as mentioned in section 2.6.5 and 2.11.2 respectively. qRT-PCR was performed in 
Y79 cells as mentioned in section 2.11.3 with the same set of primers. 
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2.1.3. Transfection of Sur-WT siRNA and Sur-ΔEx3 siRNA in Y79 cells 
For silencing Sur-WT and Sur-ΔEx3, 2x105 Y79 cells were seeded in a 6 well plate. 
Transfection was performed after the cells attained 50 % confluency for siRNA transfection. 
100 nM of Sur-WT siRNA and Sur-ΔEx3 siRNA (Dharmacon, Inc. USA) was diluted in a 
serum free RPMI media separately and was incubated for 5 min at 37°C. Similarly, 
lipofectamineTM 2000 (Invitrogen, USA) was also diluted in a serum free RPMI media and 
was incubated for 5 min at 37°C. The siRNA dilution and lipofectamine dilutions were mixed 
gently and were incubated for 20 min at room temperature for lipofectamine/Sur-WT siRNA 
and lipofectamine/Sur-ΔEx3 siRNA complex to form. After the incubation period, each 
complex was added to the cells containing serum free RPMI media.The complexes were 
removed 4 h after transfection and complete RPMI media with serum was added to the cells. 
The transfected cells were incubated at 37°C in 5 % CO2 incubator for 48 h until further 
analysis. 
2.1.4. qRT-PCR for Sur-WT and Sur-ΔEx3 silenced Y79 cells 
2x105 Sur-WT and Sur-ΔEx3 silenced Y79 cells were collected and the cells were processed 
for RNA isolation, cDNA conversion as mentioned in section 2.6.5 and 2.11.2. qRT-PCR 
was performed as mentioned in section 2.11.3 with the same set of Survivin-WT and 
Survivin-ΔEx3 primers. 
2.1.5. Immunoblotting for Sur-WT and Sur-ΔEx3 silenced Y79 cells 
5x105 Sur-WT and Sur-ΔEx3 silenced Y79 cells were collected and protein lysate prepared 
by lysing cells using RIPA buffer containing 250 µL of 1mg/mL of PIC (Sigma Aldrich, 
USA). Cells were then sonicated at 80 cycles/min. Protein estimation was carried out by the 
method of Bradford (Bradford 1976) . 100 μg of each sample was run on an 18 % SDS-
PAGE and then electrophoretically transferred onto nitrocellulose membrane. Nonspecific 
sites were blocked with 4 % nonfat dry milk. The blots were incubated with rabbit 
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monoclonal antibody against hSur-WT (Ab76424, Abcam) (1:500) and rabbit polyclonal 
antibody against hSur-ΔEx3 (Ab3731, Abcam) (1:250) overnight at 4°C. The blots were then 
incubated with anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (Sigma 
Aldrich, USA) at 1:2000 dilution for 2 h. After intermittent washes with TBS-T (Tris 
buffered saline-Tween 20), the immunoreactive bands were detected by ECL using the 
Supersignal West Femto-maximum sensitivity substrate (Thermo Scientific, USA). Mouse 
monoclonal antibody against β-actin (1:2000; Sigma Aldrich, USA) was used as the loading 
control and detected by Anti-mouse IgG HRP conjugated antibody (1:7000) (Sigma Aldrich, 
USA). The survivin band intensity was measured using a densitometer (BIORAD GS 800, 
USA) and was then normalized with respect to the loading control β-actin using Image J 
software (NIH). 
2.1.6. Annexin V staining of the Sur-WT and Sur-ΔEx3 silenced Y79 cells 
2x105 Sur-WT and Sur-ΔEx3 silenced Y79 cells were collected and washed with PBS. Five 
sets of samples/cells were prepared for apoptosis analysis using BD PharmingenTM FITC 
Annexin V Apoptosis Detection Kit I (BD Biosciences, CA, USA) as shown in Table 2.8. On 
addition of 100 µL of the mixture to each sample, the cells were incubated for 20 min at 
37°C. After the incubation period, cells were washed with PBS twice before analysing it in 
the FACS Calibur (BD Biosciences, CA, USA) using ‘CellQuest Pro’ software.  
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Table 2.8 Annexin V - PI Staining Mix 
Sample Contents 
Unstained  Untreated cells+1X Binding buffer 
Annexin alone  Untreated cells+4 µL of Annexin 
Propidium iodide alone Untreated cells+2.5 µL of Propidium iodide 
Control Untreated cells+4 µL of Annexin+2.5 µL of 
Propidium iodide 
Test Treated cells+4 µL of Annexin+2.5 µL of 
Propidium iodide 
 
2.1.7. Caspase 3/7 activity of the Sur-WT silenced Y79 cells 
2x105 Sur-WT silenced Y79 cells were collected and washed with PBS. Caspase 3/7 activity 
of the silenced samples was assessed by Apo-ONE® Homogeneous Caspase-3/7 Assay kit 
(Promega, USA). Caspase reagent was prepared by adding caspase substrate and caspase 
buffer in 1:100 dilution. The caspase reagent was then added to the cells in 1:1 ratio, 
distributed in 384 or 96 well plates and incubated at 37°C for 30 min in dark. Post-
incubation, the plate was read in a Spectra Max plus 384 (Molecular devices, USA) at an 
excitation wavelength range of 485 ± 20nm and an emission wavelength range of 530 ± 
25nm to detect caspase-3/7 activity in the silenced samples. 
 Statistical analysis 2.2.
Statistical analysis of all data was performed using SPSS® version 21 for Windows statistical 
software package. Data were assessed using student t-test for normally distributed variables 
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and Mann-Whitney U test for not normally distributed variables. In order to compare means 
of different subgroups, Kruskal-Wallis test was conducted for not normally distributed 
variables. Spearman correlation coefficient (r) was used to measure correlation of not 
normally distributed variables. For all tests, a two-sided P value of less than 0.05 was 
considered as significant. 
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Chapter 3 
 
Studies on sodium iodide 
symporter (NIS) expression in 
retinoblastoma: a 
clinicopathological report 
 
“One of the oldest examples of an imaging reporter gene in  humans is the sodium iodide 
symporter (NIS) which has emerged as  one of the most exciting and promising reporter 
genes in preclinical and translational research” – Penheiter et al, 2012
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3. Chapter 3 
 INTRODUCTION 3.1.
 
Retinoblastoma (RB) is a genetically determined pediatric intraocular tumor arising from the 
retinal cells of the infants (Xu XL et al. 2009). RB is prevalent in highly populated regions 
like Asia and Africa due to the lack of awareness about the disease and delay in diagnosis 
ultimately leading to high mortality rate in such regions (Dimaras et al. 2012). The estimated 
occurrence of RB in Australia is 14.8 (average number of cases per year) which covers 2.4% 
of all childhood cancers detected per year (Baade et al. 2010). However, in India, studies 
show that the estimated occurrence of RB is two-to-three times higher than the developed 
countries (Arora RS, Eden TO & G 2009). Also in India, human papilloma virus (HPV) 
infection is prevalent and the studies have shown that maternal transmission of HPV 16/18 
can possibly lead to the development of sporadic form of RB (Anand Bhuvaneswari, Jayshree 
& Kumar 2012; Shetty et al. 2012).  
Earlier, RB was considered a fatal disease among children but its survival rate has increased 
considerably over the past decade owing to the advancements in management and therapy 
(Naseripour 2012). To improve eye salvage, currently various treatments are available 
depending upon the size and grade of the tumors. Cryotherapy is performed on small tumors 
which are exposed to cold temperatures resulting in disruption of tumors (Shields, Shields & 
De Potter 1993) and laser photocoagulation treatment is also performed on selected small 
tumors where the lasers are used to coagulate the blood vessels near the tumor sites (Shields 
et al. 1994). Radiotherapy in RB is practised via two techniques. The first radiotherapy 
technique called plaque radiotherapy or brachytherapy (Shields et al. 2001) is meant for small 
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tumors and it uses a plaque made of gold or lead containing radioisotope which is placed near 
the tumor site to shrink the tumor. The second radiotherapy technique is External Beam 
Radiation Therapy (EBRT) which is administered on advanced tumors and is more effective 
than the brachytherapy (Stannard et al. 2013). EBRT in RB has its own limitations because 
tumors with germ line mutations are prone for secondary cancers. Its radio sensitivity could 
give rise to side effects  and current radiation treatment practices are based entirely on 
location and size of the  tumors (Finger PT 2002). Three main drugs used for chemotherapy 
in RB are carboplatin, vincristine and etoposide which are either used alone or in 
combination with other treatments (Bellaton et al. 2003). In order to avoid the undesirable 
effects of systemic chemotherapy, local chemotherapy like intra-arterial chemotherapy 
(Gobin et al. 2011), periocular chemotherapy (Schmack et al. 2006) and intra-vitreal 
chemotherapy (Buitrago et al. 2010) are practised. Apart from these conservative treatments, 
today there are studies aimed at various therapeutic targets in RB.  
Work from our laboratory has generated various therapeutic targets in RB. Epithelial cell 
adhesion molecule (EpCAM) was found to be highly expressed in RB especially in invasive 
cases and inhibition of this molecule could be a potential treatment (Krishnakumar S et al. 
2004). Another molecule known as fatty acid synthase (FASN) is also highly expressed in 
poorly differentiated and invasive tumors and has potential for treatment in RB (Vandhana S 
et al. 2011). Spleen tyrosine kinase (SYK) is extensively studied in RB with its expression 
involved in invasion and survival of tumor cells (Zhang J et al. 2012) and is considered to be 
a promising therapeutic target. Connexin 46, a gap junction protein found in hypoxic RB cell 
line was silenced to reveal an anti-tumor effect, thus establishing it as one of the therapeutic 
targets in RB (Burr DB et al. 2011). Apart from the above mentioned genes, micro RNAs 
(miRNAs) are also considered to be candidates for therapy. miRNA 17–92 cluster (Kandalam 
MM et al. 2012) has been shown to play a role in invasion and proliferation in RB and 
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inhibiting it would halt the cancer progression. In this context, one such novel therapeutic 
target that has not been studied in RB so far is sodium iodide symporter (NIS).  
 
As discussed in chapter 1, NIS is an intrinsic plasma membrane glycoprotein which plays a 
pivotal role in thyroid hormonogenesis by mediating iodide transport into thyroid cells. For 
many years, radiotherapy has been the primary and most successful treatment for follicular 
cell- derived thyroid carcinoma (Dohán O et al. 2003 ).  NIS-mediated iodide accumulation 
within the thyroid gland has played an important role for diagnostic nuclear imaging as well 
as for highly efficient molecular radionuclide-based targeted therapy of malignant thyroid 
diseases (E 1996a). NIS protein expression and NIS mediated radioiodide accumulation 
occurs not only in thyroid cells but also in other extra thyroidal tissues like salivary gland, 
gastric mucosa, lactating mammary gland, placenta and kidney (Alan R Penheiter, Stephen J 
Russell & SK 2012). NIS functions in the body in such a way that efficient adsorption of 
iodide from the food takes place. NIS present in salivary gland and stomach cells transports 
iodide from blood stream to lumen of intestinal tract (Brown-Grant 1961) and NIS present in 
intestines then transports iodide from lumen to circulation (Nicola et al. 2009). The transport 
of iodide across these organs is mainly because of NIS expression at the basolateral 
membrane of salivary gland and stomach (Josefsson et al. 2002) and apical membrane of 
intestine (Nicola et al. 2009). NIS is expressed at basolateral membrane of alveolar cells in 
lactating mammary gland and functions by transporting iodide from bloodstream to the milk 
for the feeding infants (Tazebay et al. 2000). Iodide is supplied to foetus from the mother via 
functional NIS expressed in the placenta (Bidart et al. 2000). I131 is used for ablation of 
cancer tissue after thyroidectomy, if NIS expressed in the metastatic tissues are functional 
(Arturi et al. 2000). Though NIS is exploited in follicular cell derived thyroid carcinoma 
treatment, its expression is lost in poorly differentiated thyroid tumors (Dohán O et al. 2003 ) 
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and not expressed in significant levels in non-thyroidal cancers. At present preclinical studies 
of radionuclide NIS gene imaging, accumulation of radionuclides in target cells at therapeutic 
doses are ongoing, and in future can be followed by clinical trials of NIS as an imaging agent 
as well as a therapeutic transgene (Baril P, Martin-Duque P & G 2010 ). 
With relevance to breast cancer, though NIS expression was higher, only a small fraction of 
cells possess the ability to take up radioiodide suggesting that further augmentation of the 
functional activity is required (Wapnir et al. 2003). For enhancement of NIS function, various 
ligands and hormones were identified and one among them was a group of ligands called 
retinoids (Tanosaki et al. 2003). The most influential ligand of the retinoid family is all-trans-
retinoic acid (tRA) which increased the NIS expression at transcriptional level and I- 
transport up to 10 fold. MCF-7 cell xenograft study revealed that on systemic tRA treatment 
at 160mg/kg/day for 5 days, a 15 fold increase in NIS expression and I- uptake was observed 
(Kogai et al. 2004). Stimulation of NIS expression at transcriptional level was shown not only 
in breast cancer cells but also in human follicular thyroid carcinoma cell lines like FTC-133 
and FTC-238 (Schmutzler et al. 2002).  
Similar to tRA’s transcriptional activity, lactoferrin (Lf) a natural molecule functions as a 
transcriptional trans-activator (He & Furmanski 1995). Lf is a glycoprotein which belongs to 
the transferrin protein family and is found in high concentrations in human milk and other 
epithelial secretions (Kanwar et al. 2009; Kanwar RK & JR 2013). Bovine Lf (bLf) is a 
multifunctional therapeutic protein with various properties like immunomodulatory, anti-
cancer, anti-inflammatory, anti-microbial and anti-oxidant (Kanwar RK & JR 2013; Tomita 
et al. 2009). Due to its iron binding properties, it occurs in three forms, Apo, Iron and Native. 
Apart from the above mentioned versatile functions, it is also thought to act as a 
transcriptional activator once it binds to the nucleus (He & Furmanski 1995). Studies on 
human Lf have shown it to trans-activate transcription factors like AP-1 and NFκB which 
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plays a key role in cell division and differentiation (Jiang et al. 2011). Another transcriptional 
activity of Lf was shown in increasing gene expression of IL-1β (Son KN et al. 2002) and 
TGF-β1 (Liao, Jiang & Lönnerdal 2012). More recently, the downregulation of survivin gene 
expression by bLf in colon cancer cells was reported from our laboratory (Kanwar et al. 
2014). 
While NIS expression has been widely detected in thyroid, breast and in various other 
cancers, its expression in RB has never been investigated. Since there is lack of knowledge of 
NIS expression in RB, the present chapter aims to unravel the NIS protein expression status 
in extra-thyroidal tumors, such as RB.  
 Hypothesis 3.2.
NIS expression has been studied in various extra-thyroidal cancers. This study hypothesized 
that if NIS was expressed in RB tumors, it would be associated with clinical parameters like 
histopathological high risk factors and tumor differentiation. Further it was hypothesized that 
bLf could upregulate the NIS protein expression in Y79, an established cell line from ATCC 
(American Type Culture Collection). 
 Aims 3.3.
The aims of this chapter are 
1) To investigate for the NIS expression at protein level in Grade D and Grade E RB 
tumors and in an established standard RB cell line (Y79).  
2) To explore if the NIS protein expression levels were correlated with the 
clinicopathological features of RB tumors.  
3) To study if the three forms of Bovine Lactoferrin (bLf), native-bLf, apo-bLf and Fe-
bLf could internalize in Y79 cells.  
4) To explore whether the internalised bLf upregulated NIS expression at protein level. 
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 MATERIALS AND METHODS 3.4.
 
The methodology for the experiments performed in this phase of study has been described in 
detail in chapter 2. A brief outline of the work carried out in this chapter for NIS has been 
explained in Figure 3.1. Outline of the bLf work has been explained in Figure 3.2. 
 
 
 Figure 3.1 Schematic representation of the NIS work performed in this study 
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Figure 3.2 Schematic representation of the bLf work performed in this study 
 
Tumor specimens  
Detailed clinical information of each tumor has been provided in chapter 2. Concise details of 
the cohort has been provided here as Table 3.1. 
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Table 3.1 Clinicopathological information of all RB tumors analysed for the study 
 
 
Table 3.1: Clinicopathological information of all RB tumors analysed for the study. 
 IIRC stands for International Intraocular Classification of Retinoblastoma.* No tumors 
belonged to Group A, B and C. 
Parameters No. of patients (N=41) 
Sex 
Male 
Female 
 
20 
21 
Age 
<5 years 
≥5 years 
 
34 
7 
Laterality 
Unilateral 
Bilateral 
 
33 
8 
Differentiation 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
 
8 
3 
30 
IIRC Grade* 
Group D,E 
 
41 
Invasion status 
Invasive 
Non-invasive 
 
25 
16 
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 RESULTS 3.5.
3.5.1. NIS protein is localised in membrane and cytoplasm of RB tumors  
In immunohistochemistry, all the 21 RB tumors showed strong positive immunostaining for 
NIS expression on the cell surface and in cytoplasm. Immunopositivity for NIS was observed 
mostly as membranous (Figure 3.3 A, B) and cytoplasmic (Figure 3.3 C). NIS expression 
was predominant in the tumors invading the choroid as shown in Figure 3.3 D, E and F and 
was majorly observed as cytoplasmic expression. The non-neoplastic retina showed 
immunopositivity at the inner and outer nuclear layer (Figure 3.3 H). The primary antibody 
control of both non-neoplastic retina (Figure 3.3 I) and tumor (Figure 3.3 G) showed no 
staining revealing the specificity of the procedure. An immunoscore was computed for each 
tumor using the staining intensity and percentage positive cells. The immunoscore was used 
to analyse association of NIS expression with different clinicopathological features (Table 
3.2). Though both poorly differentiated and well differentiated tumors showed NIS 
expression, 31.2% of the poorly differentiated tumors fell under higher immunoscore 
category. Additional IHC figures for NIS immunostaining are shown in Figure 3.4. 
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Figure 3.3 Immunostaining of NIS protein in RB tumor tissues 
Immunohistostaining of representative RB tumor tissues compared with non-neoplastic 
retina. NIS expression was visualized with 3,3’-Diaminobenzidine (DAB) and Hematoxylin 
was used as counter stain. (A) The photomicrograph at 20X shows strong membrane 
expression of NIS (red arrow) in tumor cells close to the retinal pigment epithelium (yellow 
arrow). Zoomed image of a portion of the immunostaining is shown at the left hand corner. 
(B) The photomicrograph at 100X shows the strong membrane expression of NIS (arrows 
show positivity) in a RB tumor at a 100X. Zoomed image of a portion of the immunostaining 
is shown at the top. (C) The photomicrograph at 100X shows the tumor cells positive for NIS 
expression, arranged around the blood vessels (arrow) at 40X. (D) (E) (F) The 
photomicrograph shows strong cytoplasmic expression of NIS in tumor cells invading the 
choroid, 10X, 20X, 40X respectively. Zoomed image of a portion of the immunostaining is 
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shown at the right hand corner. (G) The photomicrograph at 20X shows the primary antibody 
control in a RB tumor; no non- specific staining is observed. (H) The photomicrograph at 
40X shows NIS expression in a non-neoplastic retina. The staining for NIS protein observed 
in the inner and outer nuclear layers of the retina. (I) The photomicrograph at 20X shows the 
primary antibody in a non- neoplastic retina; no non- specific staining is observed. 
 
 
Figure 3.4 Immunostaining of NIS protein in different sets of RB tumor tissues 
Immunohistostaining of RB tumor tissues showing positivity for NIS visualized with 3,3’-
Diaminobenzidine (DAB) and Hematoxylin. (A-G) Zoomed image of a portion of the 
immunostaining is shown at the left hand corner. (H) & (I) The photomicrograph shows 
strong cytoplasmic expression of NIS in tumor cells invading the choroid.  
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Table 3.2 Association of NIS immunoscore by IHC with clinicopathological features. 
Category Total 
Number 
(n=21) 
Immunoscore by IHC 
2 3 4 6 
Males 11 4 (36.3%) 4 (36.3%) - 3 (27.2%) 
Females 10 5 (50%) 2 (20%) 1 (10%) 2 (20%) 
Laterality Unilateral 16 7 (43.7%) 4 (25%) - 5 (31.2%) 
Bilateral 5 2 (40%) 2 (40%) 1 (20%) - 
Differentiation* Poor 16 6 (37.5%) 5 (31.2%) - 5 (31.2%) 
Well 5 3 (60%) 1 (20%) 1 (20%) - 
Invasion 
Status  
Non Invasive 8 4 (50%) 1 (12.5%) - 3 (37.5%) 
Invasive 13 5 (38.4%) 5 (38.4%) 1 (7.6%) 2 (15.3%) 
 
Table 3.2: Association of NIS immunoscore by IHC with clinicopathological features. 
Immunoscore was calculated based on the staining intensity and percentage of positive cells. 
10 different fields were chosen and the score was assigned as 0, 1, 2 or 3 for staining 
intensity corresponding to negative, weak, intermediate and strong staining respectively. 
From each field, total number of cells and total number of stained cells were counted and 
average percentage positive was calculated. The final immunoscore of 2 to 6 was calculated 
as mentioned (Detre S 1995).* No tumor among the 21 was found to be moderately 
differentiated. 
3.5.2. Quantitative analysis of NIS by flow cytometry shows elevated expression in 
invasive tumors 
NIS was quantitatively measured by flow cytometry in another 20 RB tumor samples 
differing in their invasion status. Due to non-availability of normal retina tissue for flow 
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cytometry, analysis for normal retina could not be performed. The flow cytometric analyses 
of all the 20 tumors was correlated with different clinicopathological features and tabulated in 
the Table 3.3. Graphical representations of FACS analysis of 12 invasive tumors are shown 
in Figure 3. 5 and graphical representations of FACS analysis of 8 non-invasive tumors are 
shown in Figure 3.6. The inter-tumor differences in NIS expression with respect to invasion 
status were clear and the overall NIS protein expression was significantly elevated in the 
invasive tumors than the non-invasive tumors (P<0.05) (Figure 3.7). The expression of NIS 
did not show any statistically significant difference between poorly differentiated and well 
differentiated tumors as well as between gender and laterality (Table 3.4).  
 
Table 3.3 Association of NIS positivity with clinicopathological features on the basis of 
flow cytometry 
Category Total 
Number 
Percentage of NIS positivity by FACS (n=20) 
0-10% 11-20% 21-30% 31-40% 41-50% 
Males 9 6 2 - - 1 
Females 11 3 3 2 2 1 
IIRC 
classification 
Group D-E 20 9 5 2 2 2 
Differentiation Poor 14 6 3 1 2 2 
Moderate 3 1 1 1 - - 
Well 3 2 1 - - - 
Choroidal 
Invasion 
No invasion 10 6 4 - - - 
>3mm 5 - 1 1 2 1 
<3mm 5 3 - 1 - 1 
Optic nerve 
invasion 
No invasion 14 9 3 1 - 1 
Pre-laminar 5 - - 2 2 1 
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Table 3.3 : Association of NIS positivity by flow cytometry with clinicopathological features. 
IIRC stands for International Intraocular Retinoblastoma Classification. 
 
Figure 3.5 Flow cytometric analysis of NIS in invasive RB tumors. 
50mg of tumor was homogenized, washed with phosphate buffered saline (PBS), fixed with 
formaldehyde. Anti-human NIS, mouse monoclonal antibody at a dilution of 1:50 was added 
and incubated for 2 h. Following washing, the samples were incubated with anti-mouse IgG 
FITC antibody at a dilution of 1:750 for 1 h in dark. Following washing step, samples were 
analysed in FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA), with the 
CellQuest software program (BD Biosciences, USA). Isotype control was used for gating the 
Post-laminar 3 - 2 1 - - 
                                                                                                                                      Chapter 3 
128 
 
positive population. 10,000 events were acquired within the gating. The NIS percentage 
positivity in the graphs is shown. 
 
Figure 3.6 Flow cytometric analysis of NIS in non-invasive RB tumors. 
Flow cytometry was performed as described under Figure 3.5. 
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Figure 3.7 Computation of NIS positivity determined in flow cytometry 
The average percentage positivity of NIS by flow cytometry was computed for tumors with 
invasion and non-invasion. * Indicates significantly increased NIS expression in the invasive 
tumors with respect to non-invasive tumors (P<0.05). Mann-Whitney test was used to 
calculate the level of significance.  
Table 3.4 Association of NIS protein expression analysed in flow cytometry with 
clinicopathological features. 
 
Clinical Parameters 
 
Total number (n) P-value 
NIS 
Gender 
Male 
Female 
20 
9 
11 
0.271 
Laterality 
Unilateral 
Bilateral 
20 
17 
3 
0.153 
Differentiation 
Well Differentiated 
Moderately Differentiated 
Poorly Differentiated 
20 
3 
3 
14 
0.410 
Invasion status 
Non-invasive 
Invasive 
20 
8 
12 
0.031 
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Table 3.4: Association of NIS protein expression analysed in flow cytometry with 
clinicopathological features in 20 RB tumors. P-values were calculated by the Mann-
Whitney-test. 
3.5.3. Western Blotting reveals glycosylation status of NIS in RB 
NIS expression was semi-quantitatively assessed in 6 tumor tissues differing in invasion 
status by immunoblotting with two NIS antibodies. By using polyclonal anti-NIS antibody, 
strong partially glycosylated protein bands migrating with molecular weights of ~75kDa and 
~50kDa and a faintly underglycosylated protein band migrating with a molecular weight of 
~25kDa were observed (Figure 3.8.A). In contrast, using monoclonal antibody, the blots 
revealed strong intensity of band at 50 kDa (Figure 3.8.B).  The samples were tested for 
uniform loading with the loading control, β-actin (Figure 3.8.C). Histogram was plotted to 
show quantitative results of Western blot analysis of all the forms of glycosylated NIS protein 
detected by both polyclonal and monoclonal antibodies (Figure 3.8.D). Due to the non-
availability of normal retina tissue lysate for Western blot, analysis for normal retina could 
not be performed 
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Figure 3.8 Western blot of NIS protein expressed in RB tumor tissues 
Western blot of NIS protein expressed in 6 RB samples differing in their tumor invasion 
status. Fifty microgram of protein sample was loaded and (A) anti-human NIS rabbit 
polyclonal antibody (1:500) and (B) anti-human NIS mouse monoclonal antibody (1:500) 
were used for immunoblotting. Secondary antibodies were anti-mouse IgG-HRP (1:2000) 
and anti-rabbit IgG-HRP (1:2000) for respective primary antibodies. The immunoreactive 
bands were detected by the SuperSignal West Femto Chemiluminescent Substrate (Thermo 
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Scientific, USA) and developed by the x-ray method(C) The samples were tested for equal 
protein loading with β-actin. (D) The histogram depicts the NIS/β-actin ratio observed in 
individual lanes for all the glycosylated forms of NIS protein calculated by NIH Image J 
software.  
3.5.4. Quantitative analysis of NIS by flow cytometry in Y79 cells 
NIS was quantitatively measured by flow cytometry in Y79, a RB cell line obtained from 
American Type Culture Collection (ATCC,U.S.A) which was maintained in Roswell Park 
Memorial Institute 1640 medium (RPMI 1640, Sigma Aldrich, USA) supplemented with 
10% foetal bovine serum. The flow cytometric analysis for NIS protein in Y79 cells showed a 
clear shift in population of cells that are stained positive. This shift in intensity between the 
secondary antibody alone and the test sample shows NIS expression at endogenous level in 
Y79 cell line (Figure 3.9).  
 
Figure 3.9 Flow cytometric analysis of NIS in Y79 cells 
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1x106 cells were collected, washed with phosphate buffered saline (PBS), fixed with 
formaldehyde. Anti-human NIS, mouse monoclonal antibody at a dilution of 1:50 was added 
and incubated for 2 h. Following washing, the samples were incubated with anti-mouse IgG 
FITC antibody at a dilution of 1:750 for 1 h in dark. Following washing step, samples were 
analysed in FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA), with the 
CellQuest software program (BD Biosciences, USA). Isotype control was used for gating the 
positive population. 10,000 events were acquired within the gating. 
3.5.5. Immunofluorescence shows NIS positivity in Y79 cells 
Y79 cells were analysed for NIS protein expression and localization by immunofluorescence 
technique. The results showed strong cell surface and membrane positivity for NIS in Y79 
cells (Figure 3.10). The IgG1 control for NIS antibody did not show any fluorescence 
confirming the specificity of NIS staining. 
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Figure 3.10 Immunofluorescence of Y79 cells 
 Different fields of Y79 cells, a RB cell line showing immunofluorescence positivity for NIS 
expression. 1X106 cells were collected, washed with Phosphate Buffered Saline, fixed with 
4% paraformaldehyde and blocked with fetal bovine serum. Anti-human NIS, mouse 
monoclonal antibody at a dilution of 1:50 was added and incubated overnight at 4°C. 
Following washing, the samples were incubated with anti-mouse IgG FITC antibody at a 
dilution of 1:60 for 1 h in dark. Staining was observed using fluorescent microscope (Carl 
Zeiss, Berlin, Germany). For primary antibody control, the same procedure was performed 
with the isotype IgG1, anti-mouse antibody (Santa Cruz). The photomicrographs at 10X and 
20X show strong membrane and cell surface expression of NIS in Y79 cells.  
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3.5.6. Western Blotting shows NIS expression at 75 kDa in Y79 cells 
To detect the NIS protein expression in Y79 cells, the more sensitive technique of Western 
blotting was performed. Seventy five microgram of the protein lysate was loaded and a single 
protein band of NIS migrating at 75 KDa (red arrow) was detected in the blot when probed 
with anti-human NIS specific antibody. GAPDH migrating at 37 kDa (red arrow) was 
detected for the same sample when probed with GAPDH specific antibody (Figure 3.11).  
 
Figure 3.11 NIS protein is expressed in Y79 cells  
 Seventy five microgram of protein sample was loaded and anti-human anti-NIS mouse 
monoclonal antibody (1:500) was used for immunoblotting. Secondary antibody was anti-
mouse-HRP (1:1000) used. The protein lysate was tested for loading control, GAPDH. Anti-
human GAPDH rabbit monoclonal antibody (1:1000) was used as primary antibody and 
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anti-rabbit IgG HRP (1:80,000) was used as secondary antibody. The immunoreactive bands 
were detected by the ECL method.  
3.5.7. Endogenous level detection of Lf receptors in Y79 cells 
To detect the endogenous level of three Lf receptors, low-density lipoprotein receptor-related 
proteins-1 and -2 (LRP1 and LRP2) and transferrin receptor (Tfr) in Y79 cells, qRT-PCR was 
performed. LRP1, LRP2 and transferrin receptors specific primers were used to determine 
mRNA levels of the housekeeping gene as a control. Delta CT value was calculated by 
subtracting the CT value of receptors with CT value of GAPDH control. Based on delta CT 
value, LRP2 mRNA level was found to be higher followed by LRP1 and transferrin (Figure 
3.12).  
 
Figure 3.12 Y79 cells have endogenous Lf receptors mRNA expression 
The mRNA expression of Lf receptors (LRP1, LRP2 and Tfr) in Y79 cells analyzed by real 
time quantitative reverse transcriptase PCR (qRT-PCR).1µg of RNA was converted to cDNA. 
100 ng of cDNA, specific primers and RT² SYBR® Green qPCR Mastermix was used for the 
analysis. The data was then analysed by Livak method (Relative Quantification). Values are 
expressed as mean ± SD of triplicate analyses.  
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3.5.8. Uptake of three forms of bLf in Y79 cells by flow cytometry 
Since the Lf receptors were expressed in Y79 cells, the uptake of all three bLf forms (Native-
bLf, Apo-bLf and Fe-bLf) in Y79 cells was studied at a quantitative level by flow cytometry. 
For the uptake studies, a range of concentration such as 12.5 nmol, 25 nmol, 37.5 nmol, 
50nmol, 62.5nmol and 75 nmol of all three bLfs were chosen. Uptake study by flow 
cytometry was performed 48 h after the bLf treatments.  In case of Apo-bLf, the percentage 
of positivity was approximately 75 % in all concentrations. Similar results were observed in 
Fe-bLf and Native-bLf which shows effective uptake of bLf forms irrespective of their iron 
saturation levels (Figure 3.13).     
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Figure 3.13 Cellular uptake of Apo-bLf, Fe-bLf and Native-bLf in Y79 cells 
Y79 (RB) cells were seeded at a confluency of 1x106 cells/ well. The cells were then treated 
with 12.5nmol, 25nmol, 37.5nmol, 50nmol, 62.5nmol and 75nmol of Apo-bLf, Fe-bLf and 
Native-bLf for 48 h. Cells were fixed with 4% paraformaldehyde for 20 mins, permeabilized 
with 0.1% Triton-X-100 for 2 mins. Cells were then blocked with 3% porcine gelatin for 1 h 
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at 37°C. Following blocking, cells were incubated with anti-bovine bLf specific polyclonal 
antibody raised in goat at 1:250 dilution for 1 h at 37°C. Cells were washed and then 
incubated with secondary anti-goat IgG- FITC antibody at 1:100 dilution for 1 h in dark at 
37°C. After washing step, cells were analysed by flow cytometry (Canto II, BD Biosciences, 
USA). Isotype control was used for gating the positive population. 10,000 events were 
acquired within the gating. 
3.5.9. Cellular uptake of three forms of bLf in Y79 cells by immunofluorescence 
After the uptake of bLf was confirmed by flow cytometry, immunofluorescence followed by 
confocal microscopy was also performed to visulaize the internalized forms of bLf. The 
concentration of Native-bLf, Apo-bLf and Fe-bLf used in this experiment to study the 
cellular internalization was 12.5 nmol. The time allowed for internalization for all the three 
forms of bLfs was 30 min. This short time was chosen to observe the rate of efficiency at 
which the bLf’s get internalized. bLf’s internalization percentage was calculated by counting 
the number of cells that have taken up bLf from five different fields. In all the cases, efficient 
internalization of bLf into the cytoplasm was observed at 30 min along with strong 
fluorescence signals on cell membrane indicating the membrane binding (Figure 3.14.A). 
The percentage internalization of Apo-bLf was 92%, Fe-bLf was 94% and Native-bLf was 
97%. No significant difference was obtained for internalization among the different forms of 
bLfs (Figure 3.14.B).  
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Figure 3.14 Apo-bLf, Fe-bLf and Native-bLf bind to cell membrane and get efficiently 
internalized by 30 min. 
(A) Y79 cells were seeded at a confluency of 1X105 cells/ well. The cells were then treated 
with 12.5nmol of Apo-bLf, Fe-bLf and Native-bLf for 30 mins. Cells were fixed with 4% 
paraformaldehyde for 20 min, permeabilized with 0.1% Triton-X-100 for 2 min. Cells were 
then blocked with 3% porcine gelatin for 1 h at 37°C. Following blocking, cells were 
B
A
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incubated with anti-bovine bLf specific polyclonal antibody raised in goat at 1:250 dilution 
for 1 h at 37°C. Cells were washed and then incubated with secondary anti-goat IgG- FITC 
antibody at 1:100 dilution for 1 h in dark at 37°C. After washing step, cells were mounted 
using Vector mounting media containing DAPI which is used to stain the nucleus.  Time 
dependent internalisation of both Apo-bLf and Fe-bLf was performed. Slides were then 
visualised using Leica SP5 confocal microscopy and the images were processed using LAS 
version software. (B)Figure shows the histogram of the immunofluorescence experiment. The 
experiment was performed twice independently. Data has been expressed as mean values 
(±SD).  
 Determination of NIS protein expression after bLf treatment 3.6.
Following efficient internalization of three forms of bLf, NIS protein expression after the bLf 
treatments was analysed using Western blotting. Four different concentrations, 12.5 nmol, 25 
nmol, 50 nmol and 100 nmol of all 3 bLf samples were used for treatment of Y79 cells. 
Forty-eight hours after the treatment, NIS expression at protein level was analysed by 
Western blotting. NIS protein expression when compared to control/untreated cells showed 
an evident increase in the apo-bLf treatment at 25 nmol and Fe-bLf treatment at 50 nmol 
among the other bLf treatments which showed a slight increase in NIS expression (Figure 
3.15). Thus, via Western blotting, it was confirmed that bLf treatments did have a 
transcriptional activating effect on NIS expression in Y79 cells.  
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Figure 3.15 Western blot of NIS protein detected after three forms of bLf treatments in 
Y79 cell line 
Seventy five microgram of protein sample was loaded and anti-human anti-NIS mouse 
monoclonal antibody (1:500) was used for immunoblotting. Secondary antibody, anti-mouse-
IgG HRP (1:1000) was used. The samples were tested for equal protein loading with 
GAPDH. Anti-human anti-GAPDH rabbit monoclonal antibody (1:1000) was used as 
primary antibody and anti-rabbit IgG-HRP (1:80,000) was used as secondary antibody. The 
immunoreactive bands were detected by the ECL method. The histogram depicts the relative 
intensity of the bands observed in individual lanes for all the samples. 
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 DISCUSSION   3.7.
This study shows for the first time the presence of NIS protein in RB tumors and its 
correlation with the aggressiveness of tumors. Expression of NIS protein in RB tumors from 
patients as well as in established standard RB cell line (Y79) was determined. Earlier, NIS 
was found in ciliary body of the eye that can actively accumulate iodide (Dohán O et al. 2003 
). In this study, 41 primary RB tumors was used which belonged to advanced stage (Grade D 
or E) and NIS expression was observed in 41/41 (100%) tumors. By immunohistochemistry 
(IHC), the 13 invasive tumors which had invaded ocular coats and/or the optic nerve and 8 
non-invasive tumors showed immunoreactivity for NIS protein. The adjacent retina did not 
show evident positivity except in the inner and outer nuclear layers.  The predominant pattern 
of NIS immunoreactivity in RB tumors was both membranous and cytoplasmic. The 
expression of NIS however was also cytoplasmic staining at the invasion sites. Apart from 
more NIS presence in the invading front, intratumoral NIS protein expression was 
heterogeneous with few cells showing membrane positivity and few cells showing 
cytoplasmic positivity. A similar altered localization was also observed in many other cancers 
like thyroid cancer (Wapnir et al. 2003) and breast cancer (Tazebay et al. 2000) where the 
NIS was found to be expressed in cytoplasm than in the membrane which resulted in no 
iodide uptake activity. Recent study has shown that the intracellular NIS expressed in cancers 
indeed has a function in cell migration and invasion instead of transporting iodide ion 
(Lacoste C 2012). Since the intracellular NIS in tumors is associated with cell migration and 
invasion, the RB tumors expressing cytoplasmic NIS could be associated to aggression in RB 
tumors. This altered function of NIS has been attributed to its interaction with RhoA guanine 
exchange factor. In RB, Rho-like GTPase expression has been studied earlier although its 
role in malignancy has been reported to be minor (Adithi et al. 2006). Since the function of 
cytoplasmic NIS and its interaction partner has been elucidated, it clearly indicates that NIS 
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expression is altered in RB and whether it may interact with Rho-like GTPase to possibly 
alter the function of NIS in RB needs further studies.  
Flow cytometry assay further confirmed the IHC findings by showing varying levels of NIS 
positivity and markedly higher protein expression in tumors with invasion. The average 
percentage positivity of NIS by flow cytometry indicated a significantly higher NIS 
expression in tumors with histopathological high risk factors like invading choroid and/or 
optic nerve with respect to non-invasive tumors (P<0.05). Earlier studies in radiation therapy 
in RB showed that poorly differentiated RB tumors are more sensitive to radiation (Finger PT 
2002). Since this study reveal that NIS is expressed modestly higher in poorly differentiated 
tumors, the radiosensitivity may be attributed to NIS presence. NIS expression when analysed 
by flow cytometry did not yield a statistically significant difference among the differentiation 
status of tumors, laterality and gender. Since, moderately differentiated tumors have both 
poorly and well differentiated areas in isolation, it was challenging to correlate the NIS 
expression level. However, in this study, though moderately differentiated tumors were 
considered, the NIS expression was not statistically significant. Out of 20 RB cases analysed 
for NIS expression by flow cytometry, 3 cases were chemotherapy-treated tumors and this 
did not show any effect of drugs on NIS expression. A recent study in breast cancer showed 
such non-significant relationship between NIS expression and clinical characteristics of 
tumors (Ryan et al. 2011). However, significant correlations between NIS expression and 
histopathological high risk factors have been observed in other studies in testicular and 
prostate cancer (Micali et al. 2013; Navarra et al. 2010). Such difference in correlation 
studies of NIS and clinical parameters may be primarily due to difference in tissue origin and 
also different methodology used to analyse the expression. The limitation of the study was 
smaller cohort size and dissimilar tumor cohort used for flow cytometry and IHC. Since the 
tumor cohorts were not similar, a conclusive association between NIS expression and 
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clinicopathological features could not be achieved. Nevertheless, the significant relation of 
NIS expression with invasion of the tumors was shown by flow cytometry and by 
cytoplasmic expression in IHC. Thus, the above obtained results point to a 100% NIS 
expression and its possible role in tumor progression and invasiveness of the tumors. 
Having shown that NIS protein is expressed in RB, the next investigation was directed 
towards the glycosylation status of the expressed NIS protein. The monoclonal anti-NIS 
antibody detected only one band at 50 kDa, whereas polyclonal anti-NIS antibody detected 
three bands at ~75 kDa, ~50 kDa and ~25 kDa in all nine tumor samples tested. In thyroid 
tumors, it has been reported that fully glycosylated protein migrates at 90 kDa, partially 
glycosylated protein migrates with a molecular weight of 50 kDa and underglycosylated 
protein migrates with a molecular weight of 15 kDa (Peyrottes I et al. 2009). Earlier 
investigations also show that on treatment of membrane proteins from thyroid and lactating 
mammary gland with N-glycosidase F (an enzyme that removes N-linked carbohydrates), 
anti-NIS Ab recognized ~50-kDa polypeptide in membranes from both tissues. The results 
conclusively demonstrated that ~75 kDa and ~50 kDa immunoreactive bands detected in 
lactating mammary gland corresponded to glycosylated and nonglycosylated-NIS, 
respectively (Tazebay et al. 2000). In consistent with the published data, the Western blot 
results further reveal the presence of partially glycosylated and underglycosylated forms of 
hNIS protein in the RB tumor samples which most likely corresponds to unprocessed hNIS 
protein. A recent study on glycosylation showed that even hypoglycosylated NIS has the 
ability to locate to the cell surface and that it may function similar to mature fully 
glycosylated NIS protein during post translational modifications. Interestingly,a recent study 
on glycosylation showed that even hypoglycosylated NIS has the ability to locate to the cell 
surface and that it may function similar to mature fully glycosylated NIS protein (Beyer et al. 
2011a). Both the IHC and Western blotting results of the current study, yielded information   
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that though the expressed NIS protein in RB is partially glycosylated, it was still found to be 
on the membrane and cell surface. Therefore, it will be interesting in the future studies to find 
out if the glycosylation impact the functionality of the NIS protein. 
NIS is considered to be one of the primary therapeutic and diagnostic proteins because of its 
ability to uptake radioactive substrates and help in killing the cancer cells or in imaging the 
target (Kogai T & GA 2012 ). Our investigation on NIS protein in RB tumors showed that it 
was predominantly expressed in all tumors analysed. The same analysis was also performed 
in RB cell line, Y79, for NIS protein expression. Similar to RB tumor tissues, the NIS protein 
was expressed in Y79 cells which were studied by flow cytometric analysis revealing 
endogenous NIS expression. In addition, immunofluorescence was performed on Y79 cell 
line for NIS and found that NIS was expressed endogenously and displayed strong 
immunofluorescence for the antigen. Immunofluorescence revealed the localization of the 
expressed NIS protein to be primarily on the cell surface and in the cell membrane. Final 
confirmation of NIS protein presence was done by the sensitive technique of Western 
Blotting which revealed a single 75 kDa protein band revealing a glycosylated protein. 
Determination of functional activity of the endogenously expressed NIS protein in Y79 cells 
was performed via non-radioactive iodide uptake method (Waltz, Pillette & Ambroise 2010) 
but the attempt was unsuccessful primarily because of the difficulty in performing the assay 
in suspension cells. 
Since NIS expression was observed in all tumors studied and not in their normal surrounding 
tissues, it may be used for targeted molecular radionuclide therapy. Though NIS was found to 
be present in the inner and outer layer of retina, using tumor specific promoters, NIS can be 
specifically overexpressed in the RB tumors, thus being functional only in the tumor areas.  
Diagnostic and therapeutic applications are performed on thyroid cancer cells expressing NIS 
using its radioactive substrates. Radiopharmaceutically, NIS has significant advantages as a 
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therapeutic gene as well as a reporter gene (JK 2002 ). Thyroid follicular cells and 
differentiated thyroid cancer cells have the ability to capture radioiodide more effectively and 
this forms the basis of radionuclide therapy in the thyroid disease (Baril P, Martin-Duque P & 
G 2010 ). Like thyroid cancer, breast cancer also majorly express NIS (Tazebay et al. 2000) 
(Wapnir IL et al. 2004) but unlike thyroid cancer, breast cancer does not retain functional 
NIS expression (Hyuk Moon et al. 2001; Wapnir et al. 2004). In breast cancer (Kogai et al. 
2004; Wapnir et al. 2003) as well as in some differentiated thyroid cancers (Dohán et al. 
2001; Saito et al. 1998; Wapnir et al. 2003), NIS expression is more in cytoplasm and it fails 
to translocate to the membrane and so reduced radioiodide uptake was observed in these 
cancer cells. Various epigenetic mechanisms lead to poorly differentiated cancers and studies 
have shown in thyroid cancer cells which are poorly differentiated, that inhibition of such 
mechanisms leads to re-expression of thyroid genes like NIS (Furuya F et al. 2004). The 
phosphatidylinositol-3 kinase (PI3K) regulates the translocation of NIS to membrane in 
breast cancer cells as both transient and chronic PI3K activation was shown to increase 
underglycosylated NIS protein levels but impair NIS cell surface trafficking, thus leading to 
the absence of NIS-mediated radioiodide uptake activity in MCF-7 cells (Knostman KA et al. 
2007 ) . PI3K/AKT pathway is known to be dysregulated in RB (Cohen Y et al. 2009 ).  It 
would be interesting to study in future if the modulation of this dysregulated pathway has any 
implications for translocation of NIS to membrane for its full functionality in RB.  
 
In the case of diagnosis of RB, CT scan or MRI is primarily used. The principle of CT 
scanning is that the tumor being highly dense and calcified can be easily observed after 
administration of contrast dye containing iodide (Beets-Tan et al. 1994). Since NIS was 
found to be specifically expressed at a higher level in RB tumor tissues and absent in 
surrounding healthy tissues, the differential contrast achieved due to the uptake of iodide 
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containing contrast dye in NIS expressing tumor tissues, may lead to new diagnostic avenues 
for RB. 
In breast cancer, the localization of iodide via NIS has been attributed to the presence of 
insulin like growth factor (IGF). Studies have shown that breast cancer expresses IGF-1 
which is associated to more dense tissues which in turn shows better radiographic contrast 
(Byrne et al. 2000; Diorio et al. 2005). Another study in breast cancer revealed that IGF is a 
promoter of NIS and iodide uptake via NIS is stimulated by IGF which leads to increased 
retention of iodide by NIS in the breast cancer cells (Arturi et al. 2005). In RB, a study has 
reported that IGF pathway involving IGF-I and IGF-II plays a role in the tumorigenesis 
(Giuliano et al. 1996). So, in RB, it may be suggested that IGF may stimulate NIS to retain 
iodide for longer period which in turn could be responsible for enhanced contrast observed 
during routine CT imaging.  
In RB treatment, high energy radiation via external beam radiotherapy is given to cancer cells 
to destroy them. Since NIS protein is extensively used for radiotherapy in thyroid cancer and 
breast cancer treatment, the findings of this study implies that the radiotherapy for RB could 
be channelized via NIS. The potential for exploiting NIS mediated radioisotopic therapy is 
considerable especially if combined with standard therapies such as EBRT and also 
radiosensitizing drugs. This strategy has enormous translational potential for achieving 
tumor-specific escalation of radiation dose at various tumor sites. This may bring down the 
side effects caused by EBRT and may also make the radiotherapy be more specific.  
Currently, two strategies are used to induce NIS expression in cancer cells. One is transfer of 
NIS gene using viral and non-viral vectors. Second strategy is to stimulate the functional 
activity of endogenous NIS using stimulating agents thought to be having an upregulatory 
effect on NIS expression along with enhancing the iodide uptake ability (Alotaibi et al. 2010). 
Having studied that NIS is expressed in RB at endogenous level, an attempt was made to 
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enhance the expression of NIS protein in Y79 cells using bovine lactoferrin (bLf), a natural 
transcriptional activator of genes (Gifford, Ishida & Vogel 2012). Though many studies 
including the one from our laboratory have shown that Lf activates genes at transcriptional 
level, none have shown the effect on NIS gene expression. Initially, the status of Lf receptors 
was analysed in Y79 cells at mRNA level in order to determine the possibility of receptor 
mediated cellular uptake of bLf in these cells. The findings revealed mRNA presence of three 
receptors, LRP1, LRP2 and Tfr in Y79 cells. Following the determination of presence of Lf 
receptors, three forms of bLfwere used to enhance the NIS expression. The internalization 
studies at 30 min showed an effective internalization of all the three forms of bLf (Apo-bLf, 
Fe-bLf and Native-bLf) in the cytoplasm of Y79 cells along with strong presence of bLf on 
cell membranes. The microscopic observation of internalization was further confirmed by the 
flow cytometric analysis which also showed a maximum shift in cell population positive for 
bLf 48 h after bLf treatment. Since the internalization studies showed encouraging results, 
NIS protein expression after bLf treatments were analysed. Analysis of NIS protein level 
after treatment with various concentrations of Apo-bLf, Fe-bLf and Native-bLf revealed a 
dose dependent increase in NIS expression with the Apo-bLf and Fe-bLf treatments. Due to 
difficulty in performing the functional assay in suspension cells, the determination of the 
functional activity of the bLf induced NIS expression was unsuccessful. However, an 
increase in the NIS protein level by bLf is an encouraging outcome and future studies 
focussing on enhancing this expression and standardising protocol for functional assay for 
suspension cells could be beneficial. 
Since NIS protein expression is regulated differently in different tissues (Wapnir IL et al. 
2004), it also has to be seen in future, how NIS is regulated in RB tumor cells in the 
preclinical and clinical studies. In conclusion, using both clinical RB tumor samples and 
established RB cell line, Y79, this study to the best of the knowledge, demonstrates for the 
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first time the presence of NIS protein in RB, its association with the invasiveness of the 
tumors and its glycosylation status. Further detailed investigation of NIS molecule at RNA 
level, functional level and the fate of transported iodide are required to understand the role of 
NIS in RB tumor biology. In addition, the mechanistic importance of NIS in diagnosis, 
treatment and monitoring of RB patients can be studied by employing more number of 
patients using different tumor types. Functional activity of expressed NIS if proved through 
future experiments will be important as it may help in targeting NIS for radiotherapy in RB 
treatment. Thus, through this discovery of NIS in RB, a more targeted, less harmful 
approaches for the treatment of RB by employing natural biodrug such as bLf with clinically 
proven safe chemoprevention profile for colon cancer may be developed in future to achieve 
the goal of complete cure of this dreadly childhood disease. 
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Chapter 4 
 
EpCAM specific NIS 
expression and delivery of NIS 
gene in breast cancer cells 
 
 
 
“EpCAM is a well-established carcinoma marker that in addition to its diagnostic value for 
rapidly growing tumors of epithelial origin is used as a potential target for 
immunotherapy” 
                                                                                     - Slanchev et al. 2009 
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4. CHAPTER 4 
 INTRODUCTION 4.1.
Gene therapy is a process where exogenous genetic material is either inserted or expressed in 
cells for therapeutic benefits. On the basis of treatment, gene therapy can be broadly divided 
into three: 1) direct regulation of the disease causing gene in the case of hereditary diseases 2) 
indirect therapy of disease through gene modification in complex, acquired disease like 
Parkinson’s disease 3) immunotherapy where an introduction of a gene induces the 
generation of particular antigen (DNA vaccines) (Linden & Matte 2014).  The idea of gene 
therapy was conceived in the 1960s and currently many therapeutic genes and delivery 
vehicles have reached till clinical trials. The success of gene therapy lies mainly on the 
development of recombinant DNA technology and sequencing of human genome (Lisa Li, 
Nakano & Hotta 2014). The transfer of genetic material can be done in vivo and with 
combination of other conventional treatments for higher efficiency (Linden & Matte 2014).  
Gene therapy promises to be an effective therapy for various diseases especially cancer (Ginn 
SL et al. 2013). Gene therapy has achieved progress in recent decades but the problem of 
successful clinical application of gene therapy still persists. Though, it is the age where 
optimal vector systems are in practice, there are always problem of random integration and 
the lack of specificity (Parker 2014). 
There are many genes, expression of which will render the cells susceptible to various 
treatments. One such gene is Sodium Iodide Symporter (NIS), expression of which will 
facilitate the cells to take up radioactive iodide and thereby a therapy in itself. As described in 
chapter 1 and chapter 3, NIS, a transmembrane glycoprotein, responsible for accumulation of 
iodide in the thyroid gland is present in the basolateral side of the thyroid follicular cells (MJ 
1998). Transport of iodide through NIS mediation is an active process which is inhibited 
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competitively by thiocyanate and perchlorate anions and occurs against the electrochemical 
gradient (Eskandari S et al. 1997; Weiss SJ, Philp NJ & EF 1984). Though NIS is expressed 
widely in various extrathyroidal tissues like mammary glands, salivary glands and gastric 
mucosa apart from thyroid, the accumulated iodide in these tissues are not organified 
(Spitzweg C et al. 1998). NIS present in the lactating mammary gland is responsible for 
actively transporting iodide to the milk, which helps in the iodide supply to the infant. Thus 
NIS has a physiological role in lactating breast unlike other non-thyroidal tissues where the 
function of NIS is not known (N 1993). There have been several studies which showed iodide 
uptake in non-thyroidal cells after the transfection of NIS cDNA (Kosugi S et al. 1996; 
Spitzweg C et al. 1999 ). Expression of NIS protein in primary RB tumors and RB cell line 
(Y79 cells) has been explored to a great extent in chapter 3. Since the endogenous NIS failed 
to show any functional activity in preliminary experiments, an attempt was further made to 
overexpress NIS by stably transfecting NIS plasmid in Y79 cells. However due to the 
difficulties in manipulating gene expression (Corson & Gallie 2007) in this cell line, the 
study did not materialize. As a proof of concept, breast cancer cell line, MCF-7, an ATCC 
cell line derived from metastatic site of a breast was used in this study. NIS based therapy is 
most promising as this therapeutic gene can be over expressed in non-thyroidal cancers like 
breast cancer enabling it to accumulate radioiodide.  
Breast cancer, a complex disease with different biological characteristics and clinical 
behavior is the most common cancer among women. The fatality of the disease is attributed 
to metastasis of the disease to distant organs like liver, lungs and brain with a median survival 
time of 2.2 to 0.5 years (Kennecke et al. 2010). Various conventional chemotherapeutic drugs 
like adriamycin, cyclophosphamide and paclitaxel show promising results in treating breast 
cancer (Kim et al. 2011). Though the mortality rate has declined with advanced treatments 
(Jemal A et al. 2010 ), the lack of specificity, drug accumulation and bioavailability is still a 
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worrying factor for breast cancer therapy. The importance of gene therapy comes to the play 
where conventional therapy fails. However, gene therapy is never without challenges. The 
most challenging aspect of gene therapy is the delivery of gene itself. Targeting specific cells 
via a marker becomes utmost importance in gene delivery. 
Multitude of cancer markers have come into the foray and functions as a perfect target for 
diseased states. One such biomarker is EpCAM, an epithelial cell adhesion molecule 
expressed in all epithelial cells (Baeuerle PA & O 2007). Even though it is expressed at a 
basal level in normal cells, it is overexpressed in breast cancer and other several cancers 
(Spizzo G et al. 2002; Spizzo G et al. 2004; Went P et al. 2006) and is correlated with high 
proliferation and high metastasis (Osta WA1 2004). This overexpression makes EpCAM a 
promising molecule for future therapies and a prognostic marker (van der Gun BT1 2010). 
EpCAM is an efficient molecule for cancer-specific gene delivery because it has been widely 
used as a biomarker in cancers (Baeuerle PA & O 2007; Münz M et al. 2010). 
In this chapter, NIS gene was delivered to breast cancer cells (MCF-7 cell line) in two ways 
by targeting the overexpressed EpCAM protein. The first method is by employing tissue 
specific promoters. A tissue specific promoter is a promoter which functions only in certain 
tissues. The primary use of tissue specific promoter is that it can limit the unwanted transgene 
expression and ensures constant expression of the transgene (Zheng & Baum 2008). 
Maximum cytotoxicity to the target tumor tissues and minimum side effects to surrounding 
normal tissues can be achieved by delivering NIS gene to the malignant cells using tissue 
specific promoters (JK 2002 ). An improved approach of directing NIS specifically to the 
breast cancer tissues is to use a plasmid containing NIS gene coupled to a breast cancer 
specific promoter such as EpCAM promoter. This is the first study to target EpCAM 
molecule to deliver NIS gene in breast cancer cells. 
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The second method is by employing polymeric nanoparticle coated with specific aptamers. 
Though various polymers are available, the one polymer which satisfied all the criteria is 
Polyethylenimine (PEI). As explained in chapter 1, the advantage of polymer like PEI is that 
it can be easily synthesized, follows endosmolytic mechanism (Meyer M & E 2006), no 
immunogenicity and improved biocompatibility. The success of gene therapy highly relies on 
effective delivery vectors. An efficient delivery vehicle is the key to a successful gene 
therapy and multiple factors determine an efficient delivery vehicle. One it has to condense 
the DNA molecules, two it has to protect the DNA from degradation and release the molecule 
promptly and three it has to be less toxic and more biocompatible. Polyethylenimine, a 
common cationic polymer forms complex with pDNA and has high transfection efficiency in 
vitro as well as in vivo (Godbey WT, Wu KK & AG 1999; Kircheis R, Wightman L & E 
2001). Every third atom of this organic macromolecule is an amino nitrogen group which can 
be protonated. Irrespective of PEI form i.e., linear or branched it forms complexes with DNA. 
The ability of the PEI to trap DNA is attributed to many linker amino groups which also 
render PEI buffering capacity (Klotz IM, Royer GP & AR 1969).  
The delivery vehicle must cross several barriers to deliver its contents to the specific cells. 
This is done by modifying the surface of the delivery vehicle with targeting ligands which 
would result in overcoming undesired side effects of conventional therapy. Cell type specific 
surface molecules like antibodies, aptamers have been developed for cell-specific gene 
delivery (B 2007; Chiu SJ, Ueno NT & RJ. 2004; Germershaus O et al. 2006). Use of 
antibodies, specifically monoclonal antibodies as targeting ligands is widely practiced. For 
example, a therapeutic monoclonal antibody showed significant therapeutic effect in 
colorectal cancer by targeting vascular endothelial growth factor and epidermal growth factor 
receptor (Amado et al. 2008). However there are various limitations for monoclonal antibody 
based therapy for cancer. Few of the drawbacks are monoclonal antibodies of mouse origin 
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induce immunogenicity and monoclonal antibodies of human origin are costly and limited 
(Ikeda Y & K 2006 ; Li SD & L 2006; Lu PY, Xie F & MC 2005; Schiffelers RM et al. 2004 
). The limitations in monoclonal antibodies lead to the production of aptamers.  Aptamers are 
short oligonucleotides, either RNA or DNA molecules which at nanomolar levels can bind to 
targets with high affinity (Bunka & Stockley 2006). Since EpCAM is overexpressed in both 
primary and metastatic breast cancers and considered to be a cancer biomarker (van der Gun 
BT et al. 2010), a RNA aptamer that targets EpCAM protein was selected in this study. 
Because of PEI’s highly protonated group in its surrounding (J. Suh, H.J. Paik & Hwang 
1994), its surface can be easily modified with various ligands for targeted delivery of the 
plasmid.  
Although endogenous NIS expression is detected in breast cancer cells, it is insufficient to 
induce iodide uptake (Kogai & Brent 2012). Moreover, earlier studies have shown that 
EpCAM is overexpressed in MCF-7 cell line. These two clinically important molecules have 
never been targeted together in breast cancer. 
 Hypothesis 4.2.
The hypothesis of this study was that if NIS was specifically overexpressed in breast cancer 
cells (MCF-7) via a tissue specific promoter (EpCAM) through receptor targeted gene 
delivery, it would induce functional activity of NIS leading to higher cellular iodide uptake. 
 It was also hypothesized that NIS gene could be effectively delivered in a nanoformulation 
(nanocomplex) decorated with EpCAM aptamer for its specific delivery in EpCAM positive 
breast cancer cells (MCF-7), the successful delivery would then enhance the iodide uptake. 
 Aims 4.3.
The aims of this study were 
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1)  To clone NIS gene in EpCAM promoter containing vector and to select stable 
transfectants.  
2) To compare the promoter activity of universal promoter (Cytomegalo Virus promoter-
CMV promoter) and tissue specific promoter (EpCAM). 
3) To show the functional activity of the expressed NIS gene via CMV-NIS plasmid and 
EpCAM-NIS plasmid. 
4) To assemble a functional nanoparticle comprising NIS plasmid within PEI polymer 
carriers coated with EpCAM aptamer. 
5) To study the efficacy of nanocomplex in delivering NIS plasmid DNA to EpCAM 
positive cells and tests the functional activity of delivered NIS gene. 
 MATERIALS AND METHODS 4.4.
The methodology for the experiments performed in this study has been explained in detail in 
chapter 2. A brief outline of the work carried out in this chapter has been explained in 
Figures 4.1-4.4.  
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Figure 4.1 Schematic representation of the first part of the work performed in this 
chapter. 
Cloning mechanism has been explained in Figure 4.3 and the commercial vector obtained for 
cloning has been explained in Figure 4.2. qRT-PCR-Real Time PCR; MCF-CMV-NIS 
denotes to stably transfected cell lines using CMV-NIS plasmid and MCF-EpCAM-NIS 
denotes to stably transfected cell lines using EpCAM-NIS plasmid.  
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Figure 4.2 Vector maps of plasmids 
 Commercial vector map of pCMV6-AC (Origene, USA) with arrows indicating the multiple 
cloning sites where NIS gene was inserted. The plasmid had kanamycin resistance gene 
instead of ampicillin resistance gene. 
BamHI
XhoI
NIS gene
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Figure 4.3 Schematic representation of the cloning procedure employed in the current 
study to generate EpCAM-NIS clone. 
Vector map of the commercial vector shown in Figure 4.2. Specific restriction enzymes like 
BamHI and XhoI were used for digestion of the NIS gene from the CMV-NIS plasmid and 
EpCAM vector backbone from the EGP2-TK plasmid. The NIS gene and the EpCAM vector 
backbone were ligated to generate a new clone, EpCAM-NIS. 
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Figure 4.4 Schematic representation of the second work performed in this chapter. 
PEI based nanocomplex containing NIS pDNA and EpCAM aptamer was prepared and 
characterized using Transmission Electron Microscopy (TEM) and Zeta Sizer. Transfection 
efficiency of the nanocomplex was determined at mRNA level (qRT-PCR) and at protein level 
(Western Blotting). Functional activity of the NIS gene was determined by iodide uptake 
assays both radioactively and non-radioactively.  
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Figure 4.5 Schematic representation of synthesis of nanocomplex 
NIS plasmid DNA was initially mixed with polyethyleneimine (PEI) to form a core complex 
via electrostatic attraction. The synthetic RNA-based EpCAM aptamer (EpDT3) was then 
incorporated onto the PEI-NISpDNA complex to form the nanocomplex. This functional 
complex when added to the cells would selectively target EpCAM positive breast cancer 
(MCF-7) cells. EpCAM aptamer mediated cell binding would facilitate intracellular delivery 
of the nanocomplex. The NIS plasmid DNA would subsequently express its protein resulting 
in the uptake of radioactive iodide.  
 RESULTS 4.5.
4.5.1. PART A: NIS gene expression via EpCAM specific promoter 
4.5.1.A. EpCAM expression in MCF-7 cells 
Although EpCAM expression in breast cancer cells, MCF-7 has been reported in earlier 
studies (Sterzyńska et al. 2012), this study again analysed the basal level of EpCAM 
expression before conducting further experiments. The basal level of EpCAM protein in 
MCF-7 cells was determined by flow cytometry. The flow-cytometric histogram of MCF-7 
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cells stained with anti- EpCAM antibody (Cell Signalling Technology, USA) showed a 
highly marked percentage (95%) of MCF-7 cells to be positive for EpCAM (Figure 4.6). 
This finding confirmed MCF-7 cells to be EpCAM positive and further experiments were 
carried out with this cell line.  
 
Figure 4.6 Flow cytometric analysis of EpCAM expression in MCF-7 cell line. 
Top panel- MCF 7 cells unstained; Middle panel- MCF 7 cells stained with anti-mouse, FITC 
secondary antibody alone (1:1000); Bottom panel- MCF  cells stained with anti-EpCAM 
antibody raised in mouse (1:1000) and anti-mouse IgG, FITC secondary antibody (1:1000.). 
M1 represents the cells that are negative for EpCAM and M2 represents the population of 
EpCAM positive cells in the flow cytometric graphs. 
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4.5.1.B. Construction of clones and establishment of stable transfectants 
The NIS gene in the pCMV6-AC vector driven by CMV promoter was excised with 
restriction enzymes like BamHI and XhoI. Similarly, the EGP2 vector was restricted digested 
with the same restriction enzymes BamHI and XhoI and the vector backbone was excised 
(Figure 4.3). The excised NIS gene was then ligated into the excised EGP2 vector backbone 
containing EpCAM promoter using ligation enzymes. The ligation was a sticky end ligation 
(Figure 4.3). Cloning of NIS gene into the EGP2 vector containing EpCAM promoter was 
confirmed by restriction-digestion (Figure 4.7.A and B). Both the plasmids used in this study 
had neomycin resistant genes for mammalian cell selection. MCF-7 cells were transfected 
with both the plasmids using lipofectamine. The stable transfectants carrying the CMV-NIS 
plasmids and EpCAM-NIS plasmids were generated by the addition of Geneticin (G418), an 
antibiotic. The MCF-7 cells transfected with the plasmids were subjected to G418 treatment 
for 14 days. The concentration and period of G418 treatment was established by the kill-
curve experiment. After a period of 14 days, the cells that survived in the presence of G418 
were isolated and screened for NIS mRNA expression by qRT-PCR. The clones that showed 
NIS gene expression were taken for further functional studies 
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Figure 4.7 Restriction Digestion of EGP2-TK, EoCAM-NIS and CMV-NIS plasmids 
(A) 1% agarose gel showing restriction digestion of three plasmids, EGP2-TK, EpCAM-NIS 
and CMV-NIS. Lane 1- 1kb ladder; Lane 2- digested sample of EGP2-TK with TK gene 
running at 700 bp (red arrow) and vector backbone at ~ 9kb; Lane 3- digested sample of 
EpCAM-NIS with EpCAM vector backbone at ~9kb and NIS gene at 3kb; Lane 4- digested 
sample of CMV-NIS with NIS gene at 3kb. (B) 1% agarose gel showing the undigested and 
digested sample of EpCAM-NIS. 
4.5.1.C. Analysis of NIS overexpression in the stable MCF-7 transfectants at mRNA 
level 
As explained earlier, overexpression of NIS in breast cancer is necessary as the endogenously 
expressed NIS is non-functional. So, in order to check the NIS overexpression at mRNA level 
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in the generated stable transfectants, qRT-PCR was performed. Figure 4.8 shows that when 
compared to the vehicle control MCF-7 cells, both the MCF-CMV-NIS and MCF-EpCAM-
NIS transfectants showed significantly higher (P<0.001) NIS expression at mRNA level, 10.3 
and 8.4 fold up regulation respectively. This confirms the successful overexpression in both 
the clones. In addition, a significant difference (P<0.005) in NIS expression was also 
observed between the transfectants with MCF-CMV-NIS showing higher expression than the 
MCF-EpCAM-NIS.  
 
Figure 4.8 qRT-PCR analysis of the mRNA transcripts of the hNIS gene in the stable 
transfectants. 
The stable transfectants, CMV driven NIS gene and EpCAM driven NIS gene show significant 
increase in NIS mRNA when compared to the vehicle control cells. Significant difference is 
also seen between the transfectants. The error bar represents standard deviation of 
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experiments performed in triplicates. P-value less than 0.05 are considered as significant. 
****P<0.001and ***P<0.005. P-values were calculated by the Student’s t-test. 
4.5.1.D. Analysis of NIS overexpression in the stable MCF-7 transfectants at protein 
level 
Following the analysis of NIS overexpression in the stable transfectants at mRNA level, 
further investigation was done to confirm the overexpression at protein level. The protein 
level study was performed by Western blotting technique. Mouse monoclonal, anti-human 
NIS antibody (Abcam, USA) was used to examine the NIS protein expression. The Figure 
4.9.A shows that stable transfectants, MCF-CMV-NIS and MCF-EpCAM-NIS overexpressed 
NIS at protein level when compared to the vehicle control MCF-7 cells. The NIS protein 
band was detected at 75 kDa in all the samples including Nthy-ori 3-1(Normal human 
primary thyroid follicular epithelial cell line) which was used as a positive control. β-actin 
protein band detected at 43 kDa was used as a loading control. The image J analysis after 
normalising the NIS expression with the β-actin revealed higher expression in the stable 
transfectants when compared to the control cells. Between the stable transfectants, the MCF-
CMV-NIS transfectant showed higher NIS protein expression than the MCF-EpCAM-NIS 
transfectant (Figure 4.9.B). These results were in agreement with the aforementioned results 
of qRT-PCR analysis.  
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Figure 4.9 Western blot analysis in stable transfectants 
(A) Succeeding stable transfection of MCF-7 cell line with CMV-NIS and EpCAM-NIS 
plasmid DNA, NIS protein expression was analysed in the stable transfectants. 
Immunoblotting analysis using anti-NIS mouse monoclonal antibody revealed a 75 kDa 
protein. Lane 1: Nthy-ori 3-1 cell line lysate was used as a positive control; Lane 2: MCF-7 
vehicle control; Lane 3 and Lane 4: overexpression of NIS protein in MCF-CMV-NIS and 
MCF-EpCAM-NIS transfectants respectively. Bottom panel: β- actin as loading control, 
detected at 43 kDa using anti-human anti- β-actin mouse monoclonal antibody. HRP 
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conjugated, anti-mouse IgG secondary antibody was used and the blot developed using 
enhanced chemiluminescence (ECL) method. (B) Histogram plotted for the NIS protein after 
normalization with the β-actin protein expression.  
4.5.1.E. Radioiodide uptake assay shows higher functional activity of EpCAM 
promoter driven NIS gene 
Following the expression studies, the stable transfectants were subjected to functional 
studies. The iodide uptake assay was necessary in order to show that the expressed NIS 
protein was a functional protein. Along with the uptake studies, efflux of iodide also was 
studied. Radioactive iodide uptake was measured by incubating the NIS transfected cells 
with 4µCi/mL Na125I for 2 h. Both the stable transfectants showed significant iodide uptake 
compared to the vehicle control MCF-7 cells (P<0.05). Between the stable transfectants, 
MCF-EpCAM-NIS concentrated more iodide than the MCF-CMV-NIS. The vehicle control 
cells though expresses NIS endogenously concentrated radioiodide only at a basal level. 
Iodide uptake was blocked in the presence of 1mM Sodium perchlorate, an inhibitor of NIS 
which was important to show the iodide uptake is specifically via the expressed NIS (Figure 
4.10.A). Efflux of iodide was rapid with over 75% of the total cellular iodide released within 
15 mins in both CMV-NIS and EpCAM-NIS (Figure 4.10.B). The above results 
demonstrate significantly higher and perchlorate inhibiting radioactive iodide uptake in 
stable transfectants of MCF-7 cell line, a cell line of non-thyroidal origin.  
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Figure 4.10 Radioactive iodide uptake assay, inhibition assay and efflux assay for stable 
transfectants 
(A) NIS dependant iodide uptake was measured after treating the control and stable 
transfectants with 4µCi/mL of Na125I for 2 h. For the inhibition studies, cells were treated 
with 1mM of NaClO4 along with the 4µCi/mL of Na125I. Uptakes are expressed as counts per 
min (cpm). The error bar represents standard deviation of experiments performed in 
duplicates. (B) Efflux of iodide was faster in both CMV-NIS and EpCAM-NIS with over 75% 
released in 15 mins. Data are expressed as a percentage of the maximum uptake. P-value less 
than 0.05 were considered significant. *P<0.05 and ***P<0.005. P-values were calculated 
by the Student’s t-test. 
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4.5.1.F. Non-radioactive iodide uptake assay proves the functional activity of 
EpCAM promoter driven NIS gene 
Subsequent to assessment of functional activity of the stable clones via the standard 
radioactive iodide uptake method, a novel colorimetric assay which is fast and sensitive was 
used to measure the cell-trapped iodide in the stable transfectants. The cell trapped iodide in 
vehicle control MCF-7 cells and both the stable transfectants was assayed after 30 min of 
iodide incubation. The iodide concentrations in all the cells (MCF-7 vehicle control, MCF-
CMV-NIS & MCF-EpCAM-NIS) were determined after linear regression of the calibration 
curve (Figure 4.11.A). The uptake in both the stable transfectants was significantly higher 
than the control cells.  Maximum uptake of 349 nM of NaI by MCF-CMV-NIS (P<0.01) and 
438 nM of NaI by MCF-EpCAM-NIS (P<0.005) was observed at 30 min time period. The 
vehicle control MCF-7 cells failed to show any uptake of iodide (Figure 4.11.B). This proves 
the specific iodide uptake activity of the stable transfectants expressing NIS protein. 
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Figure 4.11 Non-radioactive iodide uptake assay for the stable transfectants 
NIS gene functional activity as measured by non-radioactive iodide method. (A) Logarithmic 
conversion of the means of A420 at 30 min (n = 3) vs. iodide standards. (B) Cell-trapped 
iodide determined by the As/Ce method (explained in methods chapter) and the iodide uptake 
expressed in nM concentration. Both the stable transfectants showed significantly higher 
iodide uptake compared to the control cells. The error bar represents standard deviation of 
experiments performed in triplicates. P value less than 0.05 were considered significant. 
***P<0.005 and **P<0.01. P-values were calculated by the Student’s t-test. 
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4.5.1.G. Stable transfectants showed increased migration ability 
After confirming the functional activity of the stable transfectants, the migration ability was 
studied. Overexpression of NIS by the stable transfectants confers higher migration ability 
than the endogenous NIS expressing untransfected MCF-7 cells. DMEM medium 
supplemented with 10% FBS was added to the cells to support migration. Wounds were 
observed to close at 24 h after wound formation. However there was little or no difference in 
the migration rate between the stable transfectants, MCF-CMV-NIS and MCF-EpCAM-NIS 
(Figure 4.12).  
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Figure 4.12 Migration assay for the stable transfectants 
Cell migration assay in the stable transfectants and control MCF-7 cells. (A) Control MCF-7 
at 0 h (B) MCF-7-CMV-NIS at 0 h (C) MCF-7-EpCAM NIS at 0 h (D) Control MCF-7 at 24 
h (B) MCF-7-CMV-NIS at 24 h (C) MCF-7-EpCAM NIS at 24 h. The dotted yellow colour 
circles shows the point of closure of the wound. Photomicrographs were taken at a 
magnification of 20X. 
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4.5.2. Part B: NIS gene delivery via EpCAM targeting nanocomplex 
4.5.2.A. EpDT3 aptamer displayed increased affinity towards EpCAM positive cells  
The basal level of EpCAM protein expression in MCF-7 cells was determined in the first part 
of the study. Although EpCAM aptamer‘s (EpDT3) affinity to EpCAM positive cells have 
been analysed by our lab in earlier studies (Subramanian et al. 2012) this study again 
analysed the affinity of the EpDT3 aptamer in MCF-7 cells before conducting further 
experiments. To optimize the cell specific binding efficiency of the EpDT3 aptamer to the 
EpCAM positive cells, various concentrations of the aptamer were incubated with MCF-7 
(EpCAM positive) and MIOM-1 (EpCAM low) cells (Danda R et al. 2013). The resultant cell 
binding by the EpDT3 aptamer was monitored by flow cytometry. The population of bound 
aptamer to the MCF-7 cells increased as the concentration of the aptamer increased (Figure 
4.13.A, B). In MIOM-1 cells, only 2% of the aptamer was bound to the cells at 200nM 
concentration (Figure 4.13.B, C) whereas 50% of the MCF-7 cells exhibited aptamer binding 
(Figure 4.13.A). This concentration of the aptamer was used for PEI/NIS/EpDT3 synthesis. 
This confirms the specificity of the aptamer. Similar concentration of the scrambled aptamer 
(Scr-EpDT3) whose non-specificity was determined in our lab (Subramanian et al. 2012) was 
used for further studies.  
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Figure 4.13 EpDT3 aptamer binding affinity studies 
(A) EpCAM aptamer (EpDT3) binding affinity in MCF-7 cells (EpCAM positive cells) (B) 
EpDT3 aptamer binding affinity in MIO-M1 cells (EpCAM low cells). Increasing 
concentration of Cy3 labelled EpDT3 aptamer was incubated in the cells for 1 h at 37°C. 
Cells were washed post incubation period and subjected to flow cytometric analysis. Isotype 
control was used for gating the positive population. 10,000 events were acquired within the 
gating. (C) Representative picture showing aptamer binding affinity towards EpCAM +ve 
and EpCAM low cells. 
                                                                                                                                      Chapter 4 
177 
 
4.5.2.B. Nanocomplex formation  
The complex formation between the positively charged PEI and negatively charged NIS 
plasmid (NISpDNA) at different charge ratios was assessed by agarose gel electrophoresis. In 
Figure 4.14.A, free NISpDNA was observed in lane 1. The NISpDNA concentration was 
kept constant and PEI concentration was increased steadily. A fraction of NISpDNA still 
migrated in the gel at NISpDNA: PEI ratio of 1:1.25, 1:2.5 and 1:3.75 (Figure 4.14.A, lane 
2-4) whereas the NISpDNA band disappeared at 1:5 and above ratio (lane 5-7), indicating 
PEI-NISpDNA complex formation.  The PEI/NISpDNA/EpCAM aptamer nanocomplex 
(PEI/NIS/EpDT3) formation was also observed by agarose gel electrophoresis (Figure 
4.14.B).  The NISpDNA is smaller than (Figure 4.14.B, lane 1) NISpDNA/PEI complex 
(Figure 14.B, lane 2). Though complete complex formation with EpDT3 aptamer was 
observed at 50nM, 100nM and 200nM concentration (Figure 4.14.B, lane 3-5), further study 
proceeded with 200nM concentration because it was found to be optimal in the aptamer 
affinity studies. Naked fluorescent EpDT3 aptamer ran as a small band with low molecular 
weight of 3 kDa (Figure 4.14.B, lane 6). The band for residual aptamer at 3 kDa was not 
observed at 200nM concentration (Figure 4.14.B, lane 5) while the PEI/NIS/EpDT3 
nanocomplex of higher molecular weight in the same lane indicated maximal coating of the 
aptamer. This nanocomplex was characterized for size, shape and serum stability. 
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Figure 4.14 Complex formation: Agarose gel electrophoresis of NISpDNA forming 
complexes at different concentration of PEI. 
(A)  Lane 1 shows naked pDNA, lane 2-7 shows complexes of NISpDNA: PEI in various 
ratios. Complete encapsulation of NISpDNA observed from the 1:5 ratio. (B) Coating of 
fluorescent EpDT3 aptamer on the NISpDNA:PEI complex. Lane 1 shows naked NISpDNA, 
lane 2 shows NISpDNA:PEI complex and lane 3-5 shows increasing concentration of EpDT3 
aptamer forming complexes with NISpDNA:PEI. Lane 6 shows fluorescent EpDT3 aptamer 
alone (red arrow) as a low molecular weight band.  
4.5.2.C. Characterisation of the nanocomplex (PEI/NIS/EpDT3)  
The DLS measurements revealed the size of the nanocomplex (PEI/NIS/EpDT3) when 
suspended in water to be at around 100 nm (z-average diameter). However, the number 
distribution of the PEI/NIS/EpDT3 was between 25-45 nm (Figure 4.15.B). The TEM 
investigation showed spherical particles with an average size of 30 nm (Figure 4.15.A). DLS, 
unlike TEM also measures the hydrodynamic diameter of the particle which leads to 
difference in size measurements (Jie Zheng  et al. 2002). The  Zeta potential was found to be 
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positive for the PEI alone and when complexed with NISpDNA, the potential drops but still 
remained positive. But when the PEI/NISpDNA was coated with EpDT3 aptamer, the 
potential changes to negative suggesting a  concentrated distribution of the anionic ligand 
over the nanocomplex (Kurosaki T et al. 2009) (Table 4.1).  
 
 
Figure 4.15 Transmission Electron Microscopy (TEM) and Dynamic Light Scattering 
(DLS) of the nanocomplex. 
(A) TEM picture of PEI/NIS/EpDT3 showing spherical shape. The PEI/NIS/EpDT3 
nanocomplex was measured in a scale of 100nm. The analysis was carried out at an 
accelerating voltage of 80 kV using JEOL JEM1400 microscope. (B) PEI/NIS/EpDT3 
characterised by Dynamic Light Scattering- Size measurement by number distribution. The 
PEI/NIS/EpDT3 was suspended in water for the analysis. The parameters used in the 
measurements included viscosity of 0.34 cP, reflective index of 1.054, and temperature of 
25°C by the Zetasizer Nano ZS. 
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Table 4.1 Zeta potential of the PEI, PEI/NISpDNA complex and PEI/NIS/EpDT3 
nanocomplex prepared in water determined by Zetasizer Nano ZS. 
 
 Zeta potential (mV) 
PEI alone +9.31 
PEI/NISpDNA +4.01 
PEI/NIS/EpDT3 -14.2 
 
 
4.5.2.D. Biostability of the PEI/NIS/EpDT3: 
Biostability of the PEI/NIS/EpDT3 in the presence of serum was monitored over a period of 
72h (Table 4.2). Size and zeta recorded every 24 h of the PEI/NIS/EpDT3 showed that the 
nanocomplex maintained its characteristics until 72 h in the presence of the serum. The 
nanocomplexes aggregated beyond 72 h with the serum treatment.  
Table 4.2 Biostability of the nanocomplexes 
PEI/NIS/EpDT3  Size (d.nm) Zeta (mV) 
0 h 29.85 -11 
24 h 24.8 -10.1 
48 h 27.1 -11.5 
72 h 25.7 -7.8 
 
Table 4.2: Biostability of the nanocomplexes over a period of 3 days determined by Zetasizer 
Nano ZS. PEI/NIS/EpDT3 was prepared and incubated in serum and size and zeta of the 
nanocomplex was recorded once every 3 days.  
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4.5.2.E. NIS gene delivery via PEI/NIS/EpDT3 leads to increased expression of NIS 
protein 
Following the nanocomplex preparation and characterisation, PEI/NIS/EpDT3 was used to 
deliver NIS gene in MCF-7 cells. In order to determine whether the gene construct delivered 
via the nanocomplexes resulted in overexpression of NIS protein, Western blotting was 
performed (Figure 4.16.A). When compared to the vehicle control, the overexpression of the 
NIS protein was observed after the NIS pDNA was delivered by the lipofectamine 
transfection reagent and PEI polymer.  However on comparing the expression of NIS pDNA 
between lipofectamine reagent and PEI polymer alone, NIS expression was higher when 
delivered with the commercial transfection reagent. But when compared to vehicle control, 
lipofectamine and PEI alone, NIS expression was remarkably higher when delivered via 
PEI/NIS/EpDT3 nanocomplex. This is because of the targeted and specific delivery of NIS 
plasmid in EpCAM positive MCF-7 cells and active overexpression expression of NIS gene 
translating into NIS protein. β-actin protein band detected at 43 kDa was used as a loading 
control. The image J analysis after normalising the NIS expression with the β-actin revealed 
higher expression in the PEI/NIS/EpDT3 nanocomplex (Figure 4.16.B).  
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Figure 4.16 Western blot image showing the overexpression of NIS protein in MCF-7 
cells after the delivery of NIS plasmid using various transfer vehicles. 
(A) 50 μg of protein sample was loaded and anti-human NIS, mouse monoclonal antibody 
(1:250) was used as primary antibody, HRP-conjugated anti-mouse IgG (1:1000) was used 
as secondary antibody; (B) β- actin as loading control, detected at 43 kDa with anti-human 
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β-actin mouse monoclonal antibody (1:4000) was used as primary antibody, HRP-conjugated 
anti-mouse IgG (1:7000) was used as the secondary antibody. The blot was developed using 
enhanced chemiluminescence (ECL) method. (B) Histogram plotted for the NIS protein after 
normalization with the β-actin protein expression using NIH’s Image J software.  
4.5.2.F. Radioactive iodide uptake by the nanocomplexes 
Following the NIS expression studies at protein level, radioactive iodide uptake was 
measured to determine if the synthesized PEI/NIS/EpDT3 nanocomplex could be used for 
targeted NIS gene therapy by incubating the NIS nanocomplex treated cells with 4µCi/mL 
Na125I for 2 h. Iodide accumulation by the MCF-7 cells transfected with NIS pDNA using 
lipofectamine as transfection reagent was higher than the vehicle control cells which had an 
endogenous NIS expression (Figure 4.17). Furthermore, the PEI/NIS/EpDT3 nanocomplex 
delivered NIS pDNA showed a significant higher uptake (P<0.05) when compared to the 
vehicle control cells. The iodide uptake in the PEI/NIS/Scr-EpDT3 nanocomplex (Scrambled 
aptamer) transfection was similar to that of the control cells, thus confirming that EpCAM 
based targeted delivery of NIS plasmid by the PEI/NIS/EpDT3 nanocomplex could lead to 
functional NIS. 
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Figure 4.17 Radioactive iodide uptake assay for various forms of NIS pDNA complexes 
Radioactive iodide uptake was measured after treating the cells with 4µCi/mL of Na125I for 2 
h in MCF-7 cells transfected with various forms of NIS pDNA complexes. The radioactive 
iodide activity is expressed in counts per min (cpm). The error bar represents standard 
deviation of experiments performed in duplicates. *P<0.05. P-values were calculated by the 
Student’s t-test. 
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4.5.2.G. Non-radioactive Iodide uptake by the nanocomplexes 
Apart from radioactive uptake assay, the nanocomplex functionality was also assessed by 
non-radioactive iodide uptake assay. The iodide uptake was studied to assess the functional 
capability of the overexpressed NIS protein by the PEI/NIS/EpDT3 nanocomplex. The iodide 
uptake decreased linearly with increasing concentration of iodide (Figure 4.18.A).  The 
standard curve obtained using the As/Ce assay was used for estimating iodide concentration 
in the cells. A significantly increased uptake of iodide was observed in the MCF-7 cells 
transfected with NIS pDNA using lipofectamine transfection reagent compared to control 
(untransfected) cells (P<0.001) (Figure 4.18.B). A lower uptake of iodide was observed in 
MCF-7 cells transfected with NIS pDNA using PEI polymer alone compared to the 
lipofectamine delivered NIS pDNA but a significantly higher uptake compared to the control 
cells (P<0.01). However, the highest uptake of 271 nM of iodide was observed in cells 
transfected with PEI/NIS/EpDT3 nanocomplex (P<0.001) reflecting the increased NIS 
protein overexpression by the nanocomplex. This was because of the targeted delivery of NIS 
pDNA to EpCAM positive cells mediated by the EpDT3 aptamer. 
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Figure 4.18 Functional studies using non-radioactive iodide uptake assays 
  (A) Logarithmic conversion of the means of A420 at 30 min (n = 3) vs. iodide standards. (B) 
Cell-trapped iodide determined by the As/Ce method and the iodide uptake expressed in nM 
concentration. NIS gene delivered by all the complexes showed significant iodide uptake 
when compared to the control cells. The error bar represents standard deviation of 
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experiments performed in triplicates. ****P<0.001, **P<0.01. P-values were calculated by 
the Student’s t-test. 
 DISCUSSION 4.6.
In the light of an urgent need of an effective and targeted treatment for cancer, the current 
study embarked upon a NIS based therapeutic strategy for breast cancer by addressing the 
issue of specificity. Firstly, NIS was expressed in breast cancer cell line using EpCAM 
specific promoter and analyzed the feasibility of specific expression. Secondly, NIS was 
delivered in breast cancer cell line using nanocomplex and the possibility of NIS targeted 
expression and function was then evaluated. 
The breakthrough in radionuclide gene therapy occurred when NIS gene of rat and human 
origin was cloned and characterized (Dai G, Levy O & N 1996; Smanik PA 1996). Various 
factors such as rate of iodide uptake, iodide retention, iodide recirculation, iodide 
organification and rate of iodide decay determine the therapeutic radiation dose (Scholz IV et 
al. 2005). NIS substrates are determined by anion size and monovalency which results in 
several anions being transported by NIS such as Technetium pertechnetate and Rhenium 
perrhenate (Maheshwari YK et al. 1981). NIS has a pivotal role consisting radioiodide 
treatment in the therapeutic management of thyroid cancer (Schmutzler C & J 1998). The 
ability of the NIS to accumulate radioactive iodide has been studied in various non-thyroidal 
tumors (Scholz IV et al. 2005; Spitzweg C et al. 2001; Spitzweg C et al. 2000; Spitzweg C et 
al. 1999 ). In order to concentrate iodide from plasma, NIS gene transfer and its functional 
expression is necessary and this in turn would enable radioiodide therapy (Spitzweg C et al. 
2001).  
NIS protein expression and its correct translocation to the plasma membrane are necessary 
for proper function of NIS. To address this issue, various attempts to re-activate NIS function 
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have been ongoing. Primary approach has been to induce the endogenous NIS expression and 
restore it using various molecules (Kogai T et al. 2000). Alternative method for achieving 
functionally active NIS was to introduce the NIS gene exogenously (Yu Yan et al. 2008). In 
breast cancer, an altered location of NIS protein results in lost capacity to concentrate 
radioiodide (Wapnir IL et al. 2003).  
It is necessary to influence NIS expression so that it is expressed only in cancer cells because 
its universal expression can cause undesirable effects during treatment. This specific 
expression can be done by cancer tissue specific promoters which will minimise non-specific 
uptake and maximise tumor specific accumulation of radioiodide. Tissue specific expression 
of the therapeutic gene is obtained as a result of the transcriptional targeting of therapeutic 
genes which in turn leads to reduction in extratumoral toxicity (IR 1996). Cancer tissue 
specific promoters for specific NIS gene expression has been used in prostate by prostate 
specific antigen promoter (Kakinuma H et al. 2003; Spitzweg C et al. 2000) and in colon by 
carcinoembryonic antigen promoter. Only a limited number of investigations have analyzed 
tissue specific promoter mediated NIS gene delivery in breast cancer. 
The approach of the current study was to address the issue of non-targeted delivery of 
therapeutics. For this, in the first part of the study, a new vector was cloned by placing the 
therapeutic gene, NIS under the control of tissue specific promoter like EpCAM. Although 
EpCAM is present in the normal epithelial cells of breast tissue, its high expression in breast 
cancer is associated with poor prognosis and decreased survival rate in patients (Spizzo G et 
al. 2004). Such high expression of EpCAM in cancer tissues than the normal cells makes it an 
attractive target in the treatment of breast cancer (Soysal et al. 2013). In this study, MCF-7 
cell line was used and its high EpCAM expression was confirmed by flow cytometry. In 
addition to the NIS gene under the tissue specific promoter like EpCAM, universal promoter, 
CMV driven NIS gene was also used for efficacy comparison studies. The expression and 
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functional studies of NIS gene by both the vectors were analysed after establishing stable cell 
lines. Transient NIS gene expression curtails options for radioiodide therapy (Trujillo MA et 
al. 2009) and this lead to studies being performed in stably transfected cell lines. The 
feasibility of targeted delivery was then analysed by evaluating the expression and function 
of NIS gene in MCF-7 transfectants. Overexpression of NIS at mRNA level was observed in 
both the stable transfectants with MCF-CMV-NIS showing significantly higher NIS 
expression than MCF-EpCAM-NIS. The reason behind this increased expression in CMV-
NIS is because of the activity of universal promoter in all the cells unlike EpCAM-NIS which 
is specific.  
Both the stable transfectants, MCF-CMV-NIS and MCF-EpCAM-NIS showed iodide uptake 
which demonstrates correct membrane translocation of the overexpressed NIS protein 
following NIS gene delivery. Between the stable transfectants, there was a difference in the 
uptake of iodide determined via both non-radioactive and radioactive iodide uptake assays. In 
both the assays, MCF-EpCAM-NIS showed evidently higher uptake of iodide than the MCF-
CMV-NIS indicating an active EpCAM promoter operating in EpCAM positive cells. The 
high uptake observed in MCF-EpCAM-NIS transfectant than the control cells is also the 
characteristic of the promoter used. It should be noted that even though the mRNA 
expression level of MCF-EpCAM-NIS was significantly lower than that of MCF-CMV-NIS, 
it resulted in a robust iodide uptake. To assess whether the accumulation of iodide was 
explicitly brought about by the functional activity of the NIS gene product, iodide uptake was 
analysed in the presence of NaClO4. Iodide uptake was significantly inhibited, revealing NIS 
mediated transport of iodide in the stable transfectants.  
However, the efflux studies in both MCF-CMV-NIS and MCF-EpCAM-NIS showed no 
difference in the rapid flushing out of iodide. Rapid efflux indicated that no organification of 
the accumulated iodide materialized. Various studies in prostate cancer have shown that even 
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in the absence of iodide organification, significant therapeutic effect of radionuclides have 
been achieved by expressing NIS gene using tissue specific promoters (Scholz IV et al. 2004; 
Spitzweg C et al. 2000; Willhauck MJ et al. 2007). A study found that because the 
microenvironment of in vivo tumor has more iodide content, the half-life of radioiodide was 
longer in tumors than in vitro cell lines (Schipper ML et al. 2003). This occurrence enhances 
NIS based gene therapy.  It is understood that specific promoter exhibit lesser activity 
compared to universal promoters like CMV promoter. But in the current study, it was found 
that EpCAM promoter driven NIS gene showed higher functional activity. These results are 
consistent with previous studies which showed a higher functional activity of NIS expressed 
via a specific promoter, human telomerase reverse transcriptase (hTERT) promoter (Zhang M 
et al. 2014). Thus, the EpCAM promoter may act not only as a specific promoter but also as a 
promoter with strong transcriptional activity.  
The migration ability of the stable transfectants was further analysed. Migration studies 
revealed an increase in migration ability in the stable transfectants overexpressing NIS. This 
enhancement in migration may due to the interaction of NIS with leukemia-associated RhoA 
guanine exchange factor (LARG) to activate RhoA which inturn escalates the cell invasion 
and migration (Lacoste C 2012 ). However, no difference in migration ability was observed 
between the stable transfectants when observed through wound healing assay. Since, NIS 
overexpression is enhancing the migration ability of the cancer cells, it has to be counteracted 
with agents to suppress the invasive quality of the overexpressed NIS. So, in future studies, 
nanoparticle could be loaded with molecules exhibiting anti-metastatic property such as 
curcumin and bovine lactoferrin (Chatterjee et al. 2003; Kanwar, Mahidhara & Kanwar 2012; 
Tsuda et al. 2010) which may arrest the migratory ability of NIS thus could enhance the NIS 
mediated radiotherapy.  
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Clinical potential of establishing a stable transfectant should be assessed after in vivo gene 
delivery in breast cancer models. In that case, ablation of thyroid has to be performed before 
radioiodide treatment for breast cancer to prevent the uptake of radioiodide by the thyroid 
cells. Furthermore, the benefit of NIS gene is that, apart from its radioiodide uptake ability, it 
can also be used as a reporter gene by positron emission tomography or single photon 
emission computed tomography to track the organs which had taken up iodide (Shin JH et al. 
2004 ). 
To further optimize the tumor selectivity, in the second phase of the study, a ligand-mediated 
NIS gene delivery to the tumor sites was studied. Therapeutic gene delivery holds great 
future and currently emerges as a great promise to be one of the major strategies for the 
treatment of cancers and various other diseases. For NIS gene delivery, various methods like 
liposomes, viral vectors, electroporation were used earlier (Boland A et al. 2000; Schipper 
ML et al. 2003; Shimura H et al. 1997). A recent study showed delivery of NIS gene using 
pseudo dendritic polymers into neuroblastoma mouse model which achieved significant 
iodide accumulation thereby, a therapeutic effect (Klutz K et al. 2009).  
Non-viral gene delivery technique also termed as “artificial viruses” is considered to be less 
potent inspite of it mimicking viral systems with less clinical risks (AP 1998; FD 1995; Roy 
K et al. 1999). As a further step towards delivery of NIS gene in this study a polycation, PEI 
was used. PEI has been used as an efficient nonviral vector for gene delivery in vitro as well 
as in vivo (Clamme JP, Azoulay J & Y 2003 ; Fischer D et al. 1999 ; Kichler A et al. 2001; 
Tang MX & FC 1997 ). Though PEI condenses DNA to form complexes, for improved 
retainability the PEI-DNA complex has to be in the nanoformulation. The downside of using 
PEI alone to deliver pDNA is that it non-specifically binds to negatively charged cell 
membrane and thus making use of PEI/pDNA complex difficult for specific gene delivery 
system (Demeneix B & JP 2005; Lemkine GF & BA 2001). So, this study embarked on 
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aptamer technology by employing a ligand which is small enough not to elicit 
immunogenicity but efficient enough to bind to specific targets.  
Studies have reported development of  EpCAM aptamers and their high specificity for the 
target (Shigdar S1 2011). However, there are few reports about using EpCAM aptamer to 
deliver a gene. Thus a novel nanocomplex of NIS pDNA/PEI coated by the EpCAM aptamer 
(EpDT3) was prepared and tested. EpDT3 aptamer affinity and its specificity along with its 
optimum concentration for the nanocomplex were first determined.  The affinity studies 
revealed an effective binding of EpDT3 aptamer to EpCAM positive MCF-7 cells but at a 
higher aptamer concentration, MIOM-1 with low EpCAM expression cells showed a faint 
affinity towards the EpDT3 aptamer. The low EpCAM expression in MIOM-1 cells has 
already been studied (Danda R et al. 2013) and thus the optimum concentration of the 
aptamer was fixed at 200nM at which there was insignificant binding for MIOM-1 cells. 
Complex formation occurred between the components of the nanocomplex based on 
electrostatic interactions. Various ratios of PEI:NISpDNA:EpDT3 were experimented and 
further analysed on agarose gel electrophoresis. Following the confirmation of complex 
formation by agarose gel electrophoresis, size and zeta potential of the nanocomplexes were 
determined. Addition of the anionic EpDT3 aptamer affected the zeta potential which was 
evident from the clear shift of potential from positive to negative. This proved the binding of 
the aptamer with NIS pDNA/PEI complex. 
One of the important properties of a nanoparticle is its stability in the presence of serum. 
Serum has the inhibitory effect and they function by disrupting the PEI/pDNA complex or 
obstruct the binding of the complex to the cell membrane (Guo W & RJ 2001). Therefore the 
PEI:NISpDNA:EpDT3 nanocomplexes was subjected to serum stability check for a period of 
5 days. It maintained its size and potential till 72 h in the presence of serum which proves its 
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bio-stability and availability. However, beyond 3 days, the nanocomplexes started to 
aggregate.  
NIS gene delivery by different vehicles such as lipofectamine, PEI and finally the 
nanocomplex was studied in MCF-7 cells by determining the NIS protein level through 
Western blotting. Overexpression of NIS protein was observed in all the samples, however 
difference in NIS protein expression delivered by different vehicles also was evident. The 
NIS protein expressed by the targeted nanocomplex was higher compared to NIS expressed 
via other vehicles. This could be the result of EpDT3 aptamer binding to EpCAM positive 
MCF-7 cells. The increased NIS protein level also reflected in the functional studies where 
the cells with NIS delivered by the nanocomplex had significantly higher iodide uptake 
compared to the cells transfected with other vehicles like lipofectamine and nanocomplex 
coated with scrambled aptamer (PEI/NISpDNA/Scr-EpDT3). This shows that the NIS pDNA 
released from the PEI/pDNA/EpDT3 nanocomplex formulation retained functional integrity 
at a higher rate. 
The high iodide uptake by the cells transfected with PEI/pDNA/EpDT3 nanocomplex could 
be attributed to the recognition of EpCAM aptamer on the nanocomplex surface by the 
EpCAM positive cells. These results suggest that the nanocomplex with a negative charge is 
taken up by cells through EpCAM-specific receptor mediated pathway (Winkler J et al. 
2009).  
Thus, in this experiment, a nanocomplex to deliver a therapeutic gene specifically to cancer 
cells was developed. Following EpCAM aptamer mediated NIS gene delivery complexed 
with PEI, in future studies, by applying different radionuclides such as Re188 and At231, the 
therapeutic efficacy of NIS can be enhanced for non-thyroidal cancers (Dadachova E et al. 
2002; Willhauck MJ et al. 2008).  
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The present study though require improvements to achieve much higher accumulation of 
iodide and more retention of iodide, application of this specific radiotherapy can also be 
applied to various other cancers where EpCAM is overexpressed.  In addition, the current 
study has been performed in in vitro, in future it can be considered for in vivo studies in 
breast cancer models which would validate at pre-clinical levels the benefit for cancer 
treatment by avoiding the undesirable effects of therapy to surrounding normal tissues.  
Thus the current study achieved the goal of showing the feasibility and specificity of EpCAM 
specific promoter to express NIS gene. In addition to comparing the promoter activity 
between universal and tissue specific promoter, the current study also showed the functional 
activity of NIS gene expressed by both the promoters. This study also assembled a functional 
nanocomplex which was successful in targeting EpCAM positive cells. Furthermore, the 
nanocomplex retained the functional activity of the NIS plasmid it carried. In conclusion, the 
above study evaluated the potentials of EpCAM receptor targeted therapeutic NIS gene 
expression in breast tumor cells and proved it to be an effective approach.  
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Chapter 5 
Study of survivin splice 
variants, Bcl-2 and Bax 
expression profiles in 
retinoblastoma by Real Time 
PCR 
“PCR technique is highly original and significant, virtually dividing biology into the two 
epochs of before P.C.R. and after P.C.R” 
                                                                                                     - The New York Times, 1998
                                                                                                                                      Chapter 5 
196 
 
 
5. Chapter 5 
 INTRODUCTION 5.1.
Cancers evade cell death by overexpressing anti-apoptotic proteins resulting in tumor 
progression and poor prognosis of the disease. Retinoblastoma progression includes various 
genetic changes like triggering of oncogenes and inactivation of tumor suppressor genes 
which leads to loss of balance between cell proliferation and apoptosis (Thompson 1995). 
Aberrations at the genetic level contribute to cancer progression by disturbing cellular 
mechanisms like apoptosis. In RB though, apoptosis and its inhibition has not been 
extensively studied. Apoptosis is a programmed cell death and a genetically organised 
process that occurs under both normal and pathological conditions (E 1996b). Apoptosis is 
one of the three forms of programmed cell death, the other two being autophagy and necrosis. 
Apoptosis is triggered by numerous death and damage signals arising physiologically and 
pathologically (Gross A, McDonnell JM & SJ 1999). As shown in Figure 5.1, a number of 
morphological changes like cell shrinkage, DNA fragmentation and nuclear condensation 
which are the characteristics of a cell undergoing apoptosis (Nishida, Yamaguchi & Otsu 
2008). As described in chapter 1, Figure 1.10, extrinsic pathway containing cell surface 
death receptors and intrinsic pathway exploiting mitochondria are the two main pathways of 
apoptosis (Tang D et al. 2011). The death receptors that are involved in the extrinsic pathway 
include members of the TNF (Tumor Necrosis Factor) family. Two of the main ligand and 
death receptors combination are TNFα/TNFR1, FasL/FasR (Ashkenazi, AviDixit & M 1998). 
When the ligand binds to their corresponding receptors, it stimulates the recruitment of 
adapter proteins. FADD adapter protein is recruited when Fas ligand binds with Fas 
receptors, similarly TRADD adapter protein along with FADD and RIP are recruited when 
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TNF ligand is bound to TNF receptors (Hsu, Xiong & Goeddel 1995; Wajant 2002). This 
results in activation of procaspase-8 to caspase-8 which finally triggers apoptosis. A protein 
called c-FLIP can inhibit apoptosis by binding to caspase-8 (Scaffidi et al. 1999). The 
intrinsic pathway is free of receptors and the signals act directly on the targets. Some of the 
signals that trigger intrinsic pathway are loss of hormones, cytokines or exposure to toxins 
and radiation (Elmore 2007). Such signals stimulate the opening of the mitochondrial 
membrane resulting in the cytosolic release of cytochrome c, Second mitochondria-derived 
activator of caspase/direct inhibitor of apoptosis-binding protein 
(Smac/DIABLO),  apoptosis-inducing factor (AIF) and  caspase-activated DNAse (CAD) 
(Du et al. 2000; Garrido et al. 2006; Joza et al. 2001).  Defects in these pathways lead to 
disturbance in the balance between proliferation and apoptosis which ultimately leads to 
cancer development and treatment resistance (Afford S & S 2000; Hanahan D & RA 2000).  
 
Figure 5.1 Schematic illustration of process of apoptosis 
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Apoptosis is a natural cellular response to any physical damage and occurs both at normal 
and pathological conditions. The process starts with shrinkage of the cell, followed by 
blebbing of the membrane, nuclear condensation and formation of apoptotic bodies. The cell 
death ends with lysis of the formed apoptotic bodies. The entire mechanism is called 
“programmed cell death”. Image adapted from 
http://www.microbiologybytes.com/virology/kalmakoff/baculo/baculohostinteract.htmL 
 
Apoptosis is regulated mainly by two families. One family is the B-cell lymphoma 2 (Bcl-2) 
family which plays a key role in regulating intrinsic pathway of apoptosis. Few of the 
members of this family functions as repressors/ anti-apoptotic (Bcl-2, Bcl-xl, Mcl-1) whereas 
others functions as promotors of apoptosis (Bax, Bad, Bid) (Adams JM & S 1998). Apoptosis 
via the pro-apoptotic molecules is initiated by the death signals which in turn stimulates post-
translational modifications leading to translocation of these pro-apoptotic molecules to the 
mitochondria (Shamas-Din et al. 2011).  Bcl-2 is considered as one of the vital genes in 
suppressing apoptosis. Its abnormal overexpression has absolute null effect on cell 
proliferation and in turn prolongs the survival of the tumor cells and abolishes the apoptotic 
effect (Llambi & Green 2011). Bcl-2 has a key role in cancer therapy as its increased 
expression leads to resistance to drugs whereas its reduced expression results in better 
response to anticancer drugs. In the case of cutaneous B-cell lymphoma, rituximab treatment 
was ineffective and the rituximab treated cells showed high expression of Bcl-2 suggesting its 
role in therapy resistance (Wobser et al. 2007). Since majority of anti-cancer drugs works by 
promoting apoptosis in cancer cells, the Bcl-2 opposes this action thus increasing drug 
resistance. Bcl-2 allows drug accumulation intracellularly and so its mechanism of drug 
resistance induction is different from other resistance genes (Geng, Wang & Li 2013).  Bcl-2 
has been considered a biomarker and has reached clinical trials with two drugs, ABT-263 and 
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ABT-199 directly targeting Bcl-2 (Roberts et al. 2012; Tse et al. 2008). However, recent 
study with the drugs, ABT-263, ABT-199 along with ABT-737 (all structural analogues) 
showed the hazardous effects of them on cancer patients with viral infections by targeting 
non-cancerous cells (Kakkola et al. 2013).  
The first pro-apoptotic members of Bcl-2 family to be discovered were Bcl-2 associated X 
(Bax) protein (Oltvai ZN, Milliman CL & SJ 1993). Bax plays a vital role as a facilitator of 
apoptosis and its function is always kept in check by the anti-apoptotic member of the Bcl-2 
family, Bcl-2 (Reed 1996). The pro-apoptotic activity of Bax is induced by functional p53 
which results in increased cell death induced by chemotherapeutic drugs (Fulda & Debatin 
2006). Sensitivity to drugs increases when more Bax/Bax homodimers are present in the 
mitochondria (Reed 2006) and its reduced concentration renders the cell resistant to apoptosis 
induced by chemotherapy even in a p53-independent manner.  Various cancers like breast, 
head and neck and ovarian have reported low expression of Bax to be a prognostic factor in 
chemotherapy treated malignancies (Kang et al. 2005; Krajewski et al. 1995; Kupryjańczyk et 
al. 2003). This confirms the prominence of Bax in the control of apoptotic cell death 
(Pietrantonio et al. 2013). 
Among the other apoptotic and anti-apoptotic molecules that facilitate the progression of 
cancer, is the main family of apoptotic molecules are Inhibitors of Apoptosis (IAP) family. 
The role of the IAP family in cancer has been associated with cell protection from anti-cancer 
drugs and also to block apoptosis induced by radiation (Jäättelä 1999). In humans, there are 
eight IAPs and one among them is survivin (BIRC5) known to be hot and validated cancer 
target (Ambrosini, Adida & Altieri 1997; Kanwar, Kamalapuram & Kanwar 2011). The 
primary mode of action of IAPs against apoptosis is by inhibiting caspases (Salvesen & 
Duckett 2002) and other alternative modes are by activating JNK signalling or TGF-β 
mediated signalling (Reffey et al. 2001; Sanna et al. 2002). Although, many studies have 
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shown interaction between survivin and caspases, few studies have indicated that the 
interaction does not really inactivate caspases thus bringing in the possibility of caspase 
independent inhibition of apoptosis (Banks et al. 2000). Apart from the cell protecting ability 
of survivin, it also regulates the cell division by forming complexes with the chromosomal 
passenger proteins which in turn regulates the checkpoint of spindle bodies, chromosomal 
movements during mitosis (Noton et al. 2006). The expression of survivin was reported to be 
high in the fetal period and trivial in the normal differentiated tissues. However, recent 
reports have suggested expression of survivin in normal tissues like prostate, stomach, colon, 
skin and various other organs (Yamada et al. 2003). In cancer, survivin overexpression 
overrides the checkpoint resulting in abnormal progression via mitosis  and high expression 
has been observed in multitude of cancers such as breast, prostate, lung, ovarian and 
pancreatic cancers (Kanwar, Kamalapuram & Kanwar 2013). Survivin plays an important 
role in progression of various cancers and so it is considered to be a potent anti-cancer target 
(Kanwar, Kamalapuram & Kanwar 2011).  In addition to its therapeutic potential, survivin 
expression has prognostic and diagnostic value because of its expression in circulating tumor 
cells and patients serum (Rodel et al. 2012). Studies from our laboratory have targeted 
survivin using bLf in a nanoformulation in colon epithelial cancer cells which showed a 
significant lapse in survivin levels (Kanwar et al. 2014).   
Alternative splicing is a regulatory process which produces distinct protein isoforms from the 
common mRNA precursor and a variety of apoptotic factors undergoes this process (Schwerk 
& Schulze-Osthoff 2005). Studies have reported six isoforms of survivin gene in humans. 
The wild type survivin consists of 4 exons, containing 426 bp of coding transcript which 
translates into 16.5 kDa protein (Caldas, Honsey & Altura 2005). Apart from the mature wild 
type survivin, the other alternative splice variants are Survivin-2β which derived its name 
because of addition of 69 bp from intron 2. Survivin ΔEx3 is created by deletion of 102 bp of 
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exon 3 (Mahotka et al. 1999) and addition of 165 bp from intron 3 gives rise to Survivin-3β 
(Badran et al. 2004). The fifth variant known as Survivin-2α is generated by the introduction 
of 197 bp from intron 2 (Caldas, Honsey & Altura 2005) and the final variant Survivin-3α is 
also produced by the addition of 209 bp from intron 2 (Huang et al. 2011b).    
In cancer, abnormal expression of both apoptosis regulating protein families has been 
associated with proliferation and resistance to drugs. While apoptosis regulatory genes have 
been widely detected in various cancers, to date, endogenous expression of the apoptotic 
regulatory proteins in RB has not been explored. Earlier publication from our laboratory 
(Sudhakar et al. 2013) showed survivin protein expression in advanced stages in RB. 
Similarly, in another recent study from our laboratory (Beta et al. 2013), it was found from 
miRNA profiling of RB patient’s serum that Bax was one of the potential target genes 
involved in RB progression. Thus, in continuation to above studies performed by our research 
groups, the current study on Bcl-2, Bax and survivin splice variants apoptotic role in RB 
tumors was warranted. Since there is lack of knowledge of endogenous expression of survivin 
splice variants, Bcl-2 and Bax in primary RB tumors, the study aims dealt in this chapter are 
to unravel the mRNA expression status Bcl-2, Bax and survivin splice variants molecules in 
RB.  
 Hypothesis 5.2.
The hypothesis of this study was that the expression of the apoptotic regulatory genes would 
be associated with clinicopathological features of the RB tumors.  
 Aims 5.3.
The aims of the work performed in this chapter were 
1) To investigate the mRNA expression of survivin splice variants like anti-apoptotic, 
Survivin-WT, Survivin-3β and Survivin-ΔEx3 and pro-apoptotic variants like 
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Survivin-2α, Survivin-2β, as well as pro-apoptotic molecule, Bax, anti-apoptotic 
molecule, Bcl-2 in 20 RB tumors and in an established standard RB cell line (Y79) 
using qRT-PCR.  
2) To investigate if the expression levels of these apoptotic molecules could be 
correlated with the clinicopathological features of RB tumors.  
3) To study the apoptotic effects on silencing the Survivin-WT and one of the anti-
apoptotic splice variant, Survivin-ΔEx3 in Y79 cells.  
 
 MATERIALS AND METHODS 5.4.
 
Figure 5.2 Schematic representation of the research work performed in this phase of 
study 
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Table 5.1 Histopathological features of RB tumor tissues analysed 
 
 
 
 
  
 
 
 
.  
 
 
 
 
 
 Table 5.1: Tumor cohort and its clinical parameters. IIRC stands for International 
Intraocular Retinoblastoma Classification. Group A-C is the early stage tumors and group D 
& E are the advanced stage tumors. Invasive tumors include both choroidal invasion cases 
and optic nerve invasion cases. 
Parameters No. of patients (N=20) 
Sex 
Male 
Female 
 
14 
6 
Age 
<5 years 
≥5 years 
 
19 
1 
Laterality 
Unilateral 
Bilateral 
 
20 
Nil 
Differentiation 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
 
5 
5 
10 
IIRC Grade 
Group A-C 
Group D,E 
 
Nil 
20 
Invasion status 
Invasive 
Non-invasive 
 
12 
8 
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 RESULTS 5.5.
5.5.1. Expression of survivin variants, Bax and Bcl-2 in RB tissues   
The transcriptional expression of survivin variants was evaluated in 20 different fresh-frozen 
RB tumors by quantitative real time PCR. The mRNA level expression in tumor was 
quantified by Relative Standard Curve method initially, and then compared with the 
expression in normal retina. The obtained results suggest that the survivin variants showed 
higher expression in majority of the tumors irrespective of sex and age when compared to 
normal retina. The relative mRNA expression of all the survivin variants was plotted onto a 
graph (Figure 5.3.A). Overall expression of Survivin-WT was detected in 90% (18/20) 
tumors, Survivin-2α in 85% (17/20), Survivin-2β in 80% (16/20), Survivin-3β in 85% (17/20) 
and Survivin-ΔEx3 in all 20 tumors (100%). All the five survivin isoforms were present in 16 
tumor samples (80%). Although all the survivin variants were highly expressed in RB, 
Survivin-WT in terms of overall mRNA expression was significantly highly expressed 
(P<0.05) when compared to Survivin-2β (Figure 5.4.A). The mRNA level expression of Bax 
and Bcl-2 was also evaluated in 20 different fresh-frozen RB tumors and then compared with 
the expression in normal retina by quantitative real time PCR. Higher expression of Bax and 
Bcl-2 was observed in tumors irrespective of clinical parameters and the relative expression 
were plotted onto a graph (Figure 5.3.B). Overall expression of Bax was detected in 80% 
(16/20) and Bcl-2 was detected in all 20 tumors (100%). Both Bax and Bcl-2 were present in 
16 tumor samples (80%) out of 20 tumors. Between Bax and Bcl-2 expression, Bcl-2 was 
highly expressed in RB with a high statistical significance of expression (P<0.001) (Figure 
5.4.B). 
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Figure 5.3 Expression level of Survivin splice variants, Bax and Bcl-2 in RB tumors 
(A) mRNA levels of Survivin-WT (Sur-WT), Survivin-2α (Sur-2α), Survivin-2β (Sur-2β), 
Survivin-3β (Sur-3β) and Survivin-ΔEx3 (Sur-ΔEx3). (B) Bax and Bcl-2 mRNA expression 
levels in RB tumors relative to non-neoplastic retina by Real Time Quantitative Reverse 
Transcriptase PCR (qRT-PCR). Relative fold expression levels are expressed as mean ± SD 
of triplicate analyses. 
A
B
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Figure 5.4 Relative mRNA level expression of survivin splice variants, Bax and Bcl-2 
(A) Relative mRNA levels of survivin variants with respect to normal retina in RB. Survivin-
WT is the dominant transcript among the variants and showed significant difference of 
expression (P<0.05) with Survivin-2β. (B) Bcl-2 and Bax were statistically significant 
(P<0.001). P-values were calculated by the Wilcoxon-test.  
5.5.2. Association with the clinicopathological characteristics of tumor 
Association of the survivin variants with invasion status, sex and differentiation of the RB 
tumors was further analysed using non-parametric tests like Mann-Whitney and Kruskal 
Wallis test due to the data not following normal distribution. The Shapiro-Wilk test was 
initially used to determine the normality of the data. Since the significance value was below 
0.05, the data deviated from normal distribution.  The association of the clinical parameters 
such as gender and invasion status and the variables with its P-value have been shown in the 
Table 5.2. The association of survivin variants expression with the invasion status of the 
tumors was analysed, and the expression level of the survivin variants did not significantly 
change between the invasive and non-invasive cases (Figure 5.5). Similarly, as shown in 
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Figure 5.7, all the survivin variants did not show a statistically significant association with 
differentiation status of tumors. However, only Survivin-2α, a pro-apoptotic protein showed a 
statistically significant (P<0.05) higher expression in moderately differentiated tumors than 
poorly differentiated tumors and well differentiated tumors with 30.9% and 35% variability 
respectively in rank score for differentiation. The other variant, Survivin-2β, a pro-apoptotic 
protein also showed a statistically significant (P<0.05) higher expression in moderately 
differentiated tumors than poorly differentiated tumors and well differentiated tumors 
(P<0.05) with 34.7% and 53.4% variability in rank score respectively. Survivin-ΔEx3, an 
anti-apoptotic protein also showed a statistically significant (P<0.05) lower expression in 
well differentiated tumors compared to moderately differentiated tumors with 43.7% 
variability in rank score for differentiation. Surprisingly, an association of gender with 
expression of proteins showed a significant increase (P<0.05) of anti-apoptotic proteins, 
Survivin-WT and Survivin-3β in males compared to females (Figure 5.9). 
Similar to survivin splice variants, association of the Bcl-2/Bax with invasion status, sex and 
differentiation of the RB tumors was further analysed using non-parametric tests like Mann-
Whitney and Kruskal Wallis test. The association of the clinical parameters such as gender 
and invasion status and the variables with its P-value have been shown in the Table 5.2. 
Unlike the survivin splice variants, Bax, a pro-apoptotic protein, showed a statistically 
significant (P<0.05) higher expression in invasive tumors than the non-invasive tumors 
(Figure 5.6). In the case of differentiation, the Bcl-2/Bax ratio showed an increased 
expression in poorly differentiated tumors compared to well differentiated and moderately 
differentiated tumors (Figure 5.8.A). However, the statistical analysis did not show any 
significant association with any of the differentiation stages either in Bax or in Bcl-2 (Figure 
5.8.B). No significant association of gender with Bcl-2 and Bax expression was observed 
(Figure 5.10). 
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Table 5.2  Association of mRNA expression of survivin splice variants, Bcl-2 and Bax 
with gender and invasion status in RB tumors 
Clinical 
Parameters 
Total 
number 
(n) 
P-value 
Sur-WT 
P-value 
Sur-2α 
P-value 
Sur-2β 
P-value 
Sur-3β 
P-value 
Sur-
ΔEx3 
P-value 
Bax 
P-
value 
Bcl-2 
Gender 
Male 
Female 
20 
14 
6 
0.048 
 
NS NS 0.013 NS NS NS 
Invasion status 
Non-invasive 
Invasive 
20 
8 
12 
NS NS NS NS NS 0.045 
 
 
 
 
NS 
 
Table 5.2: Association of mRNA expression of survivin splice variants, Bcl-2 and Bax with 
gender and invasion status in 20 RB tumors. P-values were calculated by the Mann-Whitney-
test.  
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Figure 5.5 Relative mRNA levels of all survivin variants in RB in relation to 
invasiveness of the RB tumors. 
P-values were calculated by the Mann-Whitney-test.  
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Figure 5.6 Relative mRNA levels of Bcl-2 and Bax in RB in relation to invasiveness of 
the RB tumors. 
Significant difference in expression (P<0.05) was observed in Bax. P-values were calculated 
by the Mann-Whitney-test. 
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Figure 5.7 Relative mRNA levels of survivin variants in RB in relation to differentiation 
of the RB tumors. 
Significant difference in expression (P<0.05) was observed in Survivin-2α, Survivin-2β and 
Survivin-ΔEx3. P-values were calculated by the Kruskal-Wallis-test. 
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Figure 5.8 Ratio of Bcl-2/Bax among differentiated RB tumors 
(A) Real-time PCR analysis for the ratio of Bcl-2/Bax among different differentiated RB 
tumors. (B) Relative mRNA levels of Bcl-2 and Bax in RB in relation to differentiation of the 
RB tumors. P-values were calculated by the Kruskal-Wallis-test. 
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Figure 5.9 Relative mRNA levels of survivin variants in RB in relation to gender of the 
RB tumors. 
Significant difference in expression (P<0.05) was observed in Survivin-WT and Survivin-3β. 
P-values were calculated by the Mann-Whitney-test. 
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Figure 5.10 Relative mRNA levels of Bcl-2 and Bax in RB in relation to gender of the 
RB tumors. 
P-values were calculated by the Mann-Whitney-test.  
5.5.3. Correlation among the survivin variants, Bcl-2/Bax in RB 
The five survivin isoforms showed a significant positive correlation to each other in the 
tumor samples (Table 5.3). The mRNA expression of Survivin-WT showed a significant 
positive correlation (P<0.05) with the expression of Survivin-2α with a correlation co-
efficient of 0.740 (Table 5.4). The mRNA expression of Survivin-WT demonstrated a 
statistically significant positive correlation (P<0.05) with the expression of Survivin-2β with 
a correlation co-efficient of 0.537. Similarly, the mRNA expression of Survivin-WT 
exhibited a statistically significant positive correlation (P<0.05) with the expression of 
Survivin-3β and Survivin-ΔEx3 with a correlation co-efficient of 0.889 and 0.534 
respectively. As shown in Table 5.3, the correlation among all the variants was significant 
and yielded to a strong positive correlation. Unlike, the ratios of survivin variants, the Bcl-
2/Bax ratio did not yield to a statistically significant correlation. But a significant correlation 
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was observed among all the survivin variants and Bax. The mRNA expression of Survivin-
WT, Survivin-2α, Survivin-2β, Survivin-3β and Survivin-ΔEx3   demonstrated a statistically 
significant positive correlation (P<0.05) with the expression of Bax with a correlation co-
efficient of 0.690, 0.483, 0.668, 0.595 and 0.444 respectively. There was a significant 
(P<0.05) positive correlation between Survivin-2β and Bcl-2 with a correlation co-efficient of 
0.608.  
 
Table 5.3 Correlation among the expression levels of survivin variants, Bcl-2 and Bax in 
RB tumors 
Variables P-value 
Sur-WT 
P-value 
Sur-2α 
P-value 
Sur-2β 
P-value 
Sur-3β 
P-value 
Sur-ΔEx3 
P-value 
Bax 
P-value 
Bcl-2 
Sur-WT  0.000 0.015 0.000 0.015 0.001 0.450 
Sur-2α   0.007 0.000 0.002 0.031 0.289 
Sur-2β    0.024 0.001 0.001 0.004 
Sur-3β     0.001 0.006 0.164 
Sur-ΔEx3      0.050 0.102 
Bax       0.076 
 
Table 5.3: Correlation among the expression levels of survivin variants, Bcl-2 and Bax in RB 
tumors (n=20). P-values were calculated by the Spearman correlation test. 
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Table 5.4 Spearman correlation coefficients of variables like survivin variants, Bcl-2 
and Bax in RB tumors 
Variables Sur-WT Sur-2α Sur-2β Sur-3β Sur-ΔEx3 Bax Bcl-2 
Sur-WT  0.740 0.537 0.889 0.534 0.690 0.179 
Sur-2α   0.579 0.776 0.657 0.483 0.250 
Sur-2β    0.504 0.695 0.668 0.608 
Sur-3β     0.663 0.595 0.323 
Sur-ΔEx3      0.444 0.376 
Bax       0.406 
 
Table 5.4: Spearman correlation coefficients of variables like survivin variants, Bcl-2 and 
Bax in RB tumors (n=20).  
5.5.4. Survivin and its variants mRNA expression in Y79 cells 
Y79, a retinoblastoma cell line endogenously expressed Survivin-WT and its variants at a 
higher level. The increased level of all the variants was similar to the RB tissue samples. 
Statistically significant difference (P<0.001) was observed between all survivin variants and 
a significance of P<0.05 was observed between Sur-WT and Sur-ΔEx3. No statistically 
significant difference was observed between Sur-2α and Sur-3β. Altogether, the anti-
apoptotic variants like Survivin-WT, Survivin-3β and Survivin-ΔEx3 were significantly 
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higher in the Y79 cells when compared to the pro-apoptotic variants like Survivin-2α and 
Survivin-2β (Figure 5.11).  
 
Figure 5.11 mRNA levels of survivin splice variants in Y79 cell line 
Quantification of mRNA levels of Survivin-WT (Sur-WT), Survivin-2α (Sur-2α), Survivin-2β 
(Sur-2β), Survivin-3β (Sur-3β), Survivin-ΔEx3 (Sur-ΔEx3) mRNA expression levels in RB cell 
line (Y79) relative to the non-neoplastic retina by real time quantitative reverse transcriptase 
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PCR (qRT-PCR. Relative fold expression levels are expressed as mean ± SD of triplicate 
analyses. **** (P<0.001) and * (P<0.05). P-values were calculated by the Student’s t-test. 
5.5.5. In vitro silencing of Survivin-WT and Survivin-ΔEx3 in Y79 cells 
The Survivin-WT siRNA at a concentration of 100 nM efficiently knocked down the target 
transcripts at 48 h after transfection. A time related analysis determined the optimal time for 
gene knockdown. The downregulation of Survivin-WT at the mRNA level was significant 
(P<0.001) when compared to its endogenous level (Figure 5.12.A). This downregulation of 
Survivin-WT was also observed at the protein level by Western blotting (Figure 5.12.B & 
C). Similarly, the Survivin-ΔEx3 siRNA at a concentration of 100 nM efficiently knocked 
down the target transcript at 48 h after transfection. A time related analysis determined the 
optimal time for gene knockdown. The downregulation of Survivin-ΔEx3 at the mRNA level 
was significant (P<0.005) when compared to its endogenous levels (Figure 5.13.A). 
However, this downregulation was not translated at the protein level (Figure 5.13.B).  
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Figure 5.12 Downregulation of Survivin-WT in Y79 cells after silencing with Sur-WT 
siRNA 
(A) A Real-Time Quantitative PCR (qRT-PCR) shows that 100 nM of Sur-WT siRNA 
treatment in Y79 cells showed a significant downregulation (P<0.001) compared to the 
control Y79 cells. (B) Immunoblot showed an effective silencing of Survivin in Y79 cells 
transfected with Sur-WT siRNA at 100 nM compared to the control Y79 cells. (C) Histogram 
analysis plotted with relative intensity determined by Image J analysis shows the silencing 
effect of Sur-WT siRNA in Y79 cells. P-values were calculated by the Student’s t-test. 
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Figure 5.13 Downregulation of survivin-ΔEx3 in Y79 cells after silencing with Sur- 
ΔEx3 siRNA 
(A) A Real-Time Quantitative PCR (qRT-PCR) shows that 100 nM of Sur-ΔEx3 siRNA 
treatment in Y79 cells showed a significant downregulation (P<0.005) compared to the 
control Y79 cells. (B) Immunoblot showed no effective silencing of Sur-ΔEx3 in Y79 cells 
transfected with Sur-ΔEx3 siRNA at 100 nM compared to the control Y79 cells (Image shown 
after cropping of empty lane). Histogram analysis plotted with relative intensity determined 
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by Image J analysis shows the silencing effect of Sur-ΔEx3 siRNA in Y79 cells. P-values were 
calculated by the Student’s t-test. 
5.5.6. Inhibition of Survivin-WT and Survivin-ΔEx3 leads to significant induction of cell 
apoptosis 
The silencing effect of Survivin-WT and Survivin-ΔEx3 on cell viability was analysed by 
Annexin-V/PI staining after 48 h of transfection. The proportion of viable cells notably 
decreased in the Survivin-WT silenced cells as compared to the control cells. A higher 
proportion of cells were also observed in late apoptotic phase in the silenced cells than the 
control cells (Figure 5.14.A). However, no apoptotic effects were observed in the Survivin-
ΔEx3 silenced samples. In order to determine whether the decrease in the cell viability shown 
by apoptosis is induced via caspases, caspase 3/7 activity was measured 48 h after Sur-WT 
siRNA transfection. An increased activity of caspases 3/7 `was observed in the silenced cells 
than the control cells (Figure 5.14.B).  
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Figure 5.14 Annexin V-PI staining and caspase 3/7 actvity in Sur-WT silenced cells 
(A) Annexin V and PI staining of 100 nM of Survivin-WT siRNA transfected Y79 cells. 48 h 
following transfection, Y79 cells were stained with Annexin V/PI and analyzed by flow 
cytometry. The difference in the percentage of viable and apoptotic cells between the control 
Y79 cells and Sur-WT siRNA treated cells is shown in a histogram. (B) Y79 cells were 
transfected with Survivin-WT siRNA at 100nM concentration; 48 h later, caspase-3/7 activity 
was examined and normalized to number of viable cells. Fold induction is indicated 
compared to the control cells. Data are shown as the percentage of total caspase-3 
activation. Experiments were performed in duplicates and values are shown with ± Standard 
Deviation.   
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5.5.7. Effects of Survivin-WT silencing on the splice variants 
The silencing of the Survivin-WT led to effective knockdown of mRNA expression of all the 
splice variants. Although there was a significant downregulation (P<0.05) of all the variants 
(Figure 5.15) on silencing the Survivin-WT alone, a higher downregulation was observed in 
both the pro-apoptotic variants, Survivin-2β and survivin-2α.  
 
Figure 5.15 mRNA levels of survivin splice variants on silencing Survivin-WT 
A Real-Time Quantitative PCR (qRT-PCR) of Survivin-WT silenced Y79 cells shows a 
significant downregulation of all survivin variants compared to the control Y79 cells.* 
P<0.05 and *** P<0.005. P-values were calculated by the Student’s t-test. 
 DISCUSSION 5.6.
Biallelic RB1 inactivation leads to development of retinal tumor and unlike other 
malignancies, RB is strongly predisposed to germline RB1 mutations (Gombos 2012). In a 
recent study, it was revealed that cone precursors are sensitive to Rb protein exhaustion. It 
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was shown that these Rb depleted cone precursors proliferated in intact retina and formed 
tumors in orthotopic xenografts which was similar to human RB at histological and molecular 
cytogenetic levels. Thus, the above study established a link between loss of Rb protein and 
cone precursor specific circuitries (Xu et al. 2014). In RB, apoptotic paradox is a 
phenomenon where percentage of apoptotic cells are higher than the dividing cells but the 
unique feature is that these abundant apoptotic cells does not prevent the tumor from 
growing. According to an earlier study, there was an association between apoptotic index and 
mitotic index in RB revealing a close correlation between cell proliferation and apoptosis. 
However, the tumor favoured proliferation because of net growth. It was also found from a 
small cohort of RB tumors that there are no inclination towards a single apoptotic pathway 
(Sitorus, Gumay & Van Der Valk 2009). Apoptosis is regulated by a network of molecules, 
involved either in promoting or inhibiting apoptosis. IAP and Bcl-2 family has been studied 
extensively in various cancers for their role in tumorigenesis and disease progression (Elmore 
2007). 
This study shows for the first time that the mRNA levels of endogenous expression of 
survivin splice variants, Bcl-2 and Bax in RB tumors and its correlation with the 
aggressiveness of tumors. Expression of the apoptosis related molecules in RB tumors from 
patients as well as in established standard RB cell line (Y79) was determined. The expression 
of two apoptosis regulating proteins from the Bcl-2 family, Bcl-2 and Bax in RB was 
analysed as several studies suggest that Bax is a pro-apoptotic molecule while Bcl-2 is an 
anti-apoptotic molecule and higher Bcl-2/Bax ratio leads to inhibition of apoptosis in cancer. 
One study have shown that overexpression of  Bcl-2, an antiapoptotic protein in endometrium 
signals the initiation of cancer cell overgrowth (Mitselou et al. 2002). In cancers like 
colorectal cancer, head and neck cancer, Bcl-2 family members have been shown to possess 
prognostic potential (Hector & Prehn 2009). On the other hand, overexpression of Bax, a pro-
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apoptotic protein stimulates apoptosis of cancer cells leading to arrest of progression of 
cancer. Bcl-2 and Bax coexist as a heterodimer in vivo and the balance between the two 
determines whether inhibition or induction of apoptosis has to occur (Pietrantonio et al. 
2013). Apoptotic inhibition occurs in the cell when the Bcl-2/Bax ratio is tilted towards Bcl-2 
and apoptotic induction prevails in the cell when the ratio of Bcl-2/Bax is tilted towards Bax 
(Sakuragi et al. 2002). In order to determine the status of this ratio in RB, expression of these 
two proteins were studied by real-time PCR. The expression level of Bcl-2 was significantly 
higher in RB compared to normal retina and it was also remarkably higher compared to Bax. 
When Bcl-2/Bax ratio was determined, it was found to be more than 1 favouring Bcl-2 
dominance in RB.  We next analysed the Bcl-2/Bax ratio with respect to differentiation of 
tumors and found that Bcl-2/Bax ratio to be remarkably higher in poorly differentiated 
tumors. However this difference did not yield to a significant difference when statistical 
analysis was done among the differentiated tumors. This may be due to the limitation in the 
sample size analysed for Real-Time PCR (Porichi et al. 2009). Also, in moderately 
differentiated tumors compared to well differentiated tumors, a decrease in Bcl-2/Bax ratio 
was observed. However, such difference in expression level either for Bax or for Bcl-2 was 
not observed between males and females, thus implying the fact that Bcl-2/Bax expression in 
RB is independent of gender of the tumors. 
Since, Bcl-2 was higher in both invasive and non-invasive tumors, the statistical analysis did 
not yield a statistically significant difference between invasive and non-invasive tumors. Bcl-
2 association with invasive tumors have been earlier studied in invasive bladder cancers 
where it is also related to reduced survival in patients (Kong et al. 1998). Another study in 
breast cancer showed Bcl-2 to possess prognostic value because of its high expression in 
invasive tumors (Yang et al. 2003). Surprisingly, in nasopharyngeal carcinoma, Bcl-2 
positivity showed a better outcome clinically (Vera-Sempere et al. 1997). In the case of Bax, 
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though its mRNA expression level was lower compared to Bcl-2, its expression was 
significantly higher in invasive tumors compared to non-invasive tumors. Higher expression 
of Bax signifies higher apoptotic activity followed by apoptosis of tumor cells. However, in 
RB this study shows that higher anti-apoptotic activity of Bcl-2 nullifies this apoptotic 
activity of Bax and only anti-apoptotic activity of Bcl-2 appears to prevail. Studies in 
colorectal cancer showed that Bax expression gradually decreased from well differentiated 
tumors to poorly differentiated tumors pointing an association of Bax to tumor differentiation 
(Jansson & Sun 2002). Studies related to Bax correlation with clinical parameters such as 
reduced expression in advanced stage tumors were shown in nasopharyngeal tumors (Kontos 
et al. 2013). In the case of nephroblastoma, a round cell tumor and a pediatric malignancy of 
the kidney, alterations of the Bcl-2/Bax balance deregulates apoptosis and heavily influences 
the clinical outcome of the nephroblastoma patients (Ghanem et al. 2001). Surprisingly, in 
RB tumors, Bcl-2 and Bax did not show any significant correlation with each other in terms 
of expression level. The logical reasons behind difference in findings with other studies could 
be due to the varied nature of the tumors and also different methods used to analyse the 
expression. Thus, we could suggest that this strong overexpression of anti-apoptotic protein, 
Bcl-2, may play a role in the carcinogenesis of RB.  
Survivin is considered to be one of the primary cancer associated gene because of its 
differential expression in normal as well as cancer cells, its role in cell division and inhibition 
of apoptosis (Altieri 2003b; Kanwar, Kamalapuram & Kanwar 2011). Therefore, the 
expression of members of survivin family in RB tumors was analysed. Survivin was highly 
expressed in RB tumor tissues than in normal tissues. Expression of survivin at protein level 
in RB has already been shown by a study from our group, which revealed that 86% of tumors 
expressed survivin and its expression is associated with advanced stages of RB (Sudhakar et 
al. 2013). In concurrent with the previous study from our lab, the current study also observed 
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90% of Survivin-WT positivity at mRNA level.  The current study also observed an increased 
expression of survivin and its variants in poorly differentiated tumors which are associated to 
high risk factors (Kashyap et al. 2012) in the RB tumors analysed.  
RB belong to a group of tumors called malignant round cell tumor (MRCT), which is a group 
composed of round, small undifferentiated tumors (Rajwanshi, Srinivas & Upasana 2009). 
IAPs like survivin has been shown to play a major role in some of the pediatric MRCT’s. In 
neuroblastoma, a pediatric extracranial cancer, showed high survivin expression which 
correlated with poor prognosis and advanced tumor stages (Altieri 2001). Hepatoblastoma, a 
pediatric liver neoplasm also overexpresses survivin and involved in the survival of the tumor 
cells (Uehara et al. 2013) whereas in non-Hodgkin lymphoma, survivin expression is closely 
associated to advanced stages and prognosis (Li & Wu 2006). In Wilm’s tumor, a pediatric 
kidney cancer, survivin is involved in tumorigenesis and its increased expression in the 
nucleus is considered to be favourable for prognosis of the disease (Basta-Jovanovic et al. 
2011). But in another round cell tumor like Ewing sarcoma, a pediatric bone or soft tissue 
cancer, although survivin is over expressed in tumors and plays a key role in viability, it 
serves as a poor prognostic marker (Hingorani et al. 2013).  
When compared to the normal retina, survivin and its isoforms were expressed at a higher 
percentage in the RB tumors. This suggests that survivin along with its alternatively spliced 
variants has an important role in tumorigenesis of RB and corroborates the earlier widely 
acknowledged findings about cancer specific overexpression of survivin. The predominant 
form was Survivin-WT followed by Survivin-3β and Survivin-ΔEx3. Among the pro-
apoptotic variants, the dominant form was Survivin-2α and the least expressed was Survivin-
2β, although its expression level was 3.7 fold higher than the normal retina. Given the higher 
expression of all the anti-apoptotic variants of survivin over the pro-apoptotic variants of 
survivin in RB, it could be inferred that these anti-apoptotic molecules drive the progression 
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of RB tumors. The increased expression of anti-apoptotic Survivin-3β in breast cancer was 
associated with tumor development and correlated inversely to pro-apoptotic genes (Végran 
et al. 2011). Similarly, in this study, Survivin-3β was observed to be highly expressed and 
could be suggested to have a role in tumor progression. Since in the current study, all the 20 
tumors are of high grade (Grade D or E), there is an agreement between this study and earlier 
studies on breast cancer samples where it was shown that high mRNA concentrations of the 
anti-apoptotic molecules like Survivin-WT and Survivin-ΔEx3 are associated to high grade 
phenotype (Span et al. 2006).  
In this study, not all the variants of survivin were found to be associated to all the clinical 
parameters of the tumors analysed. Only Survivin-2α, Survivin-2β and Survivin-ΔEx3 
showed correlation in the differentiation of the tumors. The Survivin-2α was found to be 
significantly decreased in poorly differentiated tumors when compared to moderately 
differentiated tumors based on the mean rank. The decrease in Survivin-2α, a pro-apoptotic 
molecule might reduce the strength of its pro-apoptotic activity in poorly differentiated 
tumors, giving rise to the generation of potent anti-apoptotic variants as the differentiation 
level of RB tumors deteriorates. Similar to Survivin-2α gene expression downregulation in 
poorly differentiated tumors, another main pro-apoptotic variant, Survivin-2β was also found 
to be significantly downregulated in poorly differentiated tumors based on the mean rank. 
The decline in the expression of two pro-apoptotic molecules in such advanced poorly 
differentiated tumors may thus result in progression and development of RB. The decreased 
mRNA expression of these pro-apoptotic variants might be related to an early event in the 
onset of RB. Such downregulation of Survivin-2β in advanced clinical stages of cancer has 
also been observed in gastric carcinoma and renal cell carcinoma (Mahotka et al. 2002a; 
Meng et al. 2004). Survivin-ΔEx3 has been shown to possess anti-apoptotic property and it 
was found to be highly detectable in chronic or advanced cancer samples (Nakagawa et al. 
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2004). The anti-apoptotic property of Survivin-ΔEx3 is counteracted by the antagonist 
property of Survivin-2β, thus the ratio of both these variants in cancer cells determines the 
progression of cancer. The ratio of Survivin-ΔEx3/Survivin-2β in RB was higher towards the 
anti-apoptotic molecule. Since Survivin-2β was decreased in poorly differentiated tumors, 
Survivin-ΔEx3 was expected to be increased in the poorly differentiated tumors. Surprisingly, 
Survivin-ΔEx3 did not show a statistically significant increase in poorly differentiated tumors 
though it showed a significant increase in the expression in moderately differentiated tumors, 
compared to well differentiated tumors based on mean rank. None of the other survivin 
variants showed any significant association with the differentiation of the tumors. Among the 
gender parameter, Survivin-WT and Survivin-3β showed statistically significant increase 
(P<0.05) in expression in males compared to females. Employing more clinical samples and 
analysing with respect to gender might throw light on the actual effect of gender on the 
expression of survivin splice variants. 
Another important clinical parameter that was considered for the expression study was 
invasiveness of the RB tumors. In concurrence with the earlier study in RB from our 
laboratory, this study also did not show any significant association with the invasion status of 
the tumors not only for Survivin-WT but also for all the variants. Correlation among the five 
variants was positive and highly significant which implies the fact that survivin family 
members are closely related to each other and work in tandem. The correlation of three of the 
alternative splice variants of survivin with the clinical parameter like differentiation of the 
tumor shows an active involvement of this hot cancer target in the development of RB.  
The current investigation on survivin and its variants in RB tumors showed that Survivin-WT 
was the predominant form expressed although its variants are also highly expressed. The 
same mRNA analysis was also performed in RB cell line, Y79, for Survivin-WT and all of its 
variants. Similar to tumor tissues, the survivin and all its variants were highly expressed in 
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Y79 cells. Among the variants, the anti-apoptotic proteins were evidently higher than the pro-
apoptotic proteins in the Y79 cells. Thus the results obtained from the RB cell line is 
concurrent with the results obtained from the RB tumors (Sudhakar et al. 2013). So, the Y79 
cell line mimics the tumor environment and further experiments were carried out with this 
cell line. Apart from Survivin-WT, the most important variant is anti-apoptotic variant, 
Survivin-ΔEx3 because of its role in proliferation and apoptosis (Altieri 2003a). Thus along 
with Survivin-WT, targeting of Survivin-ΔEx3 would be interesting from the point of 
therapeutic intervention. Since Survivin-WT along with Survivin-ΔEx3 was overexpressed in 
both the clinical samples as well as in RB cell line, hence the study was focused on targeting 
Survivin-WT and Survivin-ΔEx3 via RNAi mediated inhibition in RB.  
For siRNA transfection experiments, siRNA targeting Survivin-WT was used at 100nM after 
efficient inhibition at 48 h was observed at this particular concentration. Significant 
downregulation of Survivin-WT was observed both at mRNA level as well as at protein level. 
This effective mRNA reduction and protein reduction resulted in remarkable pro-apoptotic 
effects in the silenced samples.  In various cancer cells, it has been studied that on silencing 
survivin, the caspase-3 and caspase-7 gets activated (Shin et al. 2001). This activated 
caspase-3/7 functions by degrading the key intracellular substrates within the cell thus 
leading to apoptosis (Xu & Shi 2007). Also, survivin is known to inhibit caspase-3 and 
caspase-7, so in this study, it is shown that the apoptosis in the survivin silenced samples was 
associated with increased level of caspase-3/7 activity which are the executioner/mediator of 
apoptosis. The results obtained are concurrent with the previous study in bladder cancer 
where the inhibition of Survivin-WT exhibited similar increase in apoptosis (Wuttig et al. 
2007). Apoptosis induction on effective inhibition of Survivin-WT was observed not only in 
bladder cancer, but also in other cancers like colon and breast cancers (Li et al. 2005; 
Williams et al. 2003).  
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For siRNA transfection experiments with Survivin-ΔEx3, the siRNA showed significant 
downregulation at 100nM after 48 h incubation period. Though the downregulation of 
Survivin-ΔEx3 was observed at the mRNA level, a decrease in the corresponding protein was 
not observed by Western blotting using specific antibody against Survivin-ΔEx3. Such 
observation was seen in a similar study in bladder cancer where the Survivin-ΔEx3 inhibition 
did not result in protein reduction (Wuttig et al. 2007). The possible reasons for such a result 
is that Survivin-ΔEx3 inhibition at mRNA level does not produce noticeable difference at 
protein level and for such a noticeable inhibition, it may require more time than the 48 h of 
transfection. In addition, regulatory mechanism of alternative splice variants tends to bring 
the expression of other variants when one of the variants is inhibited (Lai & McCobb 2006). 
The inhibition of Survivin-ΔEx3 did not also induce noticeable apoptosis in the silenced 
samples. But a recent in vitro study in breast cancer on the inhibition of Survivin-ΔEx3 by 
plasmid expressing antisense Survivin-ΔEx3 showed significant anti-proliferative effects 
(Zheng et al. 2011) indicating the survivin’s role in cell divivsion. Thus the results in the 
current study for Survivin-ΔEx3 inhibition in Y79 cells, confirms that inhibition of one of the 
variants alone does not lead to effective increased response in apoptotic induction, at least 
when it was silenced via the siRNA.  
In order to check whether the variants were silenced when Survivin-WT was silenced, a qRT-
PCR was performed on the Survivin-WT silenced sample and it was observed that all the 
variants were significantly downregulated. This downregulation of gene expression was 
observed because the Survivin-WT siRNA used in this study targets a region in exon 2 which 
is common to all the variants. This complete downregulation of all variants was effective in 
inducing apoptosis. In concurrence with the previous published work (Wuttig et al. 2007), the 
current study results also showed that inhibition of one of the variants alone did not yield to 
desired results of apoptosis induction in RB. Nevertheless, inhibition of Survivin-WT 
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silenced all the alternative splice variants resulting in a desired pro-apoptotic effect in RB 
cells. 
Correlation between survivin and Bcl-2 has been studied in various cancers and positive 
correlation between the two has been observed in invasive ductal carcinoma of breast (Al-
Joudi, Iskandar & Imran 2007) in and non-small cell lung cancer (Han et al. 2009). However, 
in this study, Bcl-2 showed no such significant positive correlation with any of the survivin 
variants except Survivin-2β. Survivin-2β’s pro-apoptotic activity may be masked/suppressed 
by the increased anti-apoptotic activity of other survivin variants and Bcl-2. Such non-
correlation between survivin and Bcl-2 was also observed in various other studies like 
prostatic adenocarcinoma (Kaur et al. 2004), urothelial carcinoma (Jeong et al. 2009) and 
cervical carcinoma (Zhu et al. 2010). However, the correlation between survivin variants and 
Bax was positive and highly significant. This correlation implies that there could possibly be 
interplay between the variants and Bcl-2/Bax and the dominant player emerges and exerts its 
activity for the progression of RB tumor. Since Bcl-2 is highly expressed in RB than Bax, 
Bcl-2 exerts its activity by maintaining the integrity of the mitochondrial membrane and thus 
preventing the release of cytochrome c for the apoptosis to take place via Bax (Kirkin, Joos & 
Zörnig 2004). On the other hand, highly expressed survivin and its anti-apoptotic variants 
exert their anti-apoptotic function in the downstream pathways of Bax by targeting caspase-3 
(Tamm et al. 1998). In addition, survivin was shown to suppress the cell death induced by 
Bax (Tamm et al. 1998). Thus, the upregulation of Bcl-2 and anti-apoptotic variants of 
survivin in RB can suppress even the upregulated activity of Bax and thereby may partly 
promote the aggressiveness of RB. Therefore, considering the high expression of Bcl-2 and 
survivin in RB, a targeted therapy towards these molecules could be promising in the near 
future. By targeting Survivin-WT and Survivin-ΔEx3 at in vitro level in RB, the current study 
demonstrates that targeting induces apoptosis and that this is a viable option.  
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The limitation of the current study is that the expression of survivin splice variants, Bcl-2 and 
Bax in RB tumors were studied only at the mRNA level and not at the protein level. The 
major impediment was the non-availability of antibodies for all the splice variants of the 
survivin. Thus the future studies needs to explore whether the mRNA level expression of the 
survivin splice variants, Bcl-2 and Bax investigated in this study translates into protein level. 
Nevertheless, the current study with its modest cohort size with respect to tumor samples was 
therefore able to produce statistically significant correlation between the expression of 
apoptotic genes and few of the clinical parameters of the tumors. Future studies focussing on 
the precise role of each survivin variant and each member of Bcl-2 family in the recurrence 
and patient survival in a larger cohort of RB tumors are necessary for a conclusive report.  
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CONCLUSION AND FUTURE PERSPECTIVES 
CONCLUSION 
Therapy for cancer has eluded medical and scientific community for centuries. Many newer 
and complicated therapies have been introduced but only few established. One of the reasons 
for many failed attempts at achieving cure for cancer is lack of targeted treatments and also 
unwarranted side effects. Treatments for breast cancer and RB have such similar problems 
and this needs to be addressed. RB, though a rare form of pediatric cancer is highly fatal if 
left untreated. Our laboratory has studied various therapeutic targets for RB which has 
potential in targeting cancerous cells and arresting its growth. In line with those findings, 
Sodium Iodide Symporter (NIS) expression at protein level was explored in RB. Although 
basal level NIS is present in breast cancer, the possibility of EpCAM directed NIS 
overexpression was explored. Apart from studying NIS expression in RB, important 
apoptosis related genes such as survivin splice variants, Bcl-2 and Bax were also studied.  
 
Main conclusions from this study are: 
1) NIS protein is expressed at a higher percentage in all 41/41 tumors (100%) analysed 
and the expression is associated to invasiveness of the tumors. 
2) Overexpression of NIS gene in breast cancer cells via EpCAM specific promoter 
showed higher iodide uptake than the CMV promoter. 
3) PEI/NIS pDNA/EpDT3 nanocomplex delivered NIS pDNA specifically to EpCAM 
positive cells and retained the functional activity of the NIS plasmid. 
4) Apoptotic regulatory genes such as Survivin-WT, Survivin-2α, Survivin-2β, Survivin-
3β, Survivin-ΔEx3, Bcl-2 and Bax are expressed at a higher fold in RB when 
compared to normal retina. The expression of proapoptotic genes Bax, Survivin-2α 
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and Survivin-2β showed correlation to histopathological features of RB which means 
that it may play a role in tumorigenesis if not masked by the strong anti-apoptotic 
effects of the antiapoptotic genes. 
5) Silencing of Survivin-WT in Y79 cells silenced all the splice variants and also 
induced apoptosis. 
 
More detailed inferences from each study are summarized below: 
 
NIS expression in primary RB tumor  
In chapter 3, the NIS protein expression in primary RB tumors and RB cell line has been 
studied. This is the first study to explore NIS expression in a non-thyroidal tumor like RB. 
Immunohistochemically, NIS expression was found to be cytoplasmic and membranous 
which is consistent with results reported in other non-thyroidal cancers. NIS, being a 
membrane protein when expressed in cytoplasm takes up a different role other than iodide 
uptake. Cytoplasmic NIS is involved in cell migration and invasion and thus its expression in 
RB tumors could be associated to invasive quality of the tumor. Confirming the IHC findings, 
flow cytometric analysis showed significant association between increased expression of NIS 
protein and invasiveness of the tumors. One of the post-translational modifications of NIS 
protein is glycosylation and the NIS protein was found to be fully, partially and under 
glycosylated in RB tumors. Since recent studies have shown that glycosylation doesn’t affect 
the functionality of the NIS protein, the expressed NIS could be functionally active. Findings 
obtained in RB tumor were concurrent with RB cell line confirming the NIS expression. 
Thus, this study explored the expression of NIS in primary RB tumors and proved the 
proposed hypothesis that when NIS is expressed in RB, it is related to the histopathological 
high risk factors of the tumor. In the context of NIS’s role in RB, it can be considered as a 
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molecule capable of enhancing diagnosis. In the case of therapy, when combined with EBRT 
and drugs that lead to radiosensitivity, NIS can be a potent tool in RB.  
 
EpCAM targeted NIS overexpression in breast cancer 
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein strongly 
expressed in breast cancer supporting the disease progression. NIS being a therapeutic gene 
though endogenously expressed in breast cancer is insufficient for radiotherapy. In chapter 4, 
NIS is specifically overexpressed in breast cancer cells via two ways by targeting 
overexpressed EpCAM protein. Cloning of EpCAM specific promoter driven NIS gene was 
successful and stable transfectants in MCF-7 was established. Although the universal (CMV) 
promoter induced higher NIS mRNA and protein expression, the NIS functional activity was 
remarkably higher in stable MCF-EpCAM-NIS transfectant than the stable MCF-CMV-NIS 
transfectant. Thus the superior promoter activity of EpCAM over CMV was established in 
this study. Similarly, NIS pDNA was delivered in a nanoformulation by targeting EpCAM 
via EpCAM aptamer. The nanocomplex consisted of PEI the polymer, NIS the plasmid DNA 
and EpDT3 the EpCAM aptamer. The synthesized nanocomplex (PEI/NISpDNA/EpDT3) 
were smaller in size (30-40nm) and spherical in shape with high serum stability. The 
nanocomplex successfully delivered NIS pDNA which was analysed by NIS expression at 
mRNA and protein level. The PEI/NISpDNA/EpDT3 delivered NIS gene showed 
significantly higher iodide uptake. This ability to specifically deliver the NIS pDNA to 
EpCAM positive cells by retaining the complete functional activity proves the potential of the 
nanocomplex. The nanocomplex coated with scrambled aptamer could not deliver NIS pDNA 
in a targeted manner and therefore no iodide uptake activity was observed in EpCAM 
positive cells. In conclusion, this study proved the proposed hypothesis that targeting 
EpCAM would indeed lead to specific overexpression of NIS gene in EpCAM positive breast 
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cancer cells. Thus, in the context of NIS and EpCAM in breast cancer, a combination of 
therapeutic molecule, NIS and an ideal targeting molecule like EpCAM is bound to 
strengthen the breast cancer treatment. 
 
Apoptotic genes expression in RB 
Apoptosis in other words programmed cell death is a natural process in a healthy cell which 
occurs to balance the cell division. The status of the endogenous apoptotic regulatory 
molecules in RB has never been explored. In chapter 5, the study shows for the first time the 
endogenous mRNA expression of Bcl-2, Bax, Survivin-WT, Survivin-2α, Survivin-2β, 
survivin-3β and Survivin-ΔEx3 in 20 RB tumor cohorts. The expression studies of Bcl-2 and 
Bax mRNA showed anti-apoptotic molecule Bcl-2 to be significantly higher than Bax. 
Though Bax expression is also higher in invasive tumors compared to normal retina, Bcl-2 
appears to be the dominant player masking the pro-apoptotic activity of Bax.  
Real time PCR studies on RB tumors revealed a higher expression of wild type survivin and 
all survivin splice variants. However, the predominant form was Survivin-WT. Overall, the 
anti-apoptotic variants were highly expressed as compared to the pro-apoptotic variants. This 
tilt towards anti-apoptotic variants enhances the progression of RB. Individually, Survivin-2α 
expression was lower in poorly differentiated tumors and this could enhance the anti-
apoptotic variants. Survivin-2β also showed similar expression patterns to Survivin-2α. The 
main variant of all is Survivin-ΔEx3 because of its strong anti-apoptotic activity. The 
expression of Survivin-ΔEx3 was interesting mainly because of the ratio of Survivin-
ΔEx3/Survivin-2β which is tilted towards Survivin-ΔEx3. This conforms that Survivin-ΔEx3 
is dominant; however its mRNA expression in poorly differentiated did not turn out to be 
significant. Since Survivin-WT and Survivin-ΔEx3 expressed significantly high in tumors, 
these molecules were silenced in RB cell line which mimics the RB tumor. Silencing the 
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Survivin-ΔEx3 alone did not yield to any apoptotic effects. However silencing Survivin-WT 
lead not only to downregulation of all the variants but also induction of apoptosis. This 
confirms the role of survivin in inhibiting apoptosis in RB. In conclusion, this study proved 
the proposed hypothesis that all the survivin and its splice variants, Bax and Bcl-2 genes 
could be related to tumor progression of RB and that survivin silencing could lead to 
induction of apoptosis. Thus, the above molecules’s expression in RB not only shows its role 
in tumor progression but also helps in elucidating the apoptotic pathway involved in RB. 
 
FUTURE PERSPECTIVES 
1) Since NIS protein expression is regulated differently in different tissues, in future 
studies, it can be seen how NIS is regulated in RB tumor cells.  
2) It would be interesting to study the impact of glycosylation on the functionality of 
NIS protein expressed in RB.  
3) In future, exploitation of NIS in diagnosis, treatment and monitoring of RB patients 
can be studied by employing more number of patients using RB tumors with different 
grading.  
4) Interestingly, bLf receptors were found to be expressed in Y79 cell line and bLf was 
rapidly internalized into these cells. bLf as a transcriptional activator upregulated the 
endogenous NIS expression. Future studies focussing on further enhancing this 
expression and standardising techniques for functional assay for suspension cells 
could be beneficial.  
5) Since survivin and Bcl-2 is highly expressed in RB, in future it can be studied whether 
bLf targets survivin and Bcl-2 in RB. 
6) The future study needs to explore whether the mRNA level expression of the survivin 
splice variants, Bcl-2 and Bax investigated in RB tumors translates into protein level. 
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7) Future studies can also focus on finding out the precise role of each survivin variant 
and each member of Bcl-2 family in the recurrence and patient survival in a larger 
cohort of RB tumors. 
8) A combinatorial nano formulation targeting of anti-apoptotic molecules of survivin 
variants and Bcl-2 may be a promising therapy for RB.  
9) The PEI/NISpDNA/EpDT3 nanocomplex study was performed in in vitro, in future it 
can be considered for in vivo studies in breast cancer models which would validate at 
pre-clinical levels the benefit for cancer treatment by avoiding the undesirable effects 
of therapy to surrounding normal tissues. 
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APPENDIX 
Serial No. Chemical Composition 
1       0.1% HCl 
 
- 1mL of concentrated 
Hydrochloric acid 
- 999mL of milliQ 
 
2 4% (APES) 
 
- 4mL of aminopropyl ethoxy 
silane 
- 96mL of milliQ 
 
3 10mM citrate buffer, pH 
6.0 
 
- 0.1M trisodium citrate-41mL 
- 0.1M citric acid-9mL 
- Adjust the pH to 6.0 with 
conc.HCl and Made upto 500mL 
with milliQ 
 
4 1X Tris Buffered Saline 
(TBS), pH 7.6 
 
- 1.517gm of Tris buffer 
- 2.175gm of Sodium Chloride 
- Adjust the pH to 7.6 and Made 
upto 250mL with milliQ 
 
5 FACS buffer 
 
- 1X phosphate buffered saline 
-  10% fetal bovine serum 
- 1% sodium azide 
 
6 RadioImmunoPrecipitation 
assay (RIPA) lysis buffer  
 
- 50 mM of Tris HCl (pH 7.6) 
-  1% NP40 
- 0.28% of Deoxycholate  
- 0.1% SDS 
- 1 mM of EDTA 
- 150 mM of sodium chloride 
- 1% PMSF  
- 250 μL of 1 mg/mL Protease 
Inhibitor Cocktail 
 
7 1X Tris buffered saline-
Tween 20 (1XTBS-T) 
 
- 1.517gm of Tris buffer 
- 2.175 gm of Sodium Chloride 
- 0.1% tween-20 
- Made upto 250mL with milliQ 
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8 10X Running buffer 
 
- 144gm of Glycine 
- 30gm of Tris buffer 
- 10gm of Sodium Dodecyl 
Sulphate (SDS) 
- Made upto 1000mL 
 
9 10X Transfer buffer 
 
- 144gm of Glycine 
- 30gm of Tris buffer 
- 20% of Methanol 
- Made upto 1000mL 
10 Sample loading buffer 
(4X, 10mL) 
 
- 2.0 mL 1M Tris-HCl, pH 6.8 
  
- 0.8 g SDS    
- 4.0 mL 100% glycerol   
- 0.4 mL 14.7 M β-
mercaptoethanol  
- 1.0 mL 0.5 M EDTA  
  
- 8.0 mg bromophenol blue   
- 2.6 mL H2O 
 
11 30% acrylamide (100mL) 
 
- 29gm of acrylamide 
- 1gm of bisacrylamide 
- Made upto 100mL with milliQ 
 
12 1.5M Tris, pH 8.8 
(250mL) 
 
- 45.43gm of Tris base 
- Adjust the pH to 8.8 and Made 
upto 250mL 
 
13 1M Tris, pH 6.8 (50mL) 
 
- 6.06gm of Tris base 
- Adjust the pH to 6.8 and Made 
upto 50mL 
 
14 10% SDS (50mL) 
 
- 5gm of Sodium Dodecyl Sulphate 
- Made upto 50mL 
 
15 5% skimmed milk (50mL) 
 
- 2.5 gm of skimmed milk 
- Made upto 50mL with 1XTBS-T 
 
16 Stripping buffer 
 
- 100mM Glycine, pH 2 
 
17 0.1M CaCl2 Solution 
 
- 0.74gm of CaCl2 
- Made upto 50mL with milliQ 
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18 1X TE Buffer, pH 8.0 
 
- 10mM Tris-HCl, pH 8.0 
- 1mM EDTA 
 
19 Incubation buffer for 
RAIU assay 
 
- 4gm NaCl 
- 0.1gm KCl 
- 0.72gm Na2HPO4 
- 0.12gm KH2PO4 
- 0.5gm Bovine Serum Albumin 
- Made upto 500mL with milliQ, 
pH-7.4 
 
20 Lysis Buffer for RAIU 
assay 
 
- 0.1M NaOH 
- 1% SDS 
 
21 Uptake Buffer 
 
- HBSS 
- Hepes (10mM final) 
 
22 Cerium IV Sulphate, 
42mM 
 
- 1.25 gm of Ammonium cerium 
(IV) sulphate hydrate 
- 20mL of MilliQ 
- 5mL of Conc.H2SO4 
- Made upto 50mL with MilliQ 
 
23 Sodium Arsenite (III) 
solution, 96mM 
 
- 475mg of Arsenic III oxide 
- 2.4gm of Sodium Chloride 
- 5mL of 2M Sodium Hydroxide 
- Made upto 50mL with MilliQ 
 
24 Buffer P1 
 
- 50 mM Tris-HCl pH 8.0 
-  10 mM EDTA 
- 100 μg/mL RNaseA 
 
25 Buffer P2 
 
- 200 mM NaOH 
-  1% SDS 
 
26 Buffer N3 
 
- 4 M guanidine hydrochloride, 
     -  0.5M Potassium acetate, pH 4.2  
 
27 Buffer PB 
 
- 5 M Gu-HCl 
- 30% isopropanol 
 
28 Buffer PE 
 
- 10 mM Tris-HCl pH 7.5 
- 80% ethanol 
 
29 Buffer EB 
 
- 10 mM Tris-HCl, pH 8.5 
 
30 Buffer QBT - 750 mM NaCl 
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 - 50 mM MOPS, pH 7.0 
- 15% isopropanol 
- 0.15% Triton-X 100 
 
31 Buffer QC 
 
- 1.0 M NaCl 
- 50 mM MOPS, pH 7.0 
- 15% isopropanol 
 
32 Buffer QF 
 
- 1.25 M NaCl 
- 50 mM Tris-HCl, pH 8.5 
- 15% isopropanol 
 
33 Buffer QG 
 
- Composition unknown 
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List of Instruments 
 
S.no. Instrument Model Company  
1 SDS-PAGE setup Powerpac Hc Bio-Rad 
2 Biosafety Cabinet Safemate 1.2 Laftechnologies 
3 5% CO2 incubator Heracell 150i Thermo Scientific 
4 Chemidoc XRS XRS Bio-Rad 
5 Gel electrophoresis setup Major Science MP 300N 
6 pH meter - Labchem pH 
7 Confocal Microscope LASaf Leica 
8 Inverted Microscope - Prism Optical 
9 Sonicator Vibra-cell Sonics 
10 Microplate Reader SH-1000 Corona electric 
11 Fluorescent Reader MTO-601F Corona electric 
12 Flow cytometer CantoII BD biosciences 
13 Centrifuge 5804 Eppendorf 
14 Protein transfer system Trans-blot turbo Bio-Rad 
15 Real Time PCR AB 2500 Applied Biosystems 
16 Sample Heater HB-2 Wealtec Corp 
17 Dynamic light scattering Nano-2S Malvern Instruments 
18 UV transilluminator 3UV UVP company 
19 Shaking incubator LT Orbitek 
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List of Chemicals  
S.no. Reagent/Chemical/Antibody/Buffers Company 
1.  Acetone  Chem Supply  
2.  Acetonitrile Sigma Aldrich 
3.  Acrylamide  Sigma Aldrich  
4.  Agarose  Sigma Aldrich 
5.  Ammonium bicarbonate Sigma Aldrich 
6.  Ammonium persulfate (APS) Sigma Aldrich 
7.  Annexin V staining kit Roche 
8.  Anti-goat IgG-FITC  (F7367,Sigma Aldrich)  
9.  Anti-mouse IgG-FITC  (F0257,Sigma Aldrich)  
10.  Anti-rabbit IgG-FITC (F0382, Sigma Aldrich) 
11.  Anti-mouse IgG- horse radish peroxidise (HRP) (A9044, Sigma Aldrich)  
12.  Anti-rabbit IgG-horse radish peroxidise (HRP) (A8275, Sigma Aldrich)  
13.  Anti-goat IgG-horse radish peroxidise (HRP) (A3682, Sigma Aldrich)  
14.  Bisacrylamide Sigma Aldrich 
15.  Bradford-Coommassie plus protein assay reagent  Thermo Scientific 
16.  Bovine serum albumin (BSA) Sigma Aldrich  
17.  Bromophenol blue Sigma Aldrich  
18.  Chloroform  Sigma Aldrich  
19.  Dithiothreitol (DTT) Sigma Aldrich  
20.  Dimethyl sulfoxide (DMSO) Sigma Aldrich  
21.  Dulbecco Modified Eagles’ Media (DMEM) high 
glucose  
Sigma Aldrich  
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22.  DNA ladder Fermentas 
23.  Ethanol  Chem Supply  
24.  Ethylenediamine tetra acetic acid (EDTA) Sigma Aldrich 
25.  Fetal bovine serum (FBS) Sigma Aldrich  
26.  Fluoro shield 4’,6-diamidino-2-phenylindole 
(DAPI) 
Sigma Aldrich 
27.  Glacial acetic acid  Panreac  
28.  Glycerol Sigma Aldrich  
29.  Glycine  Sigma Aldrich  
30.  Goat anti-bLf (A10-126, Bethyl 
Scientific) 
31.  Haematoxylin Hi Media Laboratories 
32.  Isopropyl alcohol  Chem Supply  
33.  Methylene blue Sigma Aldrich 
34.  Mineral oil Bio-Rad 
35.  Mouse anti-EpCAM monoclonal antibody  Santa Cruz USA 
36.  Mouse anti-NIS monoclonal antibody  Abcam 
37.  Mouse, FP5A, anti-NIS monoclonal antibody Thermo Scientific 
38.  Mouse anti-β-actin monoclonal antibody Sigma Aldrich 
39.  Paraformaldehyde  Sigma Aldrich  
40.  Polyvinylidene difluoride (PVDF) membrane GE healthcare 
41.  Protein marker, wide range Bio Rad 
42.  Propidium Iodide (PI) stain  Sigma Aldrich  
43.  Protease inhibitory cocktails Sigma Aldrich 
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44.  Rabbit anti-NIS polyclonal antibody  Abcam 
45.  Rabbit anti-Survivin monoclonal antibody  Abcam 
46.  Rabbit anti-Survivin ΔEx3 polyclonal antibody  Abcam 
47.  Rabbit anti-GAPDH polyclonal antibody  Sigma Aldrich 
48.  RNase OUT Life Technologies 
49.  Roswell park memorial institute (RPMI) media Sigma Aldrich 
50.  Sodium azide  Sigma Aldrich  
51.  Sodium Chloride Sigma Aldrich  
52.  Sodium citrate Sigma Aldrich 
53.  Sodium do-decyl sulphate (SDS) Sigma Aldrich  
54.  Superscript III Life Technologies 
55.  SYBR green premix Life Technologies 
56.  Tris base Sigma Aldrich 
57.  Triton X-100 Sigma Aldrich  
58.  TRIzol reagent  Life Technologies  
59.  Trypan Blue  Sigma Aldrich  
60.  Trypsin/EDTA (0.25%) Life Technologies  
61.  Tween-20 Sigma Aldrich  
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